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Abstract 
Dendritic cells lie at the interface of innate and adaptive immunity, critically 
contributing to the generation of an antigen-specific immune response. Although the 
mechanisms by which they initiate protective immunity are well characterised, their 
precise contribution to the subsequent regulation of immunity, particularly in the 
context of chronic infection, is less fully described.  
 
Leishmania donovani is an intracellular protozoan parasite of mammalian phagocytes, 
capable of establishing a persistent and life-threatening infection in man. Associated 
with profound immunopathology and chronic immune suppression, visceral 
leishmaniasis is endemic to some of the world’s most resource-poor regions.  There is 
no vaccine and current therapeutic options are limited by parasite resistance, high 
toxicity and prohibitive costs. As such, a deeper understanding of the immunological 
mechanisms underlying this disease is critical for the development of effective novel 
interventions.  
 
Phenotypic and functional analysis of CD11chi conventional dendritic cell subsets 
(cDCs) revealed widespread alterations as a result of chronic infection in the murine 
spleen. cDCs displayed a limited capacity for costimulatory molecule expression and 
pro-inflammatory cytokine production ex vivo. Instead, the preferential production of 
the immunoregulatory cytokines IL-10 and IL-27 led to the establishment of an auto-
regulatory cytokine cascade, modulating cDC function and limiting their capacity to 
direct effector T cell polarisation in vitro.  
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Conditional in vivo ablation of CD11c+ cells during chronic infection suggested a key 
role for DCs in the maintenance of pathology and parasite persistence in the spleen, 
whilst adoptive transfer approaches revealed for the first time that IL-10+IL-27+ cDCs 
facilitated the expansion of IL-10 producing Th1 cells in vivo and significantly 
contributed to the progression of disease.  
 
Taken together, this study reveals a paradoxical capacity for cDCs to suppress effective 
immune responses during chronic parasitic infection and highlights novel 
immunoregulatory mechanisms associated with this neglected tropical disease.  
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 Chapter 1: Introduction 
 
1.1 Dendritic cells: potent initiators of adaptive immunity 
Dendritic cells (DCs) lie at the interface of innate and adaptive immunity. Originally 
characterised in a series of seminal studies during the 1970’s [1-4], this unique 
leukocyte population is endowed with an enhanced capacity for stimulating 
proliferation in a mixed leukocyte reaction (MLR) [5, 6] and for generating effector T 
cell populations in vitro [7]. Initially identified visually by their ‘dendritic’ morphology 
and indirectly by their functional properties, the Integrin, alpha X (complement 
component 3 receptor 4 subunit; ITGAX), CD11c is now used as a surrogate marker for 
DC identification [8].  
 
The central paradigm of DC function places them as the dominant cell population 
involved in the initiation of an antigen-specific T cell response [9]. Proposed after 
observations on the function of mouse Langerhans’ cells (LCs), a type of dendritic cell 
first observed in 1898 and formally given the ‘dendritic’ nomenclature as early as 1948 
[10], a series of studies identified sequential alterations in LC function and location 
which allowed them to induce naïve T cell activation [11-17]. When isolated from 
tissue, LCs are in an ‘immature’ state; able to take up antigen but limited in their ability 
to stimulate T cells [13]. After 48 to 72 hours of in vitro culture, LCs undergo a process 
of ‘maturation’, allowing them to much more efficiently activate naïve T cells in a MLR 
[12].  
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Associated with this maturation process, DCs begin to process and present antigen via 
both Major Histocompatibility Complex (MHC) class I and II pathways. The majority 
of antigens presented in the context of MHCI molecules are derived from the 
degradation of ubiquitinated endogenous proteins by proteasomes. These peptides reach 
the endoplasmic reticulum (ER) by associating with specialised proteins known as 
transporters associated with antigen processing (TAP) -1 and TAP-2 that enables them 
to associate with newly formed MHCI molecules residing in the ER in a complex 
composed of the chaperone proteins calreticulin, Erp57 and tapasin. Once peptide has 
bound this complex, the fully folded MHCI molecule is released from the ER and 
translocated through the golgi apparatus to the cell surface.  
 
In contrast to the bulk of MHCI antigen presentation, peptides presented in the context 
of MHCII are generated from exogenous proteins degraded in acidified endocytic 
vesicles. MHCII molecules are held in an inactive state in the ER by an association with 
the invariant chain (Ii). Upon access of this complex to acidified endosomes, the 
invariant chain is cleaved, leaving a short peptide fragment (CLIP) bound within the 
MHCII peptide-binding groove. Finally, the MHCII-like molecule Human Leukocyte 
Antigen (HLA)-DM induces the release of CLIP and facilitates the association of 
peptides generated in the endosome with the now vacant peptide-binding groove. The 
fully formed MHCII:peptide complex then translocates to the cell surface (antigen 
presentation reviewed in  [18]).  
 
Antigen processing during maturation is concurrent with enhanced expression of MHC 
surface molecules [11, 15, 16], a process also occurring in response to both DC 
developmental stage [19] and exposure to inflammatory stimuli [20]. Maturation is also 
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associated with increased expression of the co-stimulatory molecules CD80 (B7-1) and 
CD86 (B7-2) [14] (reviewed in [21]). It is the coordinate expression of these molecules 
alongside antigen in the context of surface MHCII that allows DCs to provide the two 
signals required for initial activation of naïve CD4+ T cell populations [22]. T cell 
activation does not usually occur locally, as DCs are capable of migration to local 
lymph nodes after activation, [17] (reviewed in [23]). This process is dependent on 
increased expression of the chemokine receptor CCR7 during maturation [24-26], and 
enables them to traffic via afferent lymphatic vessels to sources of CCL19 and CCL21 
in the T cell zone of the regional lymph node [24, 27, 28].  
 
The sequential processes of antigen uptake, processing, maturation, migration and 
subsequent T cell stimulation in the lymph node underlie the conceptual basis of DC 
functionality in the immune system. However the existence of multiple DC subsets, as 
well as complexities in their ontogeny and function, modulates the confidence with 
which such behaviour can be universally ascribed to cells of this type [29, 30].  
 
1.2 Dendritic cell heterogeneity 
DCs are found in a multitude of lymphoid and non-lymphoid tissues and bear many 
phenotypic and functional specialisations. Initially revealed to be a component of the 
splenic lymphoid tissue [1], DCs within steady state lymphoid organs actually comprise 
a discrete group of subsets with distinct patterns of surface protein expression. So called 
‘classical’ or ‘conventional’ DCs (cDCs), steady state lymphoid organ resident dendritic 
cells express high levels of CD11c and MHCII and can be further phenotypically 
divided into CD8α+CD4- (CD8α+), CD8α-CD4+ (CD4+) and CD8α-CD4- (double 
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negative; DN) cDC subsets [31, 32]. Recent advances in multicolour fluorescence-
activated cell sorting and novel genetic marking strategies have facilitated the 
generation of a detailed map describing the development of conventional DCs in the 
steady state and the impact of inflammation on this process (Fig 1.1).  
 
1.3 Steady state conventional dendritic cell development 
Hematopoietic stem cells in the bone marrow give rise to common lymphoid [33] and 
common myeloid [34] restricted progenitors (CLPs and CMPs, respectively), although 
emerging evidence suggests that such a binary lineage segregation may be an 
oversimplification [35, 36], particularly in humans [37]. Early adoptive transfer studies 
suggested that distinct cDC subsets were derived from either CLPs or CMPs, generating 
nomenclature designating CD8α+ cDCs as ‘lymphoid’ DCs and CD8α- cDCs as 
‘myeloid’ DCs [38, 39]. Although cDCs in spleen and thymus can derive from both 
CLPs and CMPs when these progenitors are transferred into irradiated animals, the 
majority of splenic cDCs are derived from macrophage-DC progenitors (MDPs) [40-
42], thus sharing a developmental origin with cells of the monocyte and macrophage 
lineage.  
 
MDPs are Lin-CX3CR1+CD11b-CD115+CD117+Flt3+ and capable of differentiating 
into monocytes, macrophages and DCs in response to GM-CSF in vitro or after 
adoptive transfer in vivo [43]. A further specialised progenitor derived from the MDP is 
known as the common DC progenitor (CDP- also designated as ‘pro-DCs’); first 
identified as a Lin-CD115+Flt3+CD117lo population in murine bone marrow with a 
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capacity to produce cDCs and plasmacytoid DCs (pDCs), but not monocytes or 
macrophages [44, 45].   
 
Differentiation from CDPs to fully formed DCs does not occur directly, with cells 
passing through immediate DC precursor stages. CD11c+MHCII- DC precursors (pre-
DCs) were first identified in peripheral blood and give rise to cDCs and pDCs after 
migration to the spleen [46]. Dendritic cell precursors exclusively giving rise to 
conventional DCs (pre-cDCs) are a heterogeneous population of CD11c+MHCII-
SIRPαlo cells present in the spleen, able to be segregated into CD24hi and CD24lo 
populations which respectively differentiate into CD8α+ cDCs and CD8α- cDCs in vitro 
and in vivo [47]. The existence of an immediate pre-cDC supported earlier evidence that 
distinct cDC subsets are not immediate precursors of each other [48], but until recently 
the exact processes leading to the differentiation of  cDCs from pre-cDCs in vivo 
remained poorly defined.  
 
In a landmark study, Liu et al described the phenotype and function of pre-cDCs in vivo 
and delineated the relationship of these precursors to other myeloid progenitors, their 
capacity for integration into the DC network and the control of their differentiation by 
regulatory T cells and growth factor availability [49]. CD11c+MHCII-Signal Regulatory 
Protein (SIRP)-αintFlt3+ pre-cDCs comprise 0.2% of bone marrow, 0.03% of blood, 
0.05% of spleen (see also [47]) and 0.03% of lymph nodes [49]. Incorporation of BrdU 
by pre-cDCs is observed in the bone marrow but not the spleen or blood, indicating that 
the majority of pre-cDC expansion occurs at the site of haematopoiesis, rather than in 
the periphery.  Pre-cDCs express CD62L and migrate through the bloodstream to 
lymphoid organs, where they terminally differentiate and integrate into the cDC 
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network, exhibiting classic DC probing morphology [47, 49]. Although they give rise to 
CD8α+ and CD8α- splenic cDCs at an altered ratio compared to that in unmanipulated 
animals ([49] cf. similarly skewed CD8α+ cDC differentiation in [47]), adoptive transfer 
of pre-cDCs almost exclusively gives rise to cDCs, with a significantly reduced 
potential to generate monocytes or lymphoid lineage cells compared to unfractionated 
bone marrow cells. Adoptive transfer of MDPs into non-irradiated recipients 
demonstrates that MDPs give rise to both CDPs and pre-cDCs, whereas transfer of 
CDPs gives rise only to pre-cDCs and mature cDCs [49]; confirming the precursor-
product relationship between CDPs and pre-cDCs.  
 
FMS-like tyrosine kinase 3 ligand (Flt3L) is a critical growth factor required for the 
development of lymphoid resident cDCs in vivo. Mice deficient in Flt3L have 
substantial defects in DC development [50], as Flt3L acts at multiple stages of this 
process due to conserved expression of Flt3 on several DC progenitor populations [51] 
including CDPs [44, 45] and immediate cDC precursors [47, 49]. This regulation at the 
level of progenitor cells in the bone marrow by Flt3L was initially proposed as the 
major process regulating DC homeostasis [52]. However, the regulation of cDC division 
in the periphery is now thought to play a key role. This is also dependent upon 
signalling through Flt3 [53], although lymphotoxin-α1β2 (LTα1β2) may be involved in 
the homeostatic control of CD8α- cDC populations [54]. As initial studies assessing 
splenic cDC turnover did not take into account the potential for mature cDC division 
[55, 56], the rapid turnover of around 3 days originally proposed for splenic cDCs has 
now been revised to approximately 5 to 7 days [57].  
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Combined with constant replenishing of the pre-cDC pool from the bloodstream at an 
estimated rate of up to 4,300 cells per hour [57], cDC division in situ is now thought to 
be a major mechanism of cDC homeostasis in vivo. Extrinsic immune factors are also 
involved in the regulation of peripheral cDC division and therefore homeostasis, as 
depletion of Foxp3+ Tregs leads to a dramatic expansion of splenic cDCs in vivo [58, 
59], mediated by Flt3L-driven proliferation [49]. Such tightly controlled systems of 
differentiation and homeostasis are prone to any alterations in steady state immune 
function, and as such infection and resultant inflammation can impact significantly upon 
DC development.  
 
1.4 Dendritic cell development under inflammatory conditions 
Derived from the MDP [43], monocytes are a heterogeneous myeloid cell population 
which develop in the bone marrow and exhibit CCR2-dependent mobilisation to the 
bloodstream upon infectious challenge [60]. In inflammatory settings, CX3CR1lo Ly6Chi 
monocytes can enter inflamed lymphoid tissue and acquire many of the characteristics 
of DCs, such as antigen processing and presentation, CD11c expression and the 
capacity to induce naïve T cell proliferation [47, 61-63]. Similar inflammatory DCs 
(iDCs) can develop at local sites of inflammation, with iDCs taking up antigen and 
migrating to regional lymph nodes where they control Th1 responses to cutaneous 
Leishmania major infection [64]. Inflammatory monocytes can also develop into TNFα 
and iNOS-producing ‘Tip-DCs’ during experimental infection with Listeria 
monocytogenes [60, 65], Leishmania major [66], Trypanasoma brucei [67, 68] and 
Brucella melitensis [69]. However, their designation as a population distinct from iDCs 
is not universally accepted.  
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Although precise functions and patterns of surface protein expression differ, most 
monocyte-derived iDCs in inflamed lymphoid tissue express CD11c, MHCII and 
CD11b and do not express the cDC markers CD4 or CD8; making them phenotypically 
similar  to the lymphoid-resident DN cDC subset. However, monocytes are completely 
restricted to DC development under inflammatory conditions, as the adoptive transfer of 
monocytes into steady state mice fails to generate cDC subsets in peripheral lymphoid 
organs [43, 47, 70]. Additionally, iDCs derived from monocytes express intermediate 
levels of CD11c, in contrast to the high levels of CD11c expression used to define 
lymphoid cDC subsets, suggesting that monocytes do not give rise to DC populations 
exactly equivalent to cDCs. Nevertheless, the potential links between iDCs, Tip-DCs 
and splenic DN cDCs are not robustly defined, and so some functional and phenotypic 
crossover is a possibility under inflammatory conditions (Fig 1.1).  
 
Huge progress was made in the field of DC biology by making use of GM-CSF-elicited 
DCs derived from murine bone marrow or human monocytes in vitro [71, 72]. 
However, these do not appear to have an in vivo counterpart in the steady state, and may 
be more related to monocyte-derived iDCs as they are not dependent upon Signal 
Transducer and Activator of Transcription (STAT)-3 for their differentiation; in contrast 
to cDCs [73]. More recent in vitro methods for DC generation have involved culture of 
murine bone marrow with recombinant Flt3L, allowing the generation of pDCs and 
cDC subsets more closely resembling steady state splenic DC populations [74-76]. 
However there are limitations to this approach, as a lack of CD4 and CD8α expression 
and universal CD11b expression on the subsets makes them phenotypically distinct 
from their in vivo counterparts [74]. As such, the assessment of physiologically relevant 
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lymphoid resident cDC function is likely to be restricted to studies using populations of 
primary cells isolated directly ex vivo- despite other caveats introduced by this process. 
 
1.5 Conventional dendritic cells: specific subsets - specific function? 
Irrespective of their ontogeny, the existence of multiple cDC subsets strongly suggests 
that distinct types of cDC have unique and divergent functionality in the immune 
system. This is paralleled by the existence of multiple classes of T cell, with well-
characterised and distinct function. This includes CD8+ cytotoxic T cells equipped for 
the production of perforin and granzymes and capable of initiating the death of infected 
host cells during a variety of pathogenic insults [77]. Exhibiting a greater diversity of 
potential functions, CD4+ ‘helper’ T cells represent a group of effector cells with shared 
developmental characteristics but highly divergent roles during immune responses. 
Distinct CD4+ T cell subsets include Th1 and Th2 cells, producing the ‘signature’ 
cytokines IFNγ and IL-4, respectively, the characterisation of which established the 
paradigm of distinct helper T cell classes [78]. More recently it has become apparent 
that several other CD4+ T cell subsets exist, including IL-17-producing Th17 cells [79], 
IL-9-producing Th9 cells [80] and germinal centre-generating T-follicular helper cells 
[81]. In addition, several types of regulatory T cells exist and will be discussed later in 
this study. 
 
Initial studies proposed that T cell polarising function was strictly segregated between 
CD8α+ and CD8α- cDC subsets, with CD8α+ cDCs yielding Th1 responses and CD8α- 
cDCs generating Th2 responses in vitro and after transfer in vivo [82-85]. This 
differential capacity for Th1/Th2 priming was associated with a higher potential for IL-
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12 production by CD8α+ cDCs during infection [86-88], although CD8α- cDCs can also 
produce IL-12 under some conditions [89-92]. As such, the concept of distinct cDC 
subsets only instructing certain helper T cell classes is now thought to be an 
oversimplification.  
 
However, CD8α+ and CD8α- cDC subsets possess differential antigen presentation 
capacity [93] and as such are thought to be functionally specialised for the activation of 
either CD8+ or CD4+ T cell responses, respectively. Supporting this concept, CD8α+ 
cDCs most efficiently cross present exogenous antigen on MHCI [94], in part due to 
specialised antigen handling capacity [95] and the expression of a distinct suite of 
receptors that recognise cell-associated [93, 96, 97] and soluble [98] exogenous antigen. 
Reflective of this, CD8α+ cDCs appear to be the dominant subset driving effective CTL 
responses to many classes of pathogen in vivo, due to both conventional and cross 
presentation of antigen [99-105], with their critical role underlined by the complete 
absence of antiviral CTL function in mice specifically lacking this cDC subset [106]. 
However, CD8α+ cDCs are also capable of generating CD4+ effector T cell populations 
in response to pathogens [103, 107, 108], suggesting that this subset has the capacity for 
more generalised T cell activation. Furthermore, despite the dominant role reported for 
CD8α+ cDCs, the CD8α- subset is also capable of cross presentation under 
inflammatory conditions [109, 110] and in some situations only a proportion of CD8α+ 
cDCs seem capable of optimal cross presentation [111] - indicating the potential for 
plasticity with regard to the functional specialisation of distinct cDC subsets. 
Nevertheless CD8α- cDCs favour CD4+ T cell activation in response to pathogen 
encounter [112, 113] and generate CD4+ T cell responses when specifically targeted 
with antigen in vivo [93, 114], suggesting that intrinsic differences in antigen receptor 
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expression and processing capacity imprint at least some level of specialisation upon 
cDC subsets under certain conditions. The extent to which supposedly subset-restricted 
function may be compensated for by alternative subsets in vivo is currently unclear.  
 
1.6 Dendritic cell regulation of immune responses 
As previously described, DCs are critical for the optimal initiation of adaptive immune 
responses. However, they also play key roles in maintaining steady state peripheral 
tolerance and in the active regulation of immune responses. 
 
Steady state, resting DCs are predisposed to the induction of tolerance rather than 
immunity in the periphery [115] by inducing T cell anergy [116] or deletion [117-119]; 
a result of their continuous presentation of self antigen to autoreactive T cell clones 
[120]. This process is similar to their role during negative selection in the thymus [121-
123] (reviewed in [124-126]). However, not all steady state DCs elicit T cell 
unresponsiveness [127], some are capable of generating immunity and tolerance 
simultaneously [128] and peripheral tolerance induction is often dependent upon co-
stimulatory molecule expression not always apparent on steady-state DCs [119, 129, 
130]. Therefore multiple factors in addition to their resting state are thought to control 
peripheral tolerance induction by DCs, such as indoleamine 2,3- dioxygenase (IDO)-
expression by specific splenic DC subsets [131-133].  
 
Although in vivo evidence for distinct subsets of tolerogenic DCs is limited, CD8α+ 
cDCs appear to have a major role in generating peripheral tolerance to cell associated 
antigen [134, 135], due in part to their preferential expression of the endocytic receptor 
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DEC-205 [136, 137]. This enables them to more efficiently endocytose apoptotic cells 
[138-140] and, when targeted with self antigen in vivo, initiate peripheral tolerance 
[141]. Such ‘cross tolerance’ is critical for avoiding autoimmunity induced by 
endogenous self-reactive T cell clones [142], highlighting the importance of this cross-
presenting cDC subset. However, CD8α+ cDCs and DEC-205 do not solely induce 
tolerance, evident in the crucial role for the subset in effector CTL generation ([106] 
and cf. above)  in addition to the enhanced CD4+ and CD8α+ T cell responses generated 
after targeting antigen to DEC-205+ cDCs under certain  inflammatory conditions in 
vivo [143-146]. As such it is likely that peripheral tolerance induction by DCs is part of 
an inherently flexible approach to T cell stimulation, based upon complex interactions 
over and above the level of exclusive tolerogenic function mediated by distinct DC 
subsets.  
 
The generation of regulatory T cells (Treg) also provides a method by which DCs can 
mediate peripheral tolerance in the steady state [59, 147-151]. Treg induction can also 
be achieved by the experimental targeting of DCs in vivo [152, 153], although it is in 
the context of inflammatory responses where the DC-dependent induction of Treg is 
particularly important. Several subsets of CD4+ regulatory T cell have been defined, 
including Foxp3+ Treg that are comprised of both naturally arising [154-156] and 
peripherally induced [157] populations.  In addition, Foxp3- populations such as IL-10 
producing Tr1 cells [158, 159], IL-35 producing iTr35 cells [160] and IL-10+ Th1 cells 
[161, 162] arise in response to a diverse range of pathogens and inflammatory stimuli.  
 
In contrast to DCs resident in mucosal tissues which are often specialised for the 
generation of Foxp3+ Treg [163, 164], evidence for defined subsets of splenic cDCs that 
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are capable of Treg induction during inflammation is more limited. Nevertheless, 
transfer of splenic CD8α+ cDCs can reduce pathology in a murine model of GVHD by 
inducing IL-10 producing T cells [165] and splenic CD4+, but not DN, cDCs are 
involved in regulating myelin-reactive T cell responses during experimental 
autoimmune encephalomyelitis (EAE) [166].  
 
Although falling outside the phenotypic definition of conventional DCs, IL-10 
producing CD11cloCD45RB+ ‘regulatory DCs’ [167-169] expand in the spleen during 
experimental infection with Plasmodium yoelii [170, 171] and Leishmania donovani 
[172, 173]; thereby inducing IL-10+ regulatory T cells and suppressing antigen-specific 
T cell responses. Similar IL-10 producing DCs also favour the generation of Tr1 cells 
during Bordetella pertussis infection [174, 175] and are generated in response to 
Schistosoma mansoni phosphatidylserine [176], hookworm secretory products [177] and 
virulence factors derived from Yersinia pestis [178]. Despite the clear capacity for the 
initiation of regulatory responses by some types of DC in response to infection, there is 
currently a considerable gap in our knowledge concerning the potential 
immunoregulatory function of conventional DC subsets during infection in vivo.  
However, based upon in vitro and in vivo studies of a wide range of DC types, the 
molecular pathways leading to the initiation of regulation by DCs are starting to be 
revealed.  
 
1.7 Pathways to regulatory DC function  
Whether inducing tolerance or immunity, a key property of DCs is their capacity to 
sense subtle changes in their environment. They do this by expressing a range of pattern 
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recognition receptors (PRRs) that recognise conserved elements from a multitude of 
infectious organisms, also known as pathogen-associated molecular patterns (PAMPs). 
These include Toll-like receptors (TLRs), germline encoded mammalian homologues of 
the Drosophila melanogaster Toll protein [179]. Humans and mice have 10 and 12 
functional TLRs, respectively [180], which allow for the innate recognition of diverse 
microbial stimuli and are critical for host defence [181]. However, emerging evidence 
suggests that TLRs can also recognise endogenous self ligands in the context of 
inflammation [182, 183], autoimmunity [184, 185] and cancer [186] and can thus 
potentiate inappropriate inflammatory responses.  
 
The induction of pro-inflammatory cytokine production downstream of most TLRs 
requires the adaptor protein MyD88 [187] which, via other adaptors such as TIRAP 
[188, 189] and IRAKs 1 & 4 [190], associates with TRAF6, leading to the direct [191] 
and TAK1-mediated [192] modulation of NF-κB and MAP kinase activity: resulting in 
IκBζ	  - dependent activation of pro-inflammatory cytokine genes such as IL-6 and IL-12 
[193] (reviewed in [181]). This process is tightly regulated, with non-functional adaptor 
protein variants [194], ubiquitin ligase-mediated degradation of signalling molecules 
[195], microRNAs [196] and RNase enzymes [197] all controlling levels of TLR 
activation.  
 
TLR ligation can also result in anti-inflammatory cytokine production, with the 
preferential production of IL-10 through pathogen-induced TLR signalling first 
described as an immune avoidance strategy by Yersinia pestis, a process  mediated 
through TLR2 [198]. It is now apparent that many pathogens exploit TLR2-induced IL-
10 production by APCs as a strategy to establish infection, such as Borrelia burgdoferi 
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[199], Aspergillus fumigatus [200], Candida albicans [201] and Mycobacterium 
tuberculosis [202], although the precise signalling pathways involved are not 
completely clear. However, the activation of extracellular signal-related kinase (ERK) 
appears to be a conserved component in the induction of IL-10 downstream of TLR2 in 
DCs, which occurs as a result of MyD88 or spleen tyrosine kinase (Syk)-dependent 
pathways, determined by the nature of the ligand [203]. TLR2-induced IL-10 
production may also require c-Fos, as DCs deficient in this transcription factor produce 
less IL-10 in response to TLR2 ligation [204].  
 
Signalling through Dectin-1, a C-type lectin PRR that recognises fungal β-glucans 
[205], also induces ERK and IL-10 production in a Syk- dependent process [206]. 
Interestingly, Dectin-1 and TLR2 can both recognise fungal zymosan, with signalling 
through both receptors required for efficient cytokine production [207]. Recognition of 
zymosan by both receptors also induces regulatory DCs capable of mediating IL-10-
dependent tolerance in vivo [208]. This regulatory effect is governed by TLR2 
signalling, as cDC production of IL-10 and retinoic acid in response to zymosan induces 
Foxp3+ Treg and suppresses autoimmunity; an effect abolished in zymosan-treated 
TLR2-deficient mice [209]. TLR2-mediated IL-10 production appears to be dependent 
on signalling from TLR2/6 heterodimers, as this generates IL-10+ regulatory DCs in 
response to bacterial antigen, whereas TLR2/1 heterodimers do not [178]. Such potent 
anti-inflammatory effects reveal the diversity of possible responses initiated by DCs in 
response to microbial encounter and highlight the importance of TLR2 in mediating DC 
regulatory function. 
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Alongside defined TLR-induced pathways, the activation of ERK provides a 
generalised mechanism by which the production of IL-10 by macrophages and DCs is 
enhanced. Stimuli as diverse as oxidative stress [210], cannabinoids [211] and CpG 
DNA [212] have been shown to induce ERK phosphorylation, resulting in suppression 
of IL-12p40 production and augmented production of IL-10 in APCs. In addition, FcγRI 
ligation induces IL-10 production in macrophages [213], as a result of ERK 
phosphorylation and the subsequent remodelling of chromatin around the il10 promoter, 
allowing enhanced Sp1 and STAT3 binding and augmented IL-10 production [214]. 
Signalling through FcγRIII has also been shown to result in IL-10 production by splenic 
DCs [215], in addition to modulating the phenotype of BMDCs, whereby activation of 
DCs in the presence of immune complex-mediated FcγR signalling leads to impaired 
DC IL-12p70 production and diminished in vivo Th1 responses after adoptive transfer 
[216].  
 
ERK-independent pathways can also inhibit IL-12 and enhance IL-10 production in 
dendritic cells, with two signalling pathways involving mammalian target of rapamycin 
(mTOR) and glycogen synthase kinase-3 (GSK3) favouring DC regulatory function via 
IL-10 dependent (mTOR) and independent (GSK3) pathways [217]. Irrespective of the 
signalling pathways involved, DC production of regulatory cytokines such as IL-10 
allows for potent suppressive effects on immune function, often accompanied by the 
induction of regulatory T cell populations. However, other cytokines may also play 
regulatory roles, and their production by DCs during infection is only beginning to be 
addressed.  
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1.8 IL-27: a pleiotropic cytokine with a critical role in immune regulation 
A heterodimeric cytokine formed of the Epstein-Barr virus-induced gene 3 (EBI3) and 
the IL-12p35-related protein p28, IL-27 was first described in 2002 as a cytokine that 
induced the proliferation of CD4+ T cells and synergised with IL-12 for the induction of 
Th1 polarisation [218]. The discovery of IL-27 provided a long sought ligand for the 
orphan cytokine receptor WSX-1 (TCCR) [219], previously shown to be required for 
optimal Th1 induction and effective immunity to Listeria monocytogenes [220] and 
Leishmania major [221]. The crucial role for IL-27 in Th1 polarisation is in part due to 
the STAT1 and STAT3-mediated induction of T-bet and IL-12Rβ2 expression 
downstream of a signalling complex comprising WSX-1 and gp130 [222], allowing 
optimal sensitivity to IL-12 and maximal IFNγ expression [223-227]. IL-27 is therefore 
associated with multiple Th1 and IFNγ-mediated immune responses [228-237].  
 
IL-27 has another crucial element to its functionality, originally suggested by studies 
showing that signalling through WSX-1 was required to prevent CD4+ T cell 
hyperactivity and excessive pro-inflammatory cytokine production in response to 
parasitic infection [238, 239]. This is due to the differential effects of IL-27 at distinct 
stages of CD4+ T cell activation, with IL-27 favouring the initial activation and STAT1-
dependent Th1 polarisation of naïve T cells, but limiting pro-inflammatory cytokine 
production and proliferation later in activation [240], in part by modulating T cell IL-2 
production [241, 242]. These seemingly disparate functions have led to studies showing 
directly opposed roles for IL-27 in models of the same inflammatory disease, such as 
both the initiation [228, 234] and attenuation [243] of collagen-induced arthritis. 
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This capacity for regulating Th1 differentiation is also extended to other T cell subsets, 
with IL-27 potently suppressing Th17 differentiation [244-246] via STAT1- mediated 
inhibition of the lineage-determining transcription factor RORγt [247-249]. The 
induction of IL-27 production by IFNβ in vivo also inhibits Th17 cell development, 
preventing EAE and suggesting a basis for the therapeutic effects of IFNβ in multiple 
sclerosis [250-252]. However, IL-27 does not appear to affect the function of 
established Th17 cells [253], highlighting the differential effects of this cytokine on T 
cell responses, determined by the temporal regulation of its availability.  
 
IL-27 also has the capacity to generate IL-10-producing CD4+ T cells in vitro [254-
257], via signalling pathways dependent on STAT3 [256].  The optimal generation of 
CD4+IL-10+ cells by IL-27 requires the co-ordinate initiation of c-Maf, ICOS and IL-21 
expression [258-260]. In addition, emerging evidence suggests that IL-27 may directly 
alter methylation patterns around the il10 promoter in CD4+ T cells, thus allowing 
greater IL-10 expression [261]. IL-27 also favours the production of IL-10 by IFNγ-
producing Th1 cells, although this process appears to depend upon an alternative 
signalling pathway involving STAT1, STAT4 and Notch [262, 263]. IL-27 also exerts 
effects on Foxp3+ Tregs, although both positive [264] and negative [265, 266] 
regulation of Foxp3 expression has been reported.  
 
A direct role for DC-derived IL-27 in the generation of IL-10+ T cells has been 
described in vitro, where production of this cytokine in response to galectin-1, or after 
oral tolerance induction with model antigen, favours the differentiation of IL-10-
producing T cells with potent regulatory capacity [267, 268]. Evidence for IL-27 
production by DCs determining the differentiation of CD4+ IFNγ+IL-10+ T cells in 
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response to infection in vivo is limited,  however the accumulation of IL-27p28 in 
splenic cDCs during chronic Leishmania donovani infection [108] suggests a potential 
role for this cytokine in diseases associated with immune suppression.  
 
1.9 Visceral leishmaniasis: a neglected tropical disease 
The leishmaniases encompass a group of four pathological manifestations resulting 
from the vector-mediated transmission of the obligate intracellular protozoan 
Leishmania [269]. Caused by over 20 different parasite species and transmitted to 
humans by around 30 species of sandfly [270], leishmaniasis currently threatens 350 
million people and is endemic to 88 countries: 72 of which are classified as developing 
economies (http://www.who.int/leishmaniasis/en/index.html). Inoculation of the 
infective promastigote stage of the organism to the mammalian host occurs during 
feeding by female sandflies, with transformation to the replicating, intracellular 
amastigote stage occurring after the invasion of, or phagocytosis by, mononuclear 
phagocytes [271]. Disease takes the form of cutaneous leishmaniasis (CL), 
mucocutaneous leishmaniasis (MCL), visceral leishmaniasis (VL; also described as 
kala-azar) and the relatively uncommon post-kala-azar dermal leishmaniasis (PKDL) 
[272]. Whereas CL and MCL are characterised by cutaneous lesions and the destruction 
of mucus membranes that can result in disfiguring scars, VL leads to systemic 
parasitisation of internal organs and is invariably fatal if left untreated [272-274].  
 
Caused by Leishmania donovani and Leishmania infantum, parasite species’ belonging 
to the Leishmania donovani complex [275], an estimated 500,000 new cases of VL are 
diagnosed each year, resulting in around 50,000 annual fatalities [276]. However, these 
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numbers are thought to be a significant underestimation, with underreporting of disease 
in endemic areas a major problem [277-279]. VL is a disease of resource poor and 
poverty afflicted areas, exemplified by a recent study reporting that VL patients in 
Bihar, India, faced delays of around 40 days from first presentation to initial contact 
with a fully-qualified physician: the district in question had 4 healthcare facilities with a 
resident clinician, serving a population of almost 4 million [280]. As the average cost of 
drug treatment for one episode of VL is around twice the average monthly income in 
many areas [281], partial treatment regimens and (financially necessitated) non-
compliance is widespread, resulting in significant parasite resistance to the first-line 
therapeutic agent, sodium stibogluconate (Sbv) [282, 283].  
 
Even if effective against the strain of parasite, pentavalent antimonials such as Sbv are 
highly toxic and associated with severe, sometimes life-threatening side effects [284, 
285]. Rising resistance and increasing toxicity in endemic areas [286, 287] has led to 
the substitution of Sbv for liposomal amphotericin B [288, 289] as the first-line 
treatment in many cases, with low, single dose treatments deployed in order to keep 
down otherwise prohibitive costs [290, 291]. However, Sbv remains the primary drug 
used for large numbers of newly diagnosed patients, especially in rural areas [280]. The 
only oral treatment available for VL is miltefosine [292], the use of which is limited due 
to high costs. The considerably cheaper drug paromomycin is an antibiotic that is active 
against a broad range of possible co-infections as well as being more effective than Sbv 
[293] and equal to amphotericin B [294] in inducing the complete cure of patients in 
India. However, this drug appears to have limited efficacy in other endemic areas [295]. 
Combination therapies involving the simultaneous administration of two or more 
classes of drug are currently in clinical trials, with initial data suggesting reduced 
treatment times and higher cost effectiveness as the major benefits of this approach 
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(reviewed by [296]). Nevertheless, drug resistance and toxicity will likely remain a 
persistent problem. As visceral leishmaniasis is a disease associated with profound 
immunopathology, an understanding of these pathological processes is essential for the 
development of novel therapeutic interventions. 
 
1.10 Visceral leishmaniasis and immune-mediated pathology 
Sharing many hallmarks of human disease, the majority of knowledge gained regarding 
the immunopathology of VL has been derived from mouse models of infection 
(reviewed in [297]). Although the majority of these involve the intravenous inoculation 
of relatively high numbers of the amastigote stage of the parasite, models more closely 
mimicking the natural route of infection are in use [298].  A conserved feature of human 
and murine disease is the massive enlargement of the spleen and liver, associated with 
parasitisation of tissue macrophages in these organs, in addition to the bone marrow 
[271, 297]. In the murine model, the spleen and liver display highly divergent, tissue-
specific outcomes after infection [299]. The response in the liver is characterised by the 
IFNγ, TNFα and LTα-dependent formation of tissue granuloma [300-302]. After an 
initial period of uncontrolled parasite replication, the formation of these highly 
organised effector structures allow for the efficient killing of parasites within infected 
cells, critically dependent upon the induction of iNOS by T or NK cell-derived 
IFNγ and leading to parasite clearance from this organ at around day 28 of infection 
[303-308].  
 
Granuloma do not form in the spleen or bone marrow, resulting in the persistent 
parasitisation of tissue macrophages within these organs [309, 310] (reviewed in [308]). 
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Although not sufficient to clear the infection, some level of host response occurs in the 
spleen, demonstrated by increased parasite burdens after neutralisation of IL-12 [311]. 
Chronic infection of the spleen  is  associated with the destruction of follicular DCs and 
germinal centres [312], loss of gp38+ stromal cells and the homeostatic cytokines 
CCL19 and CCL21 [313], as well as extensive TNFα-mediated tissue remodelling and 
the loss of splenic marginal zone macrophages [314]. In the absence of any therapeutic 
intervention, splenic parasite burden remains high for the life of the animal.  
 
In contrast to a key role for T cells in protection from disease, B cell deficient mice are 
highly resistant to the development of VL [315], suggesting a suppressive function for 
these cells, although this appears to be dependent on polyclonal B cell activation and 
immune complex formation, rather than B cell cytokine production or antigen 
presentation (Moore et al in preparation and [316]). As opposed to experimental 
cutaneous L. major infection, where BALB/c and C57BL/6 mice are considered 
susceptible and resistant, due to highly polarised Th2 or Th1 responses, respectively 
(reviewed in [317]), both experimental strains are susceptible to L. donovani infection 
and the CD4+ T cell cytokine profile during infection is mixed [318, 319]. However, 
host protection is dependent upon expression of IFNγ, with Ifng-/- mice developing 
uncontrolled visceral infection for 8 weeks after inoculation [320]. As discussed later in 
this study, the immunosuppressive cytokine IL-10 plays a dominant role during murine 
and human infection (cf. Chapter 3, reviewed in [321]).  
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1.11 Genetic susceptibility to Leishmania infection 
The existence of a single gene that governed the susceptibility of certain mouse strains 
to infection with L. donovani was first suggested in 1977 [322]. It is now clear that 
Solute carrier family 11 member a1 (Slc11a1-previously known as Nramp1 or Lsh), a  
metal ion transporter expressed in late endosomal and lysosomal compartments [323], 
determines the early control of L. donovani and several other intracellular pathogens in 
macrophages [324, 325]. This occurs via iNOS dependent [326] and independent [327] 
mechanisms. It is also expressed in DCs and can regulate antigen presentation by these 
cells [328], as well as affecting the expression of several  immune mediators, such as 
IL-1β and TNFα;  thus modulating systemic responses to intracellular infection 
(reviewed in [329, 330]). Common laboratory strains of mice such as BALB/c and 
C57BL/6 bear a mutation in Slc11a1, are highly permissive to infection and thus widely 
used in experimental studies of VL. Mutations in the promoter of this gene also confer 
susceptibility to VL in man [331] (reviewed in [332]).  
 
1.12 Leishmania: a ‘quiet invader of mononuclear phagocytes’ [308] 
As an obligate intracellular parasite, the innate response to Leishmania is a critical 
component in the early control of an infection. Although the signals initiating their 
recruitment are not clear, neutrophils appear to be the first cells that encounter 
Leishmania major after deposition in the skin and are required for optimal infectivity 
[333]. The next stages in the establishment of disease are more controversial, with 
macrophage uptake of apoptotic neutrophils containing viable parasites proposed as a 
mechanism by which infection can be established [334, 335]. However, other cell types 
at the site of infection can directly interact with parasites [336] and as such the precise 
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sequence of events leading to the establishment of productive infection in tissue 
macrophages is not currently known.  
 
Unlike many other pathogens, Leishmania donovani has relatively few well-defined 
PAMPs and as such, evidence for the recognition of the parasite by a distinct PRR is 
sparse. However, recognition of other Leishmania spp by PRRs is more fully described. 
Leishmania major infection of mice or macrophages lacking the adapter protein MyD88 
revealed a requirement for signalling through this pathway in the recognition of the 
parasite, however as MyD88 is a component of the signalling cascade downstream of 
the majority of TLRs, in addition to the IL-1 receptor [181], these studies provide little 
information as to the nature of the initiating signal due to interaction with Leishmania. 
Nevertheless, MyD88 appears to play a role in early IL-1α expression [337] and parasite 
clearance [338], as well as IL-12 production by DCs, efficient Th1 polarisation and the 
suppression of Th2 dominated responses in vivo [339, 340]. MyD88 deficiency also 
leads to reduced co-stimulatory molecule expression on splenic DCs and impaired 
production of IL-12p40 by BMDCs after infection with L. donovani [341] and L. 
braziliensis [342], indicating that signalling through this pathway is involved in the 
response to diverse Leishmania spp.  
 
TLR4, which recognises bacterial lipopolysaccharide [343-345], has also been 
implicated in protection from L. major infection, with the TLR4-dependent induction of 
nitric oxide (NO) and inhibition of arginase required to limit parasite replication in vitro 
and resolve cutaneous infection in vivo [346, 347]. Neutrophil activation of 
macrophages for full killing of L. major amastigotes has been shown to require TLR4 
[348] and a proteoglycolipid from L. pifanoi induces TLR4-dependent cytokine 
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production and parasite killing by macrophages in vitro [349]; suggesting the presence 
of a conserved moiety recognised by TLR4. In addition, TLR9 appears to recognise the 
DNA of several species of Leishmania, including L. major [350, 351], L. mexicana 
[352] and L. infantum [353]. However, the specific receptor-ligand interactions 
occurring during parasite recognition by APCs are still unclear.  
 
In addition to the regulation of cytokine production and co-stimulatory molecule 
expression by Leishmania spp (cf. Chapter 3), parasites are capable of fundamentally 
altering antigen presentation- a key property of dendritic cells and macrophages and 
essential for the establishment of adaptive immunity. After internalisation by 
mononuclear phagocytes, the amastigote forms of Leishmania exist in a membrane-
bound organelle referred to as the parasitophorous vacuole (PV). Although MHCII is 
able to reach the PV and is thought to be capable of binding peptide there [354], 
presentation of parasite antigen to CD4+ T cells via MHCII has been shown to be 
impaired in macrophages infected with L. major and L. amazonensis, potentially due to 
defective loading of peptide onto MHCII, rather than inhibition of antigen uptake and 
processing or limited translocation of MHC to the cell surface [355, 356].  
 
Leishmania donovani has been shown to inhibit expression of MHCI and MHCII- 
associated genes in infected macrophages [357], with the promastigote form of the 
parasite directly limiting presentation of exogenous peptides by cleavage of potential 
antigens via gp63, a parasite-secreted endopeptidase [358]. L. major appears to be 
capable of intracellular antigen sequestration, linked to a profound defect in the capacity 
for parasite-specific CD4+ T cell activation during the later stages of macrophage 
infection in vitro [359]. Further supporting the concept of an active suppression of 
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antigen presentation by Leishmania spp is evidence for the lifting of L. mexicana-
induced suppression of antigen presentation after intracellular killing of the parasite 
[360], in addition to the production of a small peptide that inhibits MHCII expression in 
human monocytes after in vitro infection with L. donovani [361]. However, the 
observed inhibitory effects may also be due to limited access of appropriate parasite 
antigen to the presentation pathway, rather than active processes of suppression, as sub-
cellular location of parasite antigen appears to be a major determinant in defining the 
likelihood of presentation on the surface of an infected APC [362, 363]. 
 
Although infection appears to impair antigen presentation in macrophages, there is 
intact presentation of functional MHCII-peptide complexes by GM-CSF-elicited 
BMDCs infected with live L. mexicana [364], as well as the effective in vitro 
stimulation of naïve T cells by L. major promastigote- infected BMDCs [365] and L. 
donovani infected human myeloid DCs [366]. Relatively few splenic cDCs are infected 
in vivo [341], suggesting that antigen presentation may not be affected in these cells as a 
whole. However, the impact of systemic infection on the antigen presenting capacity of 
splenic cDCs in vitro or in vivo has not been formally addressed.  
 
1.13 Immunochemotherapy and novel therapeutic interventions 
In light of the multiple immunological sequelae associated with VL, combining 
conventional chemotherapy with immune-related interventions has shown great 
promise: although mostly limited to the experimental treatment of disease. Early studies 
showed that the effective therapy of chronically infected mice with Sbv was critically 
dependent on T cells, with T cell-deficient nude mice undergoing Sbv treatment 
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showing no parasite clearance in response to the drug [367]. This is a result of synergy 
between Sbv and pro-inflammatory cytokines, with diminished efficacy of the drug 
observed in TNFα and IFNγ-deficient hosts after treatment [300, 368]. The link 
between IFNγ and Sbv function has also resulted in small scale human clinical trials, 
with combined administration of recombinant human IFNγ and Sbv being well tolerated 
and achieving cure of otherwise refractory patients [369, 370] as well as faster 
remission times [371]. Presumably also linked to the dependence on IFNγ for optimal 
chemotherapy, recombinant IL-12 has been used as a successful strategy to enhance the 
efficacy of Sbv and amphotericin B in murine models [372, 373]. As discussed later in 
this study, IL-10R blockade in combination with Sbv results in remarkable 
improvements in terms of drug dose and treatment length, highlighting the enormous 
impact of this cytokine on disease [374].  
 
In addition to cytokine-mediated approaches, modulation of T cell co-stimulatory 
molecules has also been successful in models of disease. This has comprised two often 
contiguous approaches; the blockade of negative regulators and the activation of 
positive regulators- with the eventual goal of enhancing T cell activity. Targets for 
blockade that have improved parasite clearance and/or potentiated drug treatment have 
included cytotoxic lymphocyte-associated antigen -4 (CTLA-4) [375, 376], CD86 [377] 
and PD-L1[378]. Successfully targeted positive regulators of T cell activity include 
CD40 [372], OX40L [375] and glucocorticoid-induced TNF receptor (GITR) [379]. 
However, none of these approaches have yet reached clinical trials in man.  
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1.14 CD11chi cDCs: part of the pathological picture?  
Despite huge advances in our knowledge of the immunopathological processes 
associated with L. donovani infection, several key questions concerning the 
immunoregulatory mechanisms involved remain. This study aimed to address the 
limited data concerning the role of conventional CD11chi in the pathogenesis of chronic 
VL, in addition to further characterising the regulatory T cell response to infection.  
 
The data presented here reveal that the majority of T cell-derived IL-10 during infection 
is produced by Foxp3-T-bet+ IFNγ -producing effector cells. cDC subsets acquire an 
immunoregulatory cytokine profile during chronic infection, characterised by 
production of IL-10 and IL-27. This cytokine profile establishes an auto-regulatory 
cascade within the CD11chi cDC population, associated with marked suppression of IL-
12p70 production as a result of autocrine IL-10 signalling and a concomitant limitation 
in the capacity for Th1 polarisation by these cells. Furthermore, conditional ablation and 
adoptive transfer in vivo revealed a critical role for CD11chi cDCs in the generation of 
IL-10+ effector T cells and for the first time indicated the considerable pathological role 
played by cDCs in the maintenance of chronic disease.  This serves to highlight the 
functional plasticity of CD11chi cDCs in the context of chronic inflammation and gives 
a greater insight into the immunopathological mechanisms underlying this neglected 
tropical disease.  
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Figure 1.1 Selected stages in the developmental pathway of steady state cDC 
subsets and inflammatory DCs 
Common lymphoid and myeloid progenitors (CLPs & CMPs) develop in the bone 
marrow from hematopoietic stem cells. CMPs give rise to a common macrophage-DC 
progenitor (MDP) which develops into monocytes, macrophages and a common 
dendritic cell progenitor (CDP). This ‘pro-DC’ gives rise to pDCs, as well as cDCs, via 
immediate cDC precursors (pre-cDCs). Pre-cDCs traffic through blood to lymphoid 
tissue where they generate mature cDCs. Distinct cDC subsets arise from distinct pre-
cDCs, segregated based on CD24 expression. Under inflammatory conditions, Ly6C+ 
monocytes can enter inflamed tissue and develop into cells with many DC 
characteristics, including Tip-DCs and iDCs. The unclear relationship between iDCs, 
Tip-DCs and CD8α- cDCs in inflammatory conditions is highlighted. Adapted from 
[380-382]; original literature cited in text.  
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Chapter 2: Materials and Methods 
 
2.1 Mice 
C57BL/6, B6J.CD45.1 and OTII.Rag2-/- mice were obtained from the Biological 
Services Facility (University of York) or supplied by Charles River Laboratories. 
B6.Irf7-/- mice were originally obtained from the RIKEN BioResource Centre (Ibaraki, 
Japan) with permission of T. Taniguchi, University of Tokyo. B6.Il10-/- mice were 
kindly provided by Marika Kullberg (University of York).  
 
C57BL/6J-Tg (Itgax-cre,-EGFP) 4097Ach/J (CD11c-cre) mice were obtained from The 
Jackson Laboratory (Bar Harbor, Maine, USA), stock number 007567 
(http://jaxmice.jax.org/strain/007567.html). C57BL/6-Gt(ROSA)26Sortm1(HBEGF)Awai/J  
(ROSA26-STOP-DTR) mice, bearing a simian Diptheria Toxin Receptor under control 
of the ROSA26 locus with an upstream  loxP-flanked STOP sequence, were obtained 
from The Jackson Laboratory, stock number 007900 
(http://jaxmice.jax.org/strain/007900.html). Hemizygous CD11c-cre mice were bred 
with homozygous ROSA26-STOP-DTR mice and genotyped for expression of Cre and 
eGFP. Genotype positive mice were designated as CD11c.iDTR.  
 
All mice were used between 6 and 12 weeks of age and maintained under specified 
pathogen free conditions at the University of York. All animal care and experimental 
procedures were carried out in accordance with United Kingdom Home Office 
requirements and performed with local ethical approval. 
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2.2 Infections 
Parasites of the Ethiopian strain of Leishmania donovani (LV9) were maintained by 
serial passage through Rag1/2-/- mice. Amastigotes were isolated from mechanically 
dissociated spleens of mice at 3-6 months post infection. Spleen tissue was disrupted in 
a glass homogeniser containing RPMI-1640 (Sigma, Falkirk, UK). The resulting 
suspension was centrifuged at 800rpm for 5 minutes and the supernatant retained. 
Erythrocytes were removed by saponin lysis (Sigma-Aldrich, 0.5mg/ml supernatant) for 
5 minutes at room temperature. Parasites were washed three times in RPMI-1640 by 
centrifugation at 3100rpm for 10 minutes. The resulting pellet was resuspended in 
RPMI-1640 and amastigotes were counted on a Thoma counting chamber (Hawksley, 
Sussex, UK). 
 
Mice were infected via the lateral tail vein with 3x107 LV9 amastigotes suspended in 
200µl RPMI-1640. Where indicated, acute infection with a high dose (4.5x107) of 
parasites was performed. The course of visceral infection was determined by measuring 
organ mass relative to total body weight (hepatosplenomegaly) and examining methanol 
fixed, Geimsa-stained (30 minutes stain) imprints of cut sections of the spleen and liver 
of infected mice. Parasite burdens in organs were quantified as Leishman-Donovan 
Units (LDU) using the formula: LDU = (number of amastigotes/1000 host cell nuclei) x 
organ weight (in mg). 
 
Where indicated, parasite load in splenic tissue was determined by flow cytometry. 
200µl aliquots of a single cell suspension of splenocytes isolated from infected mice 
were plated in triplicate in a 96 well v-bottomed plate. Samples were spiked with 5x104 
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2µM fluorescent microspheres and centrifuged for 5 mins at 3100rpm. Samples were 
resuspended in 200µl RPMI containing 2mg/ml saponin and centrifuged as before. This 
was repeated twice. Samples were washed twice in PBS, before being incubated for 20 
mins with RPMI containing 2ng/ml CFSE. Samples were washed twice in PBS and 
fixed in 1% Paraformaldehyde solution, before being acquired on a CyAn flow 
cytometer (Beckman Coulter).   
 
2.3 Splenic IFNγ  production during chronic infection 
Naïve mice or mice at days 7, 14, 21, 28 and 56 of infection with L. donovani were 
killed by cervical dislocation. Spleens were isolated and a single cell suspension 
generated in RPMI-1640 supplemented with 2mM 2-mercaptoethanol (Sigma Aldrich), 
2mM L-glutamine, 100U/ml penicillin and 100µg/ml streptomycin, (all from Gibco, 
UK) plus 10% Foetal calf serum (Hyclone, ThermoScientific, USA; Referred to 
subsequently as Complete RPMI). 10x106 splenocytes were cultured for 72 hours in the 
presence of 1µg/ml purified hamster anti-mouse CD3ε (500A2, BD Pharmingen, San 
Diego, CA, USA) or 2x106 fixed L. donovani amastigotes (generated in house). 
Supernatants were harvested and an IFNγ-specific sandwich ELISA (eBioscience, San 
Diego, California, USA) was performed according to manufacturer’s instructions. 
ELISA plates were washed using an automated SkanWasher plate washer (Molecular 
Devices, CA, USA) using PBS + 0.05% TWEEN20 (Sigma) as wash buffer. Data was 
acquired on a VersaMax plate reader (Molecular Devices) and quantified using SoftMax 
Pro software (Molecular Devices).  
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2.4 Splenic T cell cytokine and transcription factor expression 
Naïve or day 28 infected mice were killed by cervical dislocation.  Spleens were 
isolated and a single cell suspension generated in Complete RPMI. After erythrocyte 
lysis using Gey’s solution, cells were washed twice in RPMI by centrifugation at 
1200rpm for 5 minutes and 5-10x106 cells were placed in a 96 well plate (Corning 
Costar). Cells were restimulated for 90-120 minutes at 37oC, 5% CO2 with 10ng/ml 
PMA and 1µg/ml Ionomycin before the addition of 1µg/ml Brefeldin A (all from 
Sigma-Aldrich, UK) for the final 4-4.5 hours of culture.  
 
After restimulation, cells were washed once in RPMI-1640 and twice in Phosphate-
buffered saline (PBS) supplemented with 5% FCS and 5% 50mM EDTA (MACS 
buffer). Cell suspensions were labelled for 30 minutes on ice in 100µl total volume of 
MACS containing combinations of the following monoclonal antibodies: CD3ε-PE-Cy7 
(145-2C11), CD4-FITC (RM4-5), CD127-PE (A7R34), all from eBioscience, CD3ε-
PE-Cy7 (Biolegend, San Diego, USA), CD4-PerCP (RM4-5) and CD8α-PerCP (53-6.7, 
BD Pharmingen). Cells were washed twice in MACS buffer and fixed for 15 minutes on 
ice in 2% paraformaldehyde (PFA) solution. Where indicated, 1/1000 Fixable Viability 
Dye eFluor780 (eBioscience) was added after fixation. After washing in MACS buffer, 
cells were permeabilised by washing twice in PBS + 1% Saponin + 1% bovine serum 
albumin (Sigma) (PERM buffer). Cells were subsequently labelled for 45 minutes on 
ice in 100µl total volume of PERM buffer containing combinations of the following 
monoclonal antibodies or appropriate isotype controls: IFNγ-PacificBlue (XMG1.2), 
IFNγ-eFluor450 (XMG1.2), IL-10-APC (JES5-16E3),  T-bet AlexaFluor647 (ebio4BIO), 
Foxp3-FITC (FJK-16a) all from eBioscience, IFNγ-APC (XMG1.2), IL-10-PE (JES5-
16E3) from BD Pharmingen.  
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After staining period, cells were washed twice with PERM buffer and once with MACS 
buffer before resuspending in 200µl MACS buffer and acquiring data on a CyAN-ADP 
flow cytometer (Beckman Coulter, USA). Subsequent analysis was carried out using 
SummitTM Software (Beckman Coulter).  
 
2.5 Generation of bone-marrow derived dendritic cells (BMDCs) 
Femurs were removed from C57BL/6, B6.Irf7-/- or B6J.CD45.1 mice and bone marrow 
isolated. Cells were washed twice, erythrocytes lysed and resuspended at 1x106 cells/ml 
in Dulbecco’s Modified Eagle Medium (DMEM, Gibco) supplemented with 2mM L-
glutamine, 100U/ml penicillin and 100µg/ml streptomycin (all from Gibco, Paisley, 
UK) plus 10% Foetal calf serum (HyClone) (Referred to subsequently as Complete 
DMEM). Recombinant murine Granulocyte-Monocyte Colony Stimulating Factor 
(rmGM-CSF, PeproTech, London, UK) was added to a final concentration of 10ng/ml.  
 
Cells were cultured in T75 tissue culture flasks for 72 hours, when media and non-
adherent cells were removed, spun down, resuspended in complete DMEM + 10ng/ml 
rmGM-CSF and cultured for a further 96 hours. Cultures routinely contained 85-95% 
CD11c+ cells. 
 
2.6 Antigen-specific T cell restimulation  
BMDCs were generated from femurs of C57BL/6 mice as described above. On day 7 of 
culture, cells were counted and pulsed for 24 hrs with paraformaldehyde-fixed 
Leishmania donovani amastigotes at a ratio of 100 amastigotes to 1 BMDC. Antigen-
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pulsed BMDCs were subsequently used to restimulate T cells for 3 hours, prior to 
addition of Brefeldin A for 4 hours and subsequent assessment of CD4+ T cell cytokine 
production by intracellular flow cytometric analysis, as previously described. 
 
2.7 Dendritic cell costimulatory molecule expression  
Spleens were isolated from naïve and infected mice as previously described. Tissue was 
dissociated mechanically using a scalpel and digested in 10ml/spleen of RPMI-1640 
supplemented with 0.2mg/ml collagenase type IV / DNAse1 mix (Worthington 
Biochemical, NJ, USA) for 30 minutes at room temperature. 200µl of 50mM EDTA 
was added to each sample which was subsequently passed through a 100µm cell strainer 
(BD Bioscience) with MACS buffer to generate a single cell suspension. After 
erythrocyte lysis with Gey’s solution, cells were washed twice and labelled for 30 
minutes on ice in 100µl total volume of MACS containing combinations of the 
following monoclonal antibodies or appropriate isotype controls: CD11c-PE-Cy7 
(N418), Major Histocompatibility complex class II (MHCII)-APC (M5/114.15.2), 
MHCII-eFluor450 (M5/114.15.2), CD8α-FITC (53-6.7), CD4-APC (RM4-5), CD40-PE 
(1C10), CD80-FITC (16-10A1), CD86-APC (GL1), B7-H1-PE (MIH5), TLR2-PE 
(6C2), CD70-PE (FR70), CD11b-eFluor450 (MI/70), CD103-FITC (2E7) all from 
eBioscience, I-Ad/I-Ed-PE (2G9), Ly-6C-FITC (AL-21) and CD4-PerCP (RM4-5) from 
BD Pharmingen. After labelling, cells were washed twice in MACS buffer and 
resuspended in 200µl 2% PFA for subsequent data acquisition and analysis by flow 
cytometry.  
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2.8 Dendritic cell subset isolation and sorting 
Spleens were isolated from naïve or chronically infected mice and collagenase digested 
as above. After digestion a single cell suspension was generated, erythrocytes were 
lysed and cells washed twice in MACS buffer. Dead and highly phagocytic cells were 
removed by incubating splenocytes for 5 minutes at room temperature with 
unconjugated basic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany), 
followed by washing and passing the cell suspension over an LS column (Miltenyi 
Biotec) held in a strong magnetic field (Miltenyi Biotec). The flow-through from the 
column, depleted of dead and highly phagocytic cells, was washed and incubated with 
microbeads conjugated to an anti-CD11c (N418) antibody (Miltenyi Biotec) for 30 
minutes on ice. After washing in MACS buffer, the cell suspension was passed over an 
LS column in a magnetic field. CD11c+ DC were retained on the column and eluted and 
washed in 5ml MACS buffer. The CD11c enriched splenocytes were subsequently 
labelled for 45 minutes on ice in 500µl total volume of MACS containing the following 
monoclonal antibodies: CD11c-PE-Cy7 (N418), DX5-PE (DX5), CD4-APC (RM4-5) 
and CD8α-FITC (53-6.7), all from eBioscience. After staining, cells were washed twice 
and resuspended in 1.5-2ml of MACS buffer. Cells were sorted to high purity on a 
MoFlo cell sorter (Beckman Coulter) based upon expression of CD11c and one of either 
CD4 or CD8α. Double negative (DN) cDCs were sorted based on a lack of CD4 or 
CD8α expression. Sorted cDC subsets were routinely 98-99% pure.  
 
2.9 cDC subset cytokine profiling by quantitative RT-PCR 
cDC subsets were sorted from spleens of individual naïve and chronically infected mice 
as previously described. Cells were kept on ice throughout sorting and subsequent 
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washing, resuspended in 350µl RLT lysis buffer (Qiagen, California, USA) containing 
1% β-Mercaptoethanol (Sigma-Aldrich) and frozen at -80oC until required.  
 
Lysed cells were defrosted and total RNA was extracted using an RNAeasy spin column 
kit (Qiagen), according to the manufacturer’s instructions. RNA purity was assessed 
using NANOdrop technology (Thermo Scientific, Wilmington, USA) and frozen until 
required, or used immediately for cDNA conversion.  
 
cDNA was synthesised using the SuperScript III reverse transcriptase system 
(Invitrogen). The manufacturer’s protocol was slightly modified as the RNA 
concentration from small numbers of sorted cells was very low. 8µl of RNA was added 
to 1µl of 50µM oligo(dT)20 and 1µl of 10mM dNTP mix to give a total volume of 10µl. 
After incubation at 65ºC for 5 min, this mixture was placed on ice. A cDNA synthesis 
master mix containing 10x RT Buffer, 50mM MgCl2, 0.1M DTT, RNaseOUT (40U/µl) 
and SuperScriptTM III RT (200U/µl) was prepared.  10µl of this cDNA synthesis mix 
was added to 10µl of the RNA/Oligo(dT)20 mixture, mixed gently and centrifuged 
briefly at 10,000rpm for ~5 sec. This cDNA synthesis reaction mixture was incubated at 
50ºC for 50 min. The reaction was terminated by incubating at 85ºC for 5 min and then 
chilling on ice. Reaction mixtures were centrifuged briefly and 1µl of RNase H was 
added and incubated for 20 min at 37ºC. Resulting cDNA was stored at -20ºC or used 
immediately for qRT-PCR 
 
Real-time quantitative PCR was performed with the SYBR green PCR kit in an ABI 
Prism 7000 sequence detection system (Applied Biosystems) according to the 
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manufacturer's instructions. Reaction mixtures contained 12.5µl of SYBR Green, 8.5µl 
of dH2O, 1µl of forward primer (1µM) and 1µl of reverse primer (1µM) and were 
combined with 2µl target cDNA to a final volume of 25µl in a MicroAmp Optical 
reaction plate. Reactions were performed under the following conditions: 50ºC for 2 
min,  95ºC for 10 min, followed by 40 cycles of; 95ºC for 15 seconds, 62ºC for 30 sec  
and 72ºC for 30 sec, followed by 72ºC for 5 min and a final cooling to 4ºC to terminate 
the reaction. Expression of target genes was normalized to HPRT and expressed as fold 
change in expression using the change in cycle threshold ( CT) analysis method. The 
relative expression of the target mRNA in cDC subsets isolated from chronically 
infected mice was directly compared to the same subset isolated from naïve mice. 
Primer sequences for target genes are indicated (2.28).  
 
2.10 cDC cytokine production determined by ELISA 
Total cDC populations or cDC subsets were sorted from spleens of individual naïve and 
chronically infected mice of various strains, as previously described. After sorting cells 
were washed, counted and plated in triplicate in complete RPMI at 1x106 cells/ml 
(5x104 cDCs per 50µl media per well). Where indicated, LPS (1µg/ml) (Sigma 
Aldrich), anti-mouse IL-27p28 (10µg/ml), Goat IgG (10µg/ml) (both from R&D 
Systems) or anti-mouse IL-10R (1.3µg/ml) (Marika Kullberg) were added to the cDC 
cultures. After 24 hours, supernatants were harvested and stored at -80oC until required. 
Sandwich ELISAs specific for IL-10 and IL-12p40 (Mabtech, Stockholm, Sweden) and 
Quantikine ELISA kits specific for IL-27p28 and IL-12p70 (R&D Systems) were 
subsequently carried out on cDC culture supernatants, according to manufacturer’s 
instructions. ELISA plates were washed using an automated SkanWasher plate washer 
(Molecular Devices, CA, USA) using PBS + 0.05% TWEEN20 (Sigma) as wash buffer. 
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Data was acquired on a VersaMax plate reader (Molecular Devices) and quantified 
using SoftMax Pro software (Molecular Devices)  
 
2.11 Sorting of naïve OTII.Rag2-/- T cells 
OTII.Rag2-/- mice were killed by cervical dislocation and spleens and LN were isolated. 
A single cell suspension was generated, erythrocytes were lysed and cells resuspended 
in 200µl-500µl total volume of MACS buffer. Cells were labelled for 30 minutes on ice 
with the following monoclonal antibodies: CD44-APC (IM7), TCRβ-FITC (H57-597) 
and CD62L-PE (MEL-14), all from eBioscience. After staining, cells were washed 
twice and resuspended in 1-2ml MACS buffer. Naïve T cells were sorted on a MoFlo 
high-speed cell sorter (Beckman Coulter) based on a TCRβ+ CD44lo CD62Lhi cell 
population. Sorted cells were routinely 98-99% pure.  
 
2.12 CFSE labelling of naïve T cells  
Sorted naïve OTII T cells were washed twice in plain RPMI. Cells were resuspended in 
1ml of warmed (37oC) plain RPMI, followed by addition of 9ml CFSE-containing 
RPMI to a final concentration of 3µM CFSE. Cells were rested at 37oC in a water bath 
for exactly 5 minutes. After labelling, cells were washed 3 times with cold complete 
RPMI containing 20% FCS to remove excess CFSE.  After washing, cells were 
resuspended for culture in RPMI containing 10% FCS, 2mM L-glutamine, 100U/ml 
penicillin, 100µg/ml streptomycin and 5µl/ml Gentamycin (Sigma). 
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2.13 cDC subset priming of OTII.Rag2-/- T cells in vitro 
cDC subsets and naïve OVA-specific CD4+ T cells were sorted as described. 5x104 cells 
of each cDC subset were cultured with 1x105 CFSE labelled naïve T cells for 5 days in 
the presence of 5nM of the OTII CD4+ T cell epitope, OVA(323-339). After 5 days of 
culture, cells were restimulated with PMA & Ionomycin and cytokine production 
assessed by intracellular cytokine staining and flow cytometric analysis, as described 
earlier. Where indicated, LPS (Sigma-Aldrich) was added to co-cultures to a final 
concentration of 1µg/ml. 
 
2.14 Effects of cytokine supplementation or blockade on cDC subset priming of 
OTII.Rag2-/- T cells in vitro 
Where indicated, cDC subset and OTII co-cultures were supplemented with the 
following exogenous cytokines and cytokine-neutralising antibodies at the indicated 
final concentrations; 3ng/ml recombinant murine IL-12, 20ng/ml recombinant murine 
IL-27, 10µg/ml goat anti-mouse IL-27p28, 10µg/ml normal goat IgG Isotype control 
(all from R&D Systems), 1.3 µg/ml anti-mouse IL-10R (a gift from Marika Kullberg). 
After 5 days, cultures were restimulated and OTII T cells assessed for intracellular 
cytokine production as previously described.  
 
2.15 In vitro polarisation of OTII.Rag2-/- T cells by cDCs from C57BL/6 and  
B6.Il10-/- mice 
CD11chiMHCIIhi cDCs were sorted from spleens of naïve C57BL/6 and B6.Il10-/- mice, 
using CD11c-PE (N418) and MHCII-APC (M5/114.15.2) monoclonal antibodies, and 
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the method previously described. Naïve OTII.Rag2-/- T cells were sorted and cultured at 
a 5:1 ratio in complete RPMI with sorted cDCs from both strains. Where indicated, 
3ng/ml recombinant murine IL-12, 20ng/ml recombinant murine IL-27 or both were 
added to co-cultures. After 5 days, T cells were restimulated with PMA, Ionomycin & 
Brefeldin A and assessed by flow cytometry for CD4+ OTII cytokine production, as 
previously described.  
 
2.16 Assessment of serum cytokine levels by ELISA 
Peripheral blood was obtained by intra-thoracic cardiac puncture of CO2-asphyxiated 
naïve or infected mice, prior to cervical dislocation. Blood was allowed to clot, on ice, 
for 2-6 hours, before centrifugation at 13000 rpm for 10 minutes to separate fluid-phase 
serum and blood clots. Serum was isolated and frozen at -80oC until required. Cytokine 
levels in serum were determined by ELISA using Quantikine kits specific for IL-10, IL-
12p70 and IL-27p28 (R&D Systems).  
 
2.17 IL-27p28 production by cDCs from naïve C57BL/6 and B6.Irf7-/- mice in vitro.  
CD11chiMHCIIhi cDCs were sorted from naïve C57BL/6 and B6.Irf7-/- mice as 
previously described. cDCs were plated at 1x106 cells/ml and cultured for 24 hours in 
complete DMEM. Where indicated, LPS (Sigma-Aldrich) and IFNα (PBL Interferon 
Source, Piscataway, USA) were added to give final concentrations of 1µg/ml and 
1000U/ml, respectively. After culture, supernatants were assessed by ELISA for the 
presence of IL-27p28 using a Quantikine kit (R&D Systems).  
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2.18 Conditional ablation of CD11c+ cells in CD11c.iDTR mice 
Naïve or infected CD11c.iDTR mice received 4ng/g Diphtheria toxin from 
Corynebacterium diptheriae (DTx, Sigma-Aldrich) in 200µl PBS, or PBS alone, 
intraperitoneally at days 21, 23, 25 and 27 of infection. Effects of DTx treatment on 
spleen cell composition were determined on isolated splenocytes at day 28 by staining 
for 30 minutes on ice with combinations of the following monoclonal antibodies; 
CD11c-PE-Cy7, MHCII-eFluor450, CD8α-FITC, CD4-APC, CD45R-AlexaFluor647 
(RA3-6B2), NK1.1-PE (PK136), CD11b-eFluor450, Gr-1-PE (RB6-8C5), all from 
eBioscience and CD3ε-PE-Cy7 (17A2, Biolegend) and assessing frequencies of 
indicated cell types by flow cytometry.  
 
2.19 Staining of spleen cryosections for confocal analysis 
Spleen tissue (~5mm3 blocks) was isolated and embedded in Tissue-Tek OCT mounting 
medium (Sakura Finetek Europe, Netherlands) in Tissue-Tek Cryomolds (Sakura 
Finetek) and immediately snap frozen on solid CO2. Samples were subsequently stored 
at -80oC until required. 10µm thick sections of frozen tissue were cut on a CRYOSTAT 
(Leica Microsystems GmbH, Wetzlar, Germany) and adhered to poly-L-lysine coated 
slides (Thermo Scientific) and air dried before fixation in acetone for 5 minutes at room 
temperature. Slides were washed in buffer (PBS + 0.05% BSA; PAA Laboratories, 
Paris, France), before 30 minutes blocking at room temperature with PBS + 0.05% BSA 
+ 5% Goat serum. Sections were delineated with an ImmEdge pen (Vector 
Laboratories, CA, USA) and blocked with an avidin / biotin block kit (Invitrogen) for 
15 mins with each reagent, according to the manufacturer’s instructions.  
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Slides were washed and combinations of the following monoclonal antibodies were 
added in ~50µl buffer containing 5% goat serum per section; CD169-FITC (3D6.112, 
AbD Serotec, Kidlington, UK), CD3ε-Biotin (eBio500A2), B220-647 (RA3-6B2), 
F4/80-AlexaFluor647 (BM8), MHCII-Biotin (M5/214.1), all from eBioscience, or 
appropriate isotype controls. Slides were labelled for 45 minutes at room temperature, 
washed three times and were labelled with 1/200 Streptavidin-AlexaFluor546 in buffer 
containing 5% goat serum for 30 minutes at room temperature. Slides were washed in 
PBS and counterstained for 5 minutes at room temperature with DAPI diluted to 1µg/ml 
in PBS. Slides were washed twice and had ~40µl ProlongGold (Invitrogen) applied to 
allow mounting of coverslips (ThermoScientific). Slides were allowed to cure overnight 
at 4oC, protected from light, before edges of coverslips were sealed with nail varnish. 
Slides were kept at 4oC and protected from light until assessment by confocal 
microscopy.  
 
2.20 Assessment of nitric oxide production by adherent splenocytes  
Splenocytes from naïve and infected PBS or DTx-treated mice were plated in complete 
RPMI at 5x106 cells/ ml for 60 minutes at 37oC. After incubation, wells were vigorously 
washed using plain RPMI to remove non-adherent cells. 1ml of complete DMEM was 
then added to wells and cells cultured for 24 hours at 37oC. After culture, supernatant 
was frozen and stored at -80oC. Nitric oxide levels in supernatant were determined 
using a Greiss Reagent System (Promega, Madison, WI, USA), according to 
manufacturer’s instructions.  
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2.21 In vivo neutrophil depletion  
Naïve or infected C57BL/6 or infected CD11c.iDTR mice were treated with 250µg 1A8 
(anti-Ly6G- BioXcell, USA) or 2A3 (isotype control) antibodies by i.p injection at days 
21, 23 and 25 post-infection. Neutrophil depletion was determined by assessing the 
frequency of cells expressing CD11b, Gr-1 and Ly6C in isolated splenocytes by flow 
cytometry.  
 
2.22 Adoptive transfer of CD11c+ cells into DC-depleted mice 
Infected CD11c.iDTR mice were treated at day 21 post-infection with 4ng/g DTx i.p. 
Approximately 12 hours later, groups of four mice each received 1.5x105 
CD11chiMHCIIhi cells, 6.0x105 CD11cintMHCII+ cells, or a mixture of both, sorted from 
spleens of day 21-infected, congenic wildtype B6J.CD45.1 mice. Mice were 
subsequently depleted of endogenous DTx sensitive DCs at days 23, 25 and 27, as 
previously described. At day 28, mice were killed and disease parameters measured as 
previously described. 
 
2.23 Phenotypic analysis of B6.Irf7-/- mice by flow cytometry 
C57BL/6 and B6.Irf7-/- mice were killed and spleens isolated. A single cell suspension 
was generated and red blood cells lysed with Gey’s solution. Splenocytes were washed 
and labelled on ice for 30 minutes with combinations of the following monoclonal 
antibodies; CD11c-PE-Cy7, MHCII-eFluor450, CD8α-FITC, CD4-APC, TLR2-PE, 
CD3ε-PE-Cy7, CD4-FITC, CD8α-PerCP, MHCII-eFluor450, CD19-PE, CD11b-
eFluor450 and Gr-1-PE, all from eBioscience, and assessed by flow cytometry as 
previously described.  
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2.24 Activation of splenic cDCs by TLR agonists in vitro 
CD11chi dendritic cells were sorted from spleens of C57BL/6, B6J.CD45.1 and B6.Irf7-
/- mice as described previously. Cells were cultured at 5x104 cells/well in 50 µl 
complete RPMI for 24 hours. As indicated, DC were stimulated with 1µg/ml LPS, 
10µg/ml PAM3CSK4 (Invivogen, San Diego, USA), 100µg/ml Poly (I:C) (Sigma-
Aldrich, St. Louis, USA) or 10µg/ml ODN:1668 (Invivogen). Where indicated, 
1000U/ml IFNα (PBL Interferon Source, Piscataway, USA) was added to the culture at 
0hr. In some experiments, B6.Irf7-/- splenic cDCs were cultured at a 1:1 ratio with sorted 
congenic wildtype B6J.CD45.1 splenic cDCs. At indicated time points post-stimulation, 
cells were labelled with monoclonal antibodies specific for CD11c, MHCII, CD40, 
CD80 and CD86 and assessed by flow cytometry for changes in surface expression of 
MHCII, CD40, CD80 and CD86, compared to unstimulated cDCs.  
 
2.25 Generation of C57BL/6 and B6.Irf7-/- microchimeric mice 
B6J.CD45.1 mice were injected intraperitoneally with Busulfan (Pierre Fabre 
Pharmaceuticals, France) in 250µl sterile 0.9% saline (Baxter, Norfolk, UK) at a dose of 
20mg/kg and allowed to rest for 24 hours. For bone marrow transplantation (BMT), 
femurs were removed from C57BL/6 or B6.Irf7-/- mice and bone marrow flushed out 
using a 10ml syringe, 23 gauge needle and 5ml complete RPMI. Cells were washed 
twice, erythrocytes lysed and cells counted. Between 2x106 and 8x106 bone marrow 
cells from C57BL/6 or B6.Irf7-/- mice were transferred via the lateral tail vein to 
Busulfan-treated mice and allowed to engraft over a period of 7-14 days before use.  
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2.26 Dendritic cell activation by TLR agonists in vivo 
C57BL/6, B6.Irf7-/-, microchimeric C57BL/6 è B6JCD45.1 and microchimeric 
B6.Irf7-/- è B6JCD45.1 mice were injected i.v. with 5µg/mouse LPS (Sigma-Aldrich) 
or 5µg/mouse PAM3CSK4  (Invivogen, San Diego, USA) in 200µl PBS or 200µl PBS 
alone. After 24 hours, mice were killed, spleens isolated and prepared for cDC staining 
as previously described. Splenocytes isolated from individual mice were labelled with 
combinations of the following monoclonal antibodies; CD11c-PE, CD11c-FITC, 
CD45.1-PE-Cy7, MHCII-eFlour450, CD40-PE, CD86-APC, all from eBioscience and 
CD80-FITC (BD Pharmingen) and analysed by flow cytometry for changes in 
costimulatory molecule expression.  
 
2.27 Statistical analysis 
Statistical analysis was performed using a student’s T test with the exception of Fig 4.12 
where a one-way ANOVA was used. In all cases, p<0.05 was considered significant.  
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2.28 Oligonucleotide sequences for qRT-PCR 
HPRT 
Forward: 5’-GTTGGATACAGGCCAGACTTTGTTG-3’ 
Reverse: 5’-GATTCAACCTTGCGCTCATCTTAGGC-3’ 
IL-10 
Forward: 5’-AGGGTTACTTGGGTTGCCAA-3’ 
Reverse: 5’-CACAGGGGAGAAATCGATGA-3’ 
IL-12(p40) 
Forward: 5’- CATCAAGAGCAGTAGCAGTTCC-3’ 
Reverse: 5’- GAATACTTCTCATAGTCCCTTTGG-3’ 
IL-27(p28) 
Forward: 5’-GGCCATGAGGCTGGATCTC-3’ 
Reverse: 5’- AACATTTGAATCCTGCAGCCA-3’ 
IDO 
Forward: 5’-CGGACTGAGAGGACACAGGTTAC-3’ 
Reverse: 5’-ACACATACGCCATGGTGATGTAC-3’ 
TGFβ 
Forward: 5’ –GCGTGCTAATGGTGGAAAC-3’ 
Reverse: 5’ –CGGTGACATCAAAAGATAACCAC-3’ 
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2.29 Monoclonal antibodies used for flow cytometry 
Manufacturers 
eBioscience, San Diego, CA, USA 
BD Pharmingen, San Diego, CA, USA 
AbD Serotec, Kidlington, Oxon, UK 
Biolegend, San Diego, CA, USA 
 
Dendritic cells 
CD11c-PE-Cy7 (N418) and CD11c-PE-Cy7 (N418) 
CD11c-PE (N418) 
CD11c-AlexFluor488 (N418) 
MHCII-APC (M5/114.15.2) 
MHCII-eFluor450 (M5/114.15.2) 
CD8α-FITC (53-6.7) 
CD4-APC (RM4-5) 
CD40-PE (1C10) 
CD80-FITC (16-10A1) 
CD86-APC (GL1) 
B7-H1-PE (MIH5) 
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TLR2-PE (6C2) 
CD70-PE (FR70) 
CD11b-eFluor450 (MI/70) 
CD103-FITC (2E7)  
CD45.1-PE-Cy7 (A20) 
I-Ad/I-Ed-PE (2G9) 
Ly-6C-FITC (AL-21) 
 
T cells 
CD3ε-PE-Cy7 (17A2) and 1/400 CD3ε-PE-Cy7 (145-2C11) 
CD4-FITC (RM4-5) 
CD127-PE (A7R34) 
CD4-PerCP (RM4-5) 
CD8α-PerCP (53-6.7) 
IFNγ-PacificBlue (XMG1.2) 
IFNγ-eFluor450(XMG1.2) 
IL-10-APC (JES5-16E3) 
T-bet AlexaFluor647 (ebio4BIO) 
Foxp3-FITC (FJK-16a) 
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IFNγ-APC (XMG1.2) 
IL-10-PE (JES5-16E3)  
CD44-APC (IM7)  
TCR-β-FITC (H57-597) 
CD62L-PE (MEL-14) 
 
Other cells 
Gr-1-PE (RB6-8C5) 
NK1.1-PE (PK136) 
CD45R-AlexaFluor647 (RA3-6B2) 
CD19-PE (1D3) 
 
Tissue staining 
CD169-FITC (3D6.112) 
CD3ε-Biotin (eBio500A2) 
CD45R-AlexaFluor647 (RA3-6B2) 
F4/80-AlexFluor647 (BM8) 
MHCII-Biotin (M5/114.15.2) 
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Chapter 3: Immunoregulatory mechanisms during chronic Leishmania 
donovani infection 
3.1 Introduction  
Immune suppression has a long association with both experimental and human visceral 
leishmaniasis. Studies as early as 1985 revealed that T lymphocytes in chronically 
infected hamster spleen failed to proliferate in response to antigen or T cell mitogens 
and proposed  the existence of a lymphocyte population acting in a suppressive fashion 
during infection [383]. This was complemented by studies showing the direct 
suppression of T cell responses by adherent spleen cells from susceptible mouse strains 
during chronic  Leishmania donovani infection [384]. Accumulation of Il10 mRNA in 
CD4+ T cells from L. major infected BALB/c mice gave the first indication that 
Leishmania infection may be associated with this prototypical immunoregulatory 
cytokine [385], followed by the observation that IL-10 expression correlated with 
pathology in patients with L. donovani infection [386] and was reduced after successful 
treatment [387] .  
 
Evidence for the central role played by IL-10 in murine L. donovani disease progression 
came from observations that Il10-/- mice were highly resistant to infection [388] and that 
therapeutic blockade of IL-10 signalling with an IL-10 receptor-specific monoclonal 
antibody during infection significantly enhanced parasite clearance and allowed for a 
‘near cure’ under some conditions [389]. Recent advances in T cell phenotyping have 
revealed T cell populations distinct from conventional regulatory T cells as major 
producers of IL-10 in both murine and human infection with L. donovani [390, 391], 
with murine NK cells [392], CD11cloCD45RB+ DCs [172], human 
monocyte/macrophages [393] and in vitro- derived dendritic cells [394] also producing 
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IL-10 due to L. donovani infection in vivo or in vitro. Alongside enhanced IL-10 
production, impaired secretion of the Th1-promoting cytokine IL-12 by macrophages 
and DCs has also been reported as a result of L. major and L. donovani infection [108, 
395], indicating the broad impact of these parasites on immune cell cytokine 
production. The exact phenotype and origin of the IL-10-producing CD4+ T cells which 
emerge during L. donovani infection remain to be elucidated, and it is currently unclear 
as to whether conventional CD11chi DCs also acquire an IL-10 producing phenotype as 
a result of infection. 
 
Despite being instrumental in shaping the resultant immune response to infection, 
defining the cytokine milieu in isolation is insufficient to fully describe any potential 
defects in the initiation of a polarised response to a pathogen. In addition to modulation 
of antigen presentation (cf. Chapter 1), alterations in costimulatory molecule expression 
and the spatiotemporal access of APC’s to T cells bearing a cognate TCR also impact 
heavily on the functional outcome of the early adaptive immune response. Infection 
with several Leishmania spp has been shown to modulate these key properties. 
 
Alongside presentation of peptide-MHC complexes to T cells bearing a specific cognate 
TCR, costimulatory molecule expression plays a crucial role in delivering signals 
required for the optimal induction of an effector T cell response. Impaired expression of 
the costimulatory molecules CD40, CD80 and heat-stable protein (CD24, [396]) on 
macrophages during murine L. donovani infection has been reported [397, 398], a 
phenomenon also seen during infection of human monocytes and macrophages with L. 
chagasi in vitro [399]. Infection of murine DCs with L. amazonensis amastigotes 
induces limited surface expression of CD40 when compared to that induced by its 
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promastigote form [400], a process recently shown to be mediated by the MAP kinase 
ERK [401]. CD86 appears to be affected differently by infection, with L. amazonensis 
infected human DCs having reduced expression of CD80 but enhanced expression of 
CD86 [402]. BMDCs encountering L. braziliensis had intact upregulation of CD86, but 
a limited increase in surface CD80. However, when cells which have efficiently 
internalised parasites were assessed in isolation, no increase in costimulatory molecule 
expression was detectable [403]. Enhanced CD86 expression on splenic cDCs as well as 
CD86 dependent activation of CD8+ T cells has been reported early during in vivo 
infection with L. donovani [404, 405], suggesting that infection with Leishmania spp 
does elicit a partial activation of DC under some conditions. However the CD86 - CD28 
axis has been suggested to be redundant in the early stages of T cell activation in 
response to infection [377] as well as CD86 blockade being shown to result in enhanced 
clearance of L major [406]; therefore suggesting a neutral or negative correlation 
between the expression of this costimulatory molecule and effective T cell activation. 
Less is known about expression of costimulatory molecules on DC during the chronic 
stages of infection. 
 
Infection-induced segregation of APC and T cells in lymphoid tissue also provides a 
mechanism by which the initiation of immune response to Leishmania can be inhibited. 
Leishmania major promastigotes inhibited splenic DC motility [407] and the migratory 
capacity of Langerhans’ cells in vitro, in a process mediated by secreted 
phosphoglycans [408]. L. major is also capable of reducing the chemokine receptor 
expression and migratory capacity of BMDCs [409], whilst phosphoglycans of L. 
donovani are known to inhibit detachment of cultured human monocytes in vitro [410]. 
Furthermore, evidence from mice chronically infected with Leishmania donovani 
indicated that TNFα and IL-10-dependent inhibition of CCR7 expression on splenic 
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cDCs impaired their ability to migrate within lymphoid tissue in vivo [313], suggesting 
that Leishmania spp are capable of modulating DC migratory capacity, thus limiting 
their ability to reach crucial areas of lymphoid tissue and initiate optimal T cell 
activation.  
 
Despite some variability in the impact of Leishmania infection upon of macrophage and 
DCs, a picture emerges of impaired or at best sub-optimal functionality with regard to 
cytokine production, costimulatory molecule expression and the correct anatomical 
localisation of APCs during infection. However the majority of the previous dendritic 
cell oriented studies have focussed on in vitro systems, often utilising BMDCs, or have 
been restricted to assessing DC function during the early events of acute infection in 
vivo. The studies described in this chapter therefore aimed to extend the phenotypic 
analysis of IL-10 producing T cells that expand during chronic infection, in addition to 
addressing the paucity of data regarding the impact of chronic L. donovani infection 
upon the phenotype and function of conventional splenic CD11chi dendritic cell subsets 
isolated directly ex vivo.    
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3.2 Results 
3.2.1 Progressive experimental visceral leishmaniasis is associated with impaired 
splenic IFNγ production 
Female C57BL/6 mice were infected with L. donovani amastigotes via the lateral tail 
vein and infection allowed to develop over a period of 56 days. Mice developed 
pronounced splenomegaly from day 21 post infection (p.i.) (3.1A), associated with an 
increasing parasite burden in this tissue, most dramatic between days 21 and 28 p.i. and 
persisting to the end of the experimental infection at day 56 (3.1B). Hepatomegaly was 
also evident in these mice, although alterations were greatest at days 28 and 56 p.i. 
(3.1C). In contrast to the spleen, parasite burden in liver tissue began to be controlled by 
day 28 p.i. and by day 56 p.i. had been reduced to levels similar to that observed during 
the early stages of infection (3.1D). 
 
In order to make an assessment of any systemic effects of infection on the ability of 
spleen cell populations to produce IFNγ, whole splenocytes were stimulated for 72 
hours with a CD3ε-specific monoclonal antibody (αCD3) or killed parasites (LV9) as a 
source of antigen. Splenocytes from naïve mice stimulated with αCD3ε produced 4961 
± 378 pg/ml after 72 hours of culture (3.1E). Infection led to only marginally enhanced 
production of IFNγ at days 7 and 21 p.i. (5014 ± 267 pg/ml and 5490 ± 506 pg/ml, 
respectively). By day 28 p.i., IFNγ production by splenocytes was significantly lower 
than that of naïve animals (3625 ± 32pg/ml; p< 0.01). IFNγ production by splenocytes 
from mice at day 56 of infection was similarly reduced (3045 ± 394pg/ml; p<0.01).  
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To determine whether antigen specific IFNγ production was also altered during the 
course of infection, splenocytes were stimulated with 2x106 paraformaldehyde-fixed 
Leishmania donovani promastigotes. As expected, antigen stimulation of splenocytes 
isolated from naïve animals for 72 hours did not elicit detectable levels of IFNγ 
production (3.1F).  Robust antigen-specific IFNγ production was detected at day 7 and 
14 p.i. (7241 ± 446pg/ml and 6245 ± 1040pg/ml respectively). However,  IFNγ 
production was reduced by 50-60% at days 28 and 56 p.i when compared to splenocytes 
from animals at day 7 p.i. Therefore, infection with Leishmania donovani leads to 
persistent parasitisation of splenic tissue and is associated with impaired antigen-
specific production of IFNγ in the spleen during the chronic stages of infection. 
 
3.2.2 IL-10 producing CD4+ T cells expand in number and frequency during 
chronic Leishmania donovani infection 
Multiple cell types could contribute to the IFNγ response observed above. Therefore to 
more precisely determine the ability of T cells to produce IFNγ and other potentially 
immunoregulatory cytokines, intracellular cytokine staining was performed on 
splenocytes after restimulation in vitro. 
 
Non specific restimulation with PMA and Ionomycin for 2hrs revealed populations of 
splenic CD3+CD4+ T cells capable of producing IFNγ alone, IL-10 alone or IFNγ and 
IL-10 simultaneously in both naïve (upper panel) and day 28 infected (lower panel) 
mice (3.2A). However, infection led to dramatic changes in both the frequency (3.2B) 
and total number (3.2C) of all three splenic T cell populations. T cells capable of solely 
producing IFNγ increased significantly in frequency from 2.4 ± 0.4% in  spleens of 
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naïve mice to 44.4 ± 3.0% (p<0.001) in mice by day 28 of infection, mirrored by an 
increase in the number of CD4+ IFNγ+IL-10- cells (1.5x105 ± 4.8x104 vs 1.2x107 ± 
2.2x106 cells in naïve and infected mice, respectively; p<0.01). CD4+ T cells producing 
only IL-10 represented 0.2 ± 0.02% of CD3ε+CD4+ splenocytes in naïve animals, 
increasing in frequency to 0.5 ± 0.05% of this population in spleens from mice at day 28 
p.i, equating to a 10 fold increase in total CD4+ IFNγ-IL-10+ cells per spleen. Most 
strikingly, infection was accompanied by a 50 fold increase in the frequency (0.1 ± 
0.02% vs 5.0 ± 0.9% in naïve and day 28 infected mice, respectively; p<0.001) and a 
~170 fold expansion in the number of splenic T cells capable of simultaneous 
production of IFNγ and IL-10 (7.6 ± 1.2 x103 vs 1.3x106 ± 1.7x105 in naïve and day 28 
infected mice, respectively; p<0.001).  
 
To assess antigen-specific T cell polarisation during infection, L. donovani-pulsed 
BMDCs were used as a source of APCs for restimulation of T cells ex vivo. Stimulation 
by this method revealed populations of L. donovani-specific T cells with phenotypes 
analogous to those determined previously (3.2D). Again, the frequency (3.2E) and 
number (3.2F) of all three splenic CD3ε+CD4+ T cell populations was significantly 
enhanced due to infection. L. donovani specific, IFNγ producing CD4+ T cells increased 
more than 300-fold in frequency (0.1 ±0.03% to 27.6 ±2.6% in naïve vs day 28 infected 
mice; p<0.001) and their number increased from 2.5 x103 ± 2.7x102 to 6.8x106 ± 
1.1x106 (p<0.001). CDε+CD4+ T cells specific for L. donovani and capable of IL-10 
production alone increased in frequency from 0.2 ±0.04% to 0.5 ±0.11% (p<0.05) and 
in number from 6.6 ± 2.3x103 to 1.2x105 ± 2.5x104 by day 28 of infection (p<0.01).  
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Mirroring the phenotype observed after PMA and Ionomycin restimulation, a 
population of splenic CD3ε+CD4+ T cells capable of the simultaneous production of 
IFNγ and IL-10 expanded significantly in number from 4.3x102 ± 1.1x102 in naïve 
animals to 6.4 ± 1.5x103(p<0.001) cells in spleens isolated from mice at day 28 of 
infection, representing an ~1471 fold increase in the number of antigen specific 
CD4+IFNγ+IL-10+ T cells in the spleen as a result of chronic infection with this parasite.  
 
3.2.3 T-bet+ Th1 cells are the predominant IL-10-producing T cell population 
during chronic infection 
In order to further investigate the phenotype and potential origin of the CD4+IFNγ+IL-
10+ T cells, populations of Th1 (IFNγ+) Th1 + IL-10 (IFNγ+IL-10+), Th0 (no cytokine 
production) and IL-10+ cells (3.3A) were assessed by flow cytometry for intracellular 
expression of the Th1-associated transcription factor Tbx21 (T-bet), the regulatory T 
cell-associated transcription factor forkhead box transcription factor 3 (Foxp3), and 
surface expression of the IL-7 receptor alpha chain (CD127). CD3ε+CD4+ T cells 
capable of simultaneous production of IFNγ and IL-10 were exclusively T-bet+, CD127- 
and Foxp3- (3.3B).  
 
In contrast to the dramatic expansion of IL-10-producing Th1 cells, infection led to a 
slight, but significant, decrease in the frequency of nTreg, with Foxp3+ cells making up 
6.31 ± 0.49% of splenic CD3ε+CD4+ cells in naïve animals and 4.54 ± 0.38% (p<0.05) 
of the CD4+ T cell compartment in mice at day 28 p.i. (3.3C). However, these 
alterations were small and could be attributable to natural variation in Foxp3+ Treg 
frequency observed between animals. Analysis of the mean fluorescence intensity of 
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Foxp3 expression in nTreg (3.3D) confirmed that CD4+IFNγ+IL-10+ T cells did not 
express detectable levels of this transcription factor.  
 
3.2.4 Chronic infection alters the composition of the conventional splenic DC 
compartment 
In order to assess the impact of infection upon splenic DC subsets, flow cytometric 
analysis was performed on splenocytes isolated from naïve C57BL/6 mice or those at 
day 28 p.i. Conventional DCs (cDCs) were defined as CD11chi MHCIIhi cells (3.4A) and 
could be further segregated into three distinct subsets based upon surface expression of 
CD4 and CD8α  (3.4B). When assessed by flow cytometry, the frequencies of 
CD4+CD8α- (CD4+), CD4-CD8α- (double negative, DN) and CD4-CD8α+ (CD8α+) cDC 
subsets in naïve C57BL/6 mice were found to be consistent with that observed by others 
(3.4C) [31, 56]. However by day 28 p.i., all three subsets were significantly altered in 
frequency. 
 
Comprising the most abundant cDC subset in steady state spleen at 44.2 ± 3.1% of the 
total CD11chi MHCIIhi cell population, the frequency of the CD4+ cDC subset decreased 
significantly to 31.6 ± 1.0% (p<0.05) by day 28 of infection. There was also a marked 
alteration in the frequency of the CD8α+ subset, decreasing from 23.9 ± 1.6 % of total 
splenic cDCs in naïve mice to 9.4 ± 0.5% in the spleen of mice at day 28 p.i. These 
alterations in the frequencies of the CD4+ and CD8α+ cDC subsets were compensated 
for by a more than two-fold increase in the frequency of DN cDCs, reflected by an 
change from 23.9 ± 1.6% of total cDCs at steady state to 54.5 ± 1.5% of the splenic 
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cDC population by day 28 of infection. Hence, DN cDCs become the dominant splenic 
DC population in chronically infected mice. 
 
In order to further characterise the phenotype and potential origin of the splenic cDC 
subsets, splenocytes were stained for expression of the myeloid-associated markers 
CD11b and Ly6C as well as the integrin CD103, in conjunction with the cDC subset 
markers used previously (3.4D-F). As expected, the CD4+ and DN subsets were 
CD11b+, whereas the CD8α+ subset showed no expression (3.4D). Only the CD4+ and 
DN cDC subsets showed slight expression of the myeloid marker Ly6C (3.4E). CD4+ 
and DN cDC subsets also appeared to express some level of CD103, with CD8α+ cDCs 
showing no expression of this integrin (3.4F). 
 
3.2.5 Differential regulation of costimulatory molecule expression by cDC subsets 
during chronic infection 
Expression of costimulatory molecules by DCs represents an integral element of their T 
cell stimulating capacity. In addition, enhanced expression of particular TLRs can result 
in altered DC function, particularly with regard to cytokine production. The effect of 
chronic infection upon the cDC-subset restricted expression of the positive 
costimulatory molecules CD40, CD80, CD86 and CD70 was determined by flow 
cytometry alongside expression of the negative costimulatory molecule B7-H1 
(Programmed –death ligand 1, PD-L1) and the PRR TLR2 (3.5A-F). 
 
Splenic cDC subsets displayed differential alterations in expression of costimulatory 
molecules when naïve mice were compared to those at day 28 p.i. CD4+ and DN cDCs 
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had similar levels of CD40 expression by day 28 (3.5A), increasing by 2.6 ± 0.1 and 2.8 
± 0.1 fold respectively over cDC subsets from naïve mice. CD8α+ cDCs had more 
modestly enhanced surface expression of CD40, increasing 1.6 ± 0.1 fold over this 
subset in naïve spleen; significantly less than the CD4+ and DN cDC subsets (both 
p<0.01). The increase in surface expression of CD80 and CD86 in response to chronic 
infection was muted compared to that of CD40 (3.5B-C). CD4+ cDCs responded to 
infection with a 2.0 ± 0.1fold increase in surface expression of both CD80 and CD86 by 
day 28, whereas levels of surface CD80 and CD86 on DN cDCs were only 1.5 ± 0.1 and 
1.2 ± 0.02 fold higher, respectively, than on DN cDCs from naïve mice. CD4+ cDCs had 
a significantly enhanced fold upregulation of CD86 compared to the DN subset 
(p<0.01). Neither CD80 nor CD86 expression was increased on the surface of CD8α+ 
cDCs by day 28 p.i., represented by fold changes in expression of 0.9 ± 0.1 and 0.8 ± 
0.1 respectively, with CD80 expression significantly lower than both CD4+ (p<0.01) 
and DN (p<0.05) subsets. CD86 upregulation was also significantly impaired on CD8α+ 
cDCs when compared to CD4+ (p<0.01) and DN (p<0.01) subsets. In contrast to the 
previous costimulatory molecules, CD70 expression was increased on all three cDC 
subsets, which had broadly similar subset-restricted expression patterns (ie; 
CD4+>DN>CD8α+); although none of these differences were significant (3.5D). CD4+ 
cDCs had a 6.9 ±1.4 fold increase in CD70 expression, DN cDCs a 5.8 ± 0.9 fold 
increase and CD8α+ cDCs a 4.5 ±1.3 fold increase as a result of chronic infection.  
 
Analysis of cDC subset-restricted expression of the negative costimulatory molecule 
B7-H1 revealed differential effects of infection to that observed for those previously 
assessed (3.5E). CD4+ and DN cDCs subsets had modestly increased expression of B7-
H1 by day 28 p.i., with levels elevated 1.9 ± 0.3 fold and 2.0 ± 0.3 fold over cDC 
79 
 
subsets from naïve animals. In contrast to the lack of expression seen for CD80 and 
CD86, CD8α+ cDCs had the largest fold increase in surface expression of B7-H1, with 
levels elevated 3.0 ± 0.6 fold over this subset in naïve mice; significantly greater than 
that on the CD4+ cDC subset (p<0.05). TLR2 expression was increased on all three cDC 
subsets as a result of infection, with CD4+, DN and CD8α+ cDCs having 4.4 ±0.10, 6.15 
±0.76 and 2.94 ±0.64 fold increases in surface TLR2 expression, respectively, by day 28 
when compared to cDCs isolated from naïve mice. There was a trend toward DN cDCs 
showing the greatest increase in TLR2 expression, although this change was only 
significantly greater than that on the CD8α+ subset (p<0.05). 
 
3.2.6 Sorting splenic cDC subsets to high purity for downstream analysis 
In order to gain an insight into the effects of chronic infection upon cDC functionality, 
it was necessary to isolate highly purified subsets from the spleen of naïve and 
chronically infected animals. Cells were sorted as CD11chiMHCIIhi (3.6A), DX5- (3.6B) 
and could be further divided into three subsets based upon CD4 and CD8α expression 
(3.6C). Each of the CD4+ (3.6D), CD8α+ (3.6E) and DN (3.6F) cDC subsets were sorted 
to high purity (>98%) and used for subsequent downstream analysis. 
 
3.2.7 Altered accumulation of cytokine mRNA in cDC subsets during chronic 
infection 
As the cytokine producing potential of DCs impacts heavily upon the functional 
polarisation of T cell responses after activation, it was of interest to determine what 
effects chronic infection had upon the expression of mRNA encoding various activatory 
and regulatory cytokines and mediators in cDC subsets. qRT-PCR of cDC subsets 
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sorted from naïve mice and mice at day 28 p.i. revealed differential accumulation of 
cytokine mRNAs within individual subsets. 
 
Infection led to an accumulation of IL-12p40 mRNA in all three subsets, increasing 6 
fold in CD4+ cDCs, 5 fold in DN cDCs and 2 fold in the CD8α+ subset isolated from 
mice at day 28 p.i. over those isolated from naïve mice (3.7A). CD4+ and DN cDC 
subsets both had significantly greater expression of IL-12p40 mRNA than the CD8α+ 
cDC subset (both p<0.01) Assessing the accumulation of Transforming Growth Factor 
(TGF) β mRNA in cDCs during infection revealed only modest alterations in expression 
(3.7B). CD4+ cDCs showed a 3 fold increase in expression of TGFβ by day 28 p.i., 
significantly greater than the DN (p<0.001) and CD8α+ (p<0.01) subsets which did not 
express higher levels of TGFβ mRNA when compared to these subsets isolated from 
naïve mice. 
 
Production of the tryptophan catabolising enzyme Indoleamine 2, 3-dioxygenase has 
been shown to be a mechanism by which distinct subsets of DC are able to mediate 
immune regulation via suppression of T cell activity [131-133]. Therefore expression 
levels of IDO mRNA were compared in cDC subsets isolated from naïve and day 28 
infected mice (3.7C).  Chronic infection did not lead to accumulation of IDO mRNA in 
any of the three subsets when assessed at day 28 p.i.  All three cDC subsets 
accumulated IL-27p28 mRNA as a consequence of chronic L. donovani infection, most 
marked in the DN subset, although only significantly elevated compared to  the CD4+ 
cDC subset (p<0.05) (3.7D). This was reflected by 3 fold (CD4+ cDCs), 4 fold (CD8α+ 
cDCs) and 7 fold (DN cDCs) increases in IL-27p28 mRNA accumulation when cDCs 
isolated from chronically infected mice were compared to those from naïve animals. 
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Infection led to a dramatic accumulation of mRNA encoding the regulatory cytokine IL-
10 in cDCs, particularly marked in the DN and CD8α+ subsets, which both showed 
significantly higher accumulation than the CD4+ cDC subset (p<0.01 for DN; p<0.05 
for CD8α+; 3.7E). CD4+ cDCs showed a 4 fold increase in expression of IL-10 mRNA 
by day 28 p.i., whilst DN and CD8α+ cDCs showed 34 fold and 24 fold upregulation in 
IL-10 expression, respectively, when compared to subsets isolated from naïve animals. 
 
3.2.8 Impaired production of IL-12p40 and the acquisition of an 
immunoregulatory cytokine profile by cDC during chronic infection 
Despite being useful in initial assessment of any alterations in cDC cytokine profile, 
mRNA levels in isolation do not allow the definitive assessment of the ability of cells to 
produce certain cytokines, in particular due to evidence for the posttranscriptional 
modification of the Il10 gene during L. donovani infection [392]. Therefore cDC 
subsets were isolated from naïve and day 28 infected mice, cultured for 24 hours and 
cytokine-specific ELISAs performed on cDC culture supernatant. 
 
Effects of infection upon cDC subset production of IL-12p40, one subunit of a cytokine 
required for the efficient generation of IFNγ-producing Th1 cells [411], was assessed 
firstly in cDCs cultured in the absence of exogenous stimulation to determine the levels 
of spontaneous release in culture (3.8A). All cDC subsets isolated from naïve mice 
produced significantly higher amounts of IL-12p40 protein than those sorted from 
spleens of mice at day 28 p.i. This was represented by a reduction in CD4+ cDC 
production of IL-12p40 of 0.49 ± 0.04ng/ml from naïve mice to 0.15 ± 0.01 ng/ml 
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(p<0.001) from this subset isolated from mice at day 28. Infection also reduced the 
capacity for IL-12p40 production by DN cDCs, with production decreasing from 1.30 ± 
0.16 ng/ml in naïve mice to 0.21 ± 0.01 ng/ml (p<0.01) by day 28 of infection. Capable 
of the highest IL-12p40 protein production ex vivo, the CD8α+ cDC subset was also 
similarly impaired in its capacity for IL-12p40 production during infection, reflected by 
a reduction in IL-12p40 from 2.67 ± 0.32 ng/ml from this subset in naïve animals to 
0.24 ± 0.08 ng/ml by day 28 of infection. Therefore, whilst IL-12p40 mRNA levels in 
splenic cDCs were enhanced as a result of L. donovani infection, spontaneous IL-12p40 
protein production was significantly reduced.  
 
In order to determine whether infection had altered the ability of cDCs to respond to an 
unrelated IL-12-inducing stimulus, sorted cDC subsets were cultured for 24 hours in the 
presence of the TLR4 agonist, Lipopolysaccharide (LPS), before IL-12p40 protein 
levels in cell culture supernatant were determined by ELISA as before (3.8B). Although 
LPS treatment enhanced IL-12p40 production by all cDC subsets isolated from either 
naïve or chronically infected mice, total levels of IL-12p40 produced by cDCs was 
significantly inhibited due to infection with L. donovani. CD4+ cDCs from naïve 
animals produced 2.34 ± 0.08 ng/ml after stimulation with LPS, significantly higher 
than the 1.30 ± 0.08 ng/ml that CD4+ cDCs isolated from chronically infected mice 
produced after stimulation. LPS-induced production of IL-12p40 was similarly impaired 
by infection in DN and CD8α+ cDCs, represented by a reduction in production from 
3.38 ± 0.23 ng/ml to 0.83 ± 0.08 ng/ml for DN cDCs and 10.83 ± 0.04 ng/ml to 2.54 ± 
0.16 ng/ml for CD8α+ cDCs, when protein production by LPS-stimulated cDC subsets 
sorted from naïve or day 28 infected mice was measured by ELISA. 
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As qRT-PCR analysis had indicated that mRNA encoding the immunoregulatory 
cytokine IL-27 accumulated in cDCs as result of infection (3.7 and [108]), IL-27p28 
was measured in supernatant of cDC subsets sorted from naïve and day 28 infected 
mice (3.8C). No IL-27p28 protein was detectable in the supernatant of cDC subsets 
sorted from naïve mice and cultured for 24 hours without further stimulation. In 
contrast, all three cDC subsets produced IL-27p28 protein when isolated from d28-
infected mice. CD8α+ and CD4+ cDC subsets produced similar levels of IL-27p28 (321 
± 34 pg/ml vs. 314 ± 51pg/ml, respectively; p=ns), whereas DN cDCs secreted 
significantly less IL-27p28 (194 ± 18 pg/ml; p<0.05 vs. CD4+ cDCs).  
 
In addition to the alterations in IL-12p40 and IL-27p28 producing capacity observed 
during chronic infection, cDC subsets showed an enhanced propensity for IL-10 
production in the absence of exogenous stimulation ex vivo (3.8D). Infection led to 
significantly augmented IL-10 production by CD4+ cDCs, increasing from 62 ± 7pg/ml 
in naïve mice to 618 ± 150 pg/ml (p<0.05) by day 28 of infection. CD8α+ cDCs showed 
a similar response, with levels of IL-10 production increasing from 45 ± 4pg/ml in naïve 
mice to 1004 ± 231pg/ml (p<0.05). IL-10 production by DN cDCs was dramatically 
enhanced due to infection, with protein levels increasing 20 fold from 112 ± 37pg/ml in 
naïve mice to 2251 ± 196pg/ml (p<0.001) in DN cDCs isolated at day 28 of infection.  
 
As autocrine IL-10 signalling is known to suppress IL-12p40 expression [412, 413], it 
was of interest to determine whether cDC subsets, which were known to produce IL-10 
during infection, were capable of IL-10 uptake during the period of in vitro culture. In 
order to address this, cDCs were sorted from naïve and chronically infected mice and 
cultured for 24 hours in the presence of a monoclonal antibody specific for the IL-10 
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receptor (αIL-10R) (3.8E).  cDC subsets isolated from infected mice produced more IL-
10 in the presence of αIL-10R; although this increased production was not at a 
significantly enhanced level than that observed in the absence of the receptor-blocking 
antibody. However, cDCs isolated from infected mice again produced significantly 
more IL-10 than those isolated from naïve animals. Infection led to an increase in IL-10 
production by CD4+ cDCs from 56.35 ± 4.74pg/ml to 902.72 ± 226.89pg/ml (p<0.05) 
by day 28 of infection. This was accompanied by highly significant increases in IL-10 
protein production from both the DN and CD8α+ cDC subsets, represented by increases 
from 109.02 ± 1.38pg/ml to 3171.91 ± 170.21pg/ml (p<0.001) and from 101.91 ± 
45.95pg/ml to 1835.77 ± 174.53 pg/ml (p<0.001), respectively, when cDC subsets from 
naïve mice were compared to those sorted from mice at day 28 p.i.  
 
3.2.9 Effective CD4+ T cell priming and weak Th1 polarisation by cDC subsets 
isolated during chronic infection 
In order to assess whether the alterations in costimulatory molecule expression and 
cytokine profile of cDC subsets as a result of infection impacted upon T cell activation, 
splenic cDC subsets were sorted from naïve and day 28-infected mice. cDCs were 
cultured with carboxyfluorescein succinimidyl ester (CFSE)-labelled sorted naïve 
CD44lo CD62Lhi OTII.RRag2-/- CD4+ T cells at a ratio of 1 cDC : 5 OTII, in the 
presence of OVA(323-339) peptide. OTII proliferation was then assessed after 5 days of 
culture by CFSE dilution (3.9A).  
 
CD4+ cDCs isolated from chronically infected mice were equally effective at inducing 
proliferation of naïve OTII T cells as those from naïve animals (90.72% ± 0.24% vs 
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92.26% ± 0.19% of OTII cells undergoing division, respectively; p=ns, Fig. 3.9B) 
CD8α+ cDCs induced similar proliferation levels in OTII, with 90.30 ± 0.64% of OTII 
having divided in cultures containing cDCs from infected mice compared to 90.07 ± 
0.58% (p=n.s) dividing in response to CD8α++ cDCs sorted from naïve animals. DN 
cDCs were also equivalent in their ability to induce OTII proliferation with 89.79 ± 
1.30% of OTII dividing in response to DN cDCs from naïve animals and 90.21 ± 0.42% 
(p=n.s) dividing in cultures containing this subset sorted from chronically infected mice. 
There were no significant inter-subset differences in the T cell priming potential of 
cDCs; all subsets were broadly equivalent in their ability to induce naïve CD4+ T cell 
proliferation in vitro.  
 
cDC subsets from both naïve and day 28-infected mice were capable of inducing IFNγ 
production by OTII T cells, with the majority of IFNγ being produced by T cells having 
undergone several rounds of division (3.9A). However, cDCs from chronically infected 
mice had only a moderately increased capacity for the polarisation of OTII T cells 
toward a Th1 response, with CD4+ cDCs having a 1.2 ± 0.07 fold, DN cDCs a 1.05 ± 
0.10 fold and CD8α+ cDCs a 1.18 ± 0.03 fold enhanced capacity to generate IFNγ+ OTII 
T cells over the respective subset isolated from naïve mice (3.8C).  No significant 
differences in Th1 polarising capacity between the cDC subsets were observed.  Despite 
the production of IL-10 and IL-27 by cDCs and the potential role for these cytokines in 
the development of IL-10-producing T cells [167, 254] (and discussed later in this 
chapter), there was no evidence that any cDC subset isolated from chronically infected 
mice was capable of inducing OTII T cells to produce IL-10 alone, or in combination 
with IFNγ, after co-culture in vitro.  
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In order to further assess any potential defect in the Th1 polarising capacity of cDCs 
isolated from chronically infected mice, cDC subsets were sorted from naïve and day 
28-infected mice and cultured with sorted naïve OTII T cells as before. Culture media 
was left plain or contained LPS to a final concentration of 1µg/ml in order to activate 
cDC cytokine production and subsequent T cell polarisation. The addition of LPS to 
cDC/OTII co-cultures containing cDCs from naïve mice significantly enhanced the 
polarisation of OTII toward an IFNγ-producing Th1 phenotype (3.9D). This was 
represented by an increase in CD4+ cDC-induced IFNγ+ OTII from 15.64 ± 0.98% to 
40.76 ± 0.75% (p<0.01) in the presence of LPS, an increase from 13.60 ± 0.76% to 
37.47 ± 0.14% (p<0.01) when DN cDCs were used to activate OTII in the presence of 
LPS and from 21.55 ± 0.74% to 34.2 ± 1.41 % (p<0.05) of IFNγ+ OTII when LPS was 
added to cultures containing CD8α+ cDCs.  
 
In contrast, cDCs isolated from chronically infected mice showed no enhanced capacity 
for Th1 induction in the presence of LPS (3.9E). cDCs from chronically infected mice 
showed a moderately enhanced ability to generate Th1 responses, consistent with that 
seen previously. The addition of LPS had no significant effect on the Th1-inducing 
capacity of cDCs from chronically infected mice, with percentages of IFNγ+ OTII T 
cells induced by each subset remaining equivalent in the presence or absence of LPS. 
cDCs from chronically infected mice did not polarise OTII T cells toward an IL-10 
producing phenotype in the presence or absence of LPS (not shown). Therefore, in spite 
of  LPS being able to increase levels of IL-12p40 production by cDCs isolated from 
infected mice, this did not augment Th1 polarisation in vitro.    
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3.2.10 Coordinate inhibition of IL-10 and IL-27 signalling improves the Th1 
polarising capacity of cDC subsets isolated from chronically infected mice  
As cDCs produced IL-10 and IL-27 during infection and OTII were not polarised 
toward an IL-10-producing phenotype when cultured with cDCs from infected mice, it 
was of interest to elucidate the potential impact that these cDC-derived cytokines had on 
T cell polarisation in vitro. To address this, cDC subset / OTII co-cultures were 
established as previously, with the addition of either control IgG, neutralising antibodies 
to IL-27p28 (αIL-27p28), IL-10-receptor blocking antibodies (αIL-10R) or a 
combination of both αIL-27p28 and αIL-10R.  
 
In all cases, the addition of control IgG had little effect on the capacity for Th1 
polarisation, a value calculated by dividing the percentage of IFNγ+ OTII T cells 
induced by a cDC subset in cultures containing indicated antibody / antibodies divided 
by the percentage of IFNγ+ OTII T cells induced by a cDC subset in cultures containing 
media and OVA (323-339) alone. When assessed in cultures containing cDC subsets 
isolated from naïve mice, the addition of αIL-27p28 had no impact on the Th1 
polarising capacity of any cDC subset. Addition of αIL-10R had no effect on cultures 
containing CD4+ cDCs (3.10A), but augmented the Th1 polarising capacity of DN and 
CD8α+ cDCs isolated from naïve mice by 3.2 ± 0.2 fold and 2.8 ± 0.3 fold, respectively 
(3.10B-C). This was significantly greater than the addition of control IgG for both the 
DN (p<0.01) and CD8α+ (p<0.05) subsets. Adding a combination of αIL-27p28 and 
αIL-10R similarly augmented the Th1 polarising capacity of DN and CD8α+ cDCs from 
naïve mice, with dual blockade increasing the capacity to induce Th1 commitment 3.5 ± 
0.6 fold and 2.9 ± 0.2 fold, respectively. This enhanced Th1 polarisation was again 
significantly greater for both DN (p<0.05) and CD8α+ (p<0.01) cDCs when compared to 
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the effect of a control IgG, however the addition of αIL-27p28 did not significantly alter 
the ability for IL-10R blockade alone to improve the Th1 polarising capacity of either 
cDC subset.  
 
The addition of control IgG had little effect on the capacity of cDCs isolated from 
chronically infected mice for Th1 polarisation (3.10D-E).  Blockade of IL-27 signalling 
in isolation had no effect on the Th1 polarising capacity of CD4+ and DN cDCs isolated 
from chronically infected mice. In contrast, addition of αIL-27p28 increased the 
capacity for CD8α+ cDCs to induce Th1 polarisation 2.8 ± 0.1 fold (p<0.01; 3.10F). IL-
10R blockade enhanced the Th1 polarising capacity of CD4+ cDCs 3.0 ± 0.8 fold, DN 
cDCs 4.3 ± 1.3 fold and CD8α+ cDCs 4.6 ± 0.7 fold. Other than for CD8α+ cDCs 
(p<0.05), this increased ability to drive Th1 commitment was not significantly greater 
than the addition of control IgG alone.  
 
Blockade of IL-10R alongside neutralisation of IL-27p28 improved the capacity for Th1 
induction by CD4+ and CD8α+ cDC subsets isolated from chronically infected mice. 
This was reflected by a 3.8 ± 0.7 fold, 5.5 ± 1.6 fold and 8.0 ± 0.2 fold increase in the 
ability of CD4+, DN and CD8α+ cDC subsets to polarise OTII toward an IFNγ-
producing phenotype, respectively. These enhancements in Th1-generating ability were 
significantly higher than the addition of control IgG for the CD4+ (p<0.05) and CD8α+ 
(p<0.01) cDC subsets. In the case of the CD8α+ cDC subset, αIL-10R in combination 
with αIL-27p28 led to a significantly enhanced increase in Th1 polarising capacity 
when compared with αIl-10R alone (p<0.05). Although not significantly changed, 
addition of a combination of αIL-10R and αIL-27p28 to cultures containing CD4+ and 
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DN cDCs also resulted in a trend toward increased capacity for Th1 induction when 
compared to IL-10R blockade alone.  
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3.3 Discussion 
The data presented in this chapter demonstrate that alongside a dramatic expansion in 
the frequency and number of IL-10-producing Th1 cells, there are clear alterations in a 
number of key mediators of effective splenic DC functionality as a result of chronic 
infection with Leishmania donovani. Infection profoundly alters the composition of the 
conventional splenic DC compartment, as well as being responsible for differential 
regulation of costimulatory molecule expression on cDC subsets. cDC subsets show an 
impaired ability to produce IL-12p40 and instead acquire an IL-10 and IL-27 producing 
immunoregulatory cytokine phenotype during the chronic stages of infection. Although 
cDCs are still capable of activating and polarising naïve TCR-transgenic T cells, their 
capacity for inducing Th1 responses in vitro is relatively limited, but can be enhanced 
by IL-10 receptor blockade and neutralisation of IL-27p28 during priming. Despite 
production of IL-10 and IL-27, cDCs from chronically infected mice do not stimulate 
naïve TCR transgenic T cells to become IFNγ+IL-10+ co-producing T cells in vitro.  
 
Unlike the majority of earlier studies, this investigation focussed on determining the 
impact of chronic infection upon populations of DCs that are as physiologically relevant 
as possible. Despite limitations in the process by which DCs are experimentally 
isolated, assessing the effects of infection with Leishmania donovani on DCs sorted to 
high purity directly ex vivo hopefully reduces the caveats introduced when experimental 
approaches are restricted to in vitro infection or the use of  bone marrow-derived DCs 
with poorly-defined in vivo counterparts.  
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Previously shown to be a feature of chronic infection of C57BL/6 mice with L. 
donovani [391, 414], this data confirms that splenic CD4+ T cells acquire an IFNγ and 
IL-10 co-producing phenotype by day 28 of infection. Furthermore by utilising parasite 
pulsed BMDC as a source of antigen during restimulation,  CD4+IFNγ+IL-10+ T cells 
are revealed as a major component of the antigen-specific T cell response to L. 
donovani, suggesting that cells with this phenotype do arise in vivo and are not an 
artefact of PMA and Ionomycin restimulation. The phenotypic analysis of these cells 
was extended by characterising them as Foxp3-, T-bet+ and CD127-, a phenotype of IL-
10-producing effector T cell analogous to that found in experimental Toxoplasma gondii 
[162], Plasmodium yoelii [415] and Listeria monocytogenes [262] infection, in addition 
to human peripheral blood [416]. Such Foxp3- CD4+ T cells also appear to be 
responsible for IL-10 production during cutaneous infection of mice with L. major [161, 
417], although antigen specific CD25+ Foxp3+ natural regulatory T cells may be playing 
a more significant role in the establishment of chronic disease in that model [418-420]. 
 
IL-10 production by conventional Th1 cells also appears to be a feature of human 
infections. Expanded numbers of antigen-specific T cells co-expressing IFNγ and IL-10 
have been reported in the peripheral blood of patients successfully treated for L. 
donovani infection [421], in patients chronically infected with Borrelia burgdorferi 
[422] and are present in the bronchoalveolar lavage of patients with active pulmonary 
tuberculosis [423]. Furthermore, splenic CD4+ Foxp3- T cells accumulate IL-10 mRNA 
during human L. donovani infection [390].  As Foxp3+ regulatory T cells have a great 
capacity for regulating immune responses [424], it was important to determine whether 
infection led to an expansion of this population of cells. Infection led to a slight, but 
significant, decrease in the frequency of CD4+ T cells which express Foxp3, suggesting 
that these cells are not expanded as a result of L. donovani infection. This is consistent 
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with recent clinical data, indicating that visceral leishmaniasis in humans is not 
associated with an enhanced number or augmented functionality of natural regulatory T 
cell populations in spleen or peripheral blood [425]. However, expression of Foxp3 in 
lesions of patients with an uncommon form of dermal pathology caused by L. donovani 
has been reported [426], but as this is a form of cutaneous infection, it is potentially 
more similar to the response to L. major infection. The data presented here therefore 
supports the growing body of evidence suggesting that co-production of IFNγ and IL-10 
by a population of T-bet+ Foxp3- CD4+ T cells is a common outcome of chronic 
infection with this parasite in mouse and man.  
 
Chronic infection led to significant alterations in the balance of cDC subsets in the 
spleen. In particular the frequencies of the CD4+ and CD8α+ subsets were markedly 
reduced. It is unclear whether such alterations in subset ratio are due to a loss of surface 
CD4 and CD8α expression as a result of their functional activation or due to the death 
of individual cDC subsets, such as the loss of CD8α+ cDCs during bacterial sepsis [427, 
428] experimental murine malaria [112] and salmonella infection [429]. Similar 
alterations in splenic cDC subset ratios are also seen after intravenous administration of 
LPS [56] and so it is possible that the observed effects are due to non-specific effects of 
inflammation, rather than an effect of Leishmania infection per se.  
 
The observed increase in DN cDC frequency could also be explained by an influx of 
monocyte-derived dendritic cells, known to occur at the site of infection with L. major 
[64] or be representative of an increased number of TNF/iNOS-producing DC (‘Tip-
DC’), previously shown to play a role in protection from Listeria monocytogenes [430]. 
Although DN cDCs expressed similar levels of CD11b to the cell types mentioned, 
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further phenotypic analysis revealed them to have low expression of Ly6C; a key 
marker used for the identification of monocyte-derived DC [64]. In addition, both the 
types of iDC detailed above show only intermediate levels of CD11c expression, 
whereas the DN cDCs characterised in this study were derived exclusively from the 
CD11chi splenic cDC population.  Therefore, it is unlikely that the increased frequency 
of DN cDCs observed during infection with Leishmania donovani represents an influx 
of monocyte-derived or Tip-DC, but whether these cells are capable of increasing 
expression of CD11c and can thus phenotypically resemble DN cDCs remains to be 
determined.   
 
Dendritic cell-restricted expression of the alpha-E integrin CD103 has a well-defined 
role in the initiation of tolerance and regulatory T cell development. CD103-expressing 
mucosal DCs in the small intestine have the capacity to induce Foxp3+ Treg [163, 164], 
as well a subset of CD8α+CD103+CD207+ splenic DC, located in the marginal zone, 
being responsible for tolerance to cell-associated antigens [135]. Despite these previous 
observations, no expression of CD103 was detectable on CD8α+  cDCs in either steady 
state or during infection, and only a low level was present on CD4+ and DN cDC 
subsets.  
 
As previously stated, enhanced expression of costimulatory molecules by APCs is an 
essential component of their T cell activating capacity. Although numerous studies have 
identified altered costimulatory molecule expression in macrophages and DCs infected 
with Leishmania spp in vitro, studies of costimulatory molecule expression during L. 
donovani infection in vivo have mostly been restricted to the acute (5hr p.i.) stages of 
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infection [108, 404]. This data suggests that differential regulation of costimulatory 
molecule expression on cDC subsets occurs as a result of chronic infection.  
 
Chronic infection led to increased CD40 expression, most markedly on the CD4+ and 
DN cDC subsets. However, there are conflicting reports as to the requirement for this 
costimulatory molecule in the generation of protective immunity during Leishmania 
infection. Early studies indicated that accumulation of IL-12p40, the generation of a 
Th1 response and macrophage leishmaniacidal activity was significantly impaired in 
CD40-deficient mice, resulting in an enhanced susceptibility to infection with L. major 
[431]. In addition, infection of cd40l-/- mice revealed a crucial role for CD40L-induced 
IL-12 production by APCs in limiting infection with this parasite [432], suggesting that 
the CD40 – CD40L axis was critical for control of intracellular parasitic infection. This 
is supported by a recent study in which murine BMDC, engineered to express high 
levels of CD40, act as an effective therapeutic when adoptively transferred to infected 
mice [433]. However, other studies have suggested the initiation and maintenance of a 
robust Th1 response to L. major to be independent of CD40 – CD40L costimulation 
[434, 435], and instead to be reliant on TRANCE-RANK signalling [436]. Therefore, 
despite enhanced expression of CD40 on cDCs during chronic infection, it is possible 
that signalling via this costimulatory molecule may be redundant in respect to the 
generation of a Th1 response during infection, and is not necessarily indicative of fully 
effective DC activation.  
Expression of CD80 and CD86 on cDC subsets was muted relative to CD40 and 
broadly similar to that seen at 5hr and 24hr p.i.[108, 404]. The greatest fold increases in 
expression occurred on the CD4+ subset. This may reflect differential levels of infection 
between the cDC subsets, although direct infection of DC in vivo, at least at the acute 
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stages of infection, is reportedly absent [341] or very low [405], with no apparent bias 
in cDC subset infection [108]. No studies have addressed levels of direct cDC subset 
infection by Leishmania in the latter stages of infection, so it cannot be ruled out that 
the differential expression of costimulatory molecules is due to different levels of cDC 
subset infection.  
 
As CD70 has been reported to be a key mediator of IL-12-independent Th1 polarisation 
[437], it was interesting that the expression of this costimulatory molecule was 
dramatically enhanced on all cDC subsets. This may underlie the capacity for intact 
cDC subset-induced Th1 polarisation despite the relatively limited production of IL-
12p40 protein production by these cells when isolated during chronic infection. 
However, enhanced CD70 expression may not always be beneficial to the host, as the 
CD70-mediated depletion of B cells has been reported to result in the destruction of the 
marginal zone in [438]; pathology similar to that seen during chronic infection with L. 
donovani. As such it cannot be assumed that the enhanced CD70 expression identified 
in this study would have a positive impact on the progression of disease. 
 
In contrast to the relatively modest increases in expression of CD80 and CD86 on cDCs, 
chronic infection led to enhanced expression of the negative costimulatory molecule 
Programmed Death Ligand 1 (PD-L1, B7-H1). Increased expression of this molecule on 
DC has recently been proposed as a mechanism by which the functional exhaustion of 
CD8+ T cells is mediated during chronic L. donovani infection [378]. Enhanced PD-L1 
expression was previously assessed on the whole CD11c+ population, whereas this 
study revealed distinct subset-specific patterns of expression during infection. In 
particular, the CD8α+ cDC subset showed the greatest increase in surface PD-L1 
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expression, whereas the CD4+ cDC subset showed the most modest increase. As CD8α+ 
cDCs have a well described, dominant role in cross presentation and the generation of 
effector CD8+ T cell responses to exogenous antigen [94], it is possible that the 
enhanced expression of PD-L1 observed on this subset would have the most marked 
effect on the process of CD8+ T cell exhaustion as proposed by Joshi et al.  
 
Inhibition of T cell priming by enhanced expression of PD-L1 on DC during viral 
infection has been proposed to ‘overwhelm’ any positive effects of costimulatory 
molecule expression by these cells [439], suggesting that even with the relatively intact 
expression of costimulatory molecules, particularly CD40, on some cDC subsets during 
chronic L. donovani infection, enhanced PD-L1 expression may abrogate any positive 
impact of  this. Furthermore, ‘reverse signalling’ via PD-L1 or PD-L2 on DC has been 
shown to result in their impaired functional maturation [440], providing a potential 
explanation as to the greater impairment of CD40, CD80 and CD86 expression on the 
CD8α+ cDC subset,  associated in part with their more significantly enhanced PD-L1 
expression.  
 
Sorting cDC subsets to high purity from spleens of naïve and chronically infected mice 
and assessing the accumulation of mRNA encoding several cytokines and 
immunoregulatory mediators by qRT-PCR yielded interesting results. All cDC subsets 
accumulated mRNA encoding IL-27, but this was particularly evident in the DN subset. 
This differs slightly from previous observations in day 28-infected BALB/c mice which 
had the highest accumulation (5-10 fold) of IL-27p28 mRNA in the CD8α+ cDC subset, 
only a 2-5 fold increase in DN cDCs and less than 2 fold upregulation in CD4+ cDCs 
[108]. Nonetheless, the data presented here are broadly supportive of the previous 
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observations and suggest that IL-27 expression is associated with chronic L. donovani 
infection in both strains of mice.  This study extended the cytokine profiling carried out 
previously to include IL-10. The effects of infection upon IL-10 mRNA were dramatic. 
Transcripts were 30-40 fold higher in DN and CD8α+ cDCs from infected mice, 
indicating a vast alteration in transcriptional activity within these subsets, similar to that 
seen in NK cells as a result of L. donovani infection [392].  
 
Despite a clear propensity for cDCs to accumulate mRNA encoding the regulatory 
cytokines IL-10 and IL-27p28 by day 28 of infection, there were no major increases in 
expression of other immunoregulatory cytokines and mediators, at least at the mRNA 
level. There was no alteration in the levels of IDO mRNA in sorted cDCs, indicating 
that this mechanism of limiting T cell function may not be a component of disease 
progression. However, previous studies reporting IDO-producing DCs as negative 
regulators of immunity have focussed on very rare B220+ [133] or CD19+ [131] splenic 
DCs, and so they may not have been included in the stringent cDC gates used for 
sorting in this study.   
 
qRT-PCR analysis also revealed only modest accumulation of TGFβ mRNA in splenic 
cDCs, restricted to the CD4+ subset. This is in contrast to the association of this 
regulatory cytokine with human L. donovani infection [441] and data reporting 
production of TGFβ by T cells and macrophages of mice chronically infected with 
Leishmania infantum [442-444]; a parasite species’ distinct from L. donovani also 
capable of inducing visceralising infection. Although T cell or macrophage production 
of TGFβ was not directly addressed in this study, previous work has shown no increase 
in TGFβ  production by liver mononuclear or spleen cells as a result of chronic infection 
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with L. donovani [375]. As such the lack of significant TGFβ mRNA accumulation by 
splenic cDCs observed in this study is perhaps unsurprising. Collectively it would 
appear that the strain of Leishmania responsible for causing VL determines whether the 
immunoregulatory cytokine milieu is dominated by both TGFβ and IL-10 or solely IL-
10. The reason for slightly enhanced accumulation of TGFβ mRNA in the CD4+ subset 
remains to be formally addressed, however as this subset is known to also accumulate 
higher levels of IL-23p19 during infection of BALB/c mice [108], it is possible that this 
subset could be capable of Th17 induction. Such IL-17 producing cells are known to be 
associated with protection from L. donovani infection in humans [445] however, no 
evidence for IL-17 production by CD4+ T cells as a result of infection was found during 
this study.  
 
An important finding of this study was the impaired capacity for IL-12p40 protein 
production by cDCs during the chronic stages of infection in C57BL/6 mice. This 
occurred despite observed increases in IL-12p40 mRNA in cDCs as a result of 
infection, suggesting perhaps that post-transcriptional suppression of IL-12p40 may be 
occurring (cf Chapter 4). All three cDC subsets sorted from chronically infected mice 
showed significantly reduced production of IL-12p40 protein when compared to those 
from naïve animals after 24 hours culture ex vivo, as well as an impaired ability for 
cDCs to produce this cytokine in response to LPS stimulation. For cDCs from both 
naïve and chronically infected mice, in the absence or presence of LPS, the CD8α+ 
subset produced the highest amount of IL-12, consistent with observations from other 
studies [88, 92]. The impairment in IL-12p40 production supplements a large body of 
data concerning the regulation of IL-12 production by DCs and Leishmania infection, 
with this study extending observations to include CD11chi splenic cDCs isolated from 
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infected mice, rather than in vitro derived macrophages or BMDCs which comprised the 
bulk of the cells used for previous studies.   
 
Several Leishmania species have been reported to directly suppress IL-12 production by 
macrophages in vitro, including transcriptional inhibition of IL-12 promoter activity by 
L. major, L. donovani and L. chagasi [446] and the direct modulation of NF-κB 
signalling and subsequent IL-12 production by cysteine peptidases secreted by L. 
Mexicana amastigotes [447]. Leishmania-derived lipophosphoglycan is also capable of 
directly suppressing LPS-induced IL-12 production in macrophages, in part due to 
activation of ERK [448]. Sustained inhibition of IL-12 production is also seen in 
macrophages after phagocytosis of L. mexicana amastigotes [449]. The situation with 
DCs appears to be more complex. Leishmania major infection leads to impaired IL-12 
production by BMDC in vitro [395], an effect potentially mediated by 
lipophosphoglycans produced by the parasite [450]. However, Langerhans cells and 
other types of skin DCs are capable of internalising L. major amastigotes, producing IL-
12 and activating T cells in vitro and in vivo [365, 451, 452]. The ability of human DCs 
to produce IL-12 in response to Leishmania infection appears to be strain specific, with 
L. major inducing intact IL-12p70 production in response to CD40 engagement, in 
contrast to L. donovani and L. tropicana which are unable to prime DCs for production 
of this cytokine [453].  
 
Despite an evident capacity for some species of Leishmania to suppress production of 
IL-12 by DCs and macrophages,  acute in vivo infection with L. donovani results in 
production of IL-12p40 by DC, peaking at 24hr p.i. but returning to baseline levels 
within three days [454], as well as initiating the rapid mobilisation of pre-formed stores 
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of IL-12p70 from DC and macrophages within minutes of pathogen encounter [455]. 
IL-12p40 production by CD8α+ DC has also been reported as early as 5hr p.i with L. 
donovani [108], mediated by a process involving vascular cell adhesion molecule-1 
(VCAM-1) and its ligand, very late antigen-4 (VLA-4) [456].  
 
The production of IL-12p70 protein by cDC subsets isolated from BALB/c mice 
chronically infected with L. donovani has been shown to be completely suppressed, due 
to a lack of accumulation of IL-12p40, rather than IL-12p35, mRNA in these cells 
[108]. This is in contrast to earlier (5hr) stages of infection, where intact accumulation 
of both IL-12 p40 and p35 mRNA accompanies production of IL-12p70 protein by cDC 
subsets [108]. As such, the reduced capacity for IL-12p40 protein production described 
in this study supports a model by which impaired IL-12 production by DC is acquired as 
disease progresses. Furthermore, this defect, acquired in the chronic stages of infection, 
is not restricted to an inability for cDCs to produce IL-12 in response to inflammatory 
stimuli encountered during infection, as cDCs from chronically infected mice stimulated 
with a high dose of LPS ex vivo also show a significantly impaired capacity for 
production of IL-12; suggesting a more generally impaired capacity for production of 
this cytokine.  
 
Defective production of IL-12 by professional APCs is likely to play a significant role 
in the immunopathology associated with Leishmania donovani infection. This is 
underlined by the fact that infection of Il12-/- mice with this parasite leads to 
exacerbated disease, although this is accompanied by reduced hepatic pathology [457]. 
Furthermore, abrogating IL-12 function by administration of a neutralising antibody 
during infection leads to reduced IFNγ production and significantly increased parasite 
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burdens in spleen and liver at day 28 p.i. [458], although a similar experimental 
approach suggested that neutralisation of IL-12 only affects liver parasite burden and 
granuloma assembly in the first 28 days, with effects upon splenic parasite burden 
restricted to the later time points of infection [311]. Treatment with recombinant IL-12 
also indicates the importance of this cytokine for disease progression, with substantially 
reduced parasite burdens being achieved after therapeutic administration of recombinant 
cytokine as a result of IFNγ-dependent and independent mechanisms [320, 459]. 
Therapeutic DC vaccination against L. major and L. donovani infection both require IL-
12, as infusion of IL-12-deficient DCs during these experimental approaches severely 
impairs their efficacy [391, 460].  
 
In summary, the evidence for a lack of IL-12 production by cDCs during chronic 
infection and the impaired capacity for LPS-induced secretion of IL-12 presented in this 
study is concordant with previous observations that IL-12p40 production by DC is 
reduced to baseline levels 72 hours after infection of C57BL/6 mice [454], that IL-
12p70 production by cDC subsets is completely suppressed during chronic infection of 
BALB/c mice [108] and that Leishmania-derived LPG and cysteine peptidases impair 
IL-12 production and interfere with signal transduction after LPS stimulation of 
macrophages [447, 448, 461]. In addition, PBMC isolated from patients with active, 
chronic VL are incapable of IL-12p40 production in response to stimulation with 
Leishmania antigen; a defect that is lifted after drug treatment and eventual cure [462]. 
Taken together, this suggests that an impaired capacity for IL-12 production may be 
associated with chronic disease in both murine and human systems. 
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In addition to an impaired ability to produce IL-12 during infection, cDCs acquired an 
enhanced capacity for production of the immunoregulatory cytokine IL-10 and the 
effector / regulatory cytokine IL-27. The regulation of IL-27 production is discussed in 
further detail in Chapter Four of this study, but the capacity for cDCs to produce IL-10 
during chronic infection revealed a potentially intriguing situation in which cDCs, 
instead of potentiating T cell responses, are actually endowed with a paradoxical 
capacity for the negative regulation of on-going immune responses.   
 
Concordant with the alterations in cytokine production by cDCs seen in this study, a 
coordinate suppression of IL-12 production and enhancement of IL-10 production has 
been reported in L. major-infected macrophages, where modulation of CD40 signalling 
results in impaired p38MAPK function, limited production of IL-12 and a shift toward 
IL-10 production [463, 464]. This is suggested to be due to the formation of an atypical 
TRAF6 and Syk-containing CD40 signalosome that promotes IL-10 production and is 
induced by depletion of cholesterol in the cell membrane [465]. Such dysregulated 
signalling downstream of CD40 suggests that the enhanced expression of this 
costimulatory molecule on cDCs during chronic infection observed in this study may 
actually augment the production of IL-10, similar to that seen during the generation of 
human  tolerogenic DCs in vitro [466],  rather than the usual situation of enhancing IL-
12 production by DCs and macrophages. Further work will be required to determine 
whether a similar signalosome is also formed in DCs and whether L. donovani initiates 
alterations in DC membrane composition and host signalling analogous to that in L. 
major- infected macrophages.  
 
103 
 
As mentioned in Chapter 1, activation of ERK provides a mechanism by which IL-10 
production is initiated in DCs in response to a diverse range of pathogens. However, 
there are conflicting reports as to whether the activation of ERK occurs in response to 
infection or encounter with Leishmania spp. As previously mentioned, Leishmania 
LPGs are known to be capable of subverting macrophage production of IL-12; a process 
which is dependent upon the direct stimulation of ERK by these parasite-derived 
molecules [448]. Further evidence for ERK activation as a result of Leishmania 
infection comes from studies and that infection of macrophages [467] and DCs [401] 
with L. amazonensis leads to phosphorylation of this MAP kinase. Furthermore, L. 
donovani has been shown to suppress p38MAPK activity and enhance ERK1/2 
phosphorylation in human peripheral blood monocytes and a THP-1 monocyte cell line 
in a contact-dependent manner, leading to suppressed TLR-induced IL-12p40 induction 
and enhanced production of IL-10 [393].  
 
Despite the activation of ERK reported by the above studies, enhanced ceramide 
synthesis in L. donovani-infected macrophages has been shown to result in the 
dephosphorylation of ERK1/2 [468, 469] and  L. donovani promastigotes appear to 
evade activation of ERK upon infection of naïve macrophages [470], suggesting that 
ERK activation may not occur in all cell types or upon infection with all stages of the 
parasite lifecycle. Furthermore, L. donovani amastigotes do not express LPGs [471], 
suggesting that LPG-mediated induction of ERK would play a limited role in generating 
the DC cytokine profile described in this study. 
As previously discussed, PRR signalling strongly influences the cytokine-producing 
capacity of DCs and macrophages, with TLR2 engagement leading to enhanced ERK 
phosphorylation [204, 472] and IL-10 production by APCs [473], as well as the direct 
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transition from IL-12 to IL-10 production by macrophages as a result of TLR2-
dependent ERK activation due to stimulation with bacterial teichoic acids [474].  In 
response to TLR2 signalling in splenic DCs, production of IL-10 and retinoic acid leads 
to autocrine signalling and enhanced suppressor of cytokine signalling (SOCS)-3 
expression and the suppression of pro-inflammatory cytokine production, including IL-
12p40, IL-12p70, TNFα and IL-6 [209], suggesting that a potential consequence of 
enhanced retinoic acid production may be to shift cDCs away from a pro-inflammatory 
cytokine profile, in addition to its role in the generation of Foxp3+ Treg [163, 164]. 
However, it is not clear whether L. donovani infection results in enhanced retinoic acid 
metabolism by cDCs at this point.  
 
In addition to TLR2 signalling, engagement of the Dendritic cell-specific intercellular 
adhesion molecule-3-grabbing non-integrin (DC-SIGN, CD209) also leads to enhanced 
ERK1/2 phosphorylation and increased production of IL-10 by DCs [475],  as well as 
the negative regulation of DC costimulatory molecule expression and a switch to IL-10 
production due to recognition of Mycobacterium tuberculosis [476]. Furthermore, as 
DC-SIGN has been reported to directly bind amastigotes of L. pifanoi [477], L. 
mexicana [478] and L. infantum [479], there is the possibility that direct recognition of 
Leishmania by this lectin may be responsible for the observed modulation in cytokine 
profile. However, functional comparison of the mouse DC-SIGN homologue CIRE 
showed no capacity for engagement of this receptor by L. mexicana [480], suggesting 
that this may not be the case in the murine system.  
 
Unlike other infectious organisms with well characterised moieties on their surface 
capable of recognition by TLRs, Leishmania spp do not have as clear-cut capabilities 
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for TLR activation. Perhaps of greatest importance in the context of the altered cDC 
cytokine-producing capacity reported in this study is the recognition by TLR2 of several 
species’ of Leishmania, including L. donovani. In agreement with the enhanced 
expression of TLR2 on cDC subsets from chronically infected mice observed in this 
study, lipophosphoglycan from L. major induces TLR2 expression and IFNγ gamma 
production by human NK cells [481], in addition to LPG from L. donovani 
promastigotes inducing TLR2-dependent production of NO and TNFα in IFNγ-primed 
murine macrophages [482]. Whilst these studies reveal components of Leishmania 
capable of signalling through TLR2 and inducing an anti-parasitic response, L. major 
LPG is also able to induce expression of IL-10 [483], SOCS-1 and SOCS-3 [338]; 
components of a suppressive immune environment and permissive to parasite 
expansion. Furthermore, TLR2-deficient mice, infected with L. braziliensis, show 
greater IL-12p40 production, enhanced IFNγ expression and reduced disease severity 
[342], as well enhanced parasite clearance at the site of infection after L. amazonensis 
infection [484]. Although IL-10 expression was not addressed in these in vivo studies, 
the enhanced parasite clearance in both models may suggest that TLR2 signalling has a 
negative effect on productive immunity to these pathogens. As TLR2 directly 
recognises components of L. infantum [485] and TLR2 signalling is directly modulated 
by L. donovani to favour IL-10 production [393], it is possible that engagement of 
TLR2 contributes to the switch from IL-12 to IL-10 production and subsequent 
impairment of immune responses during visceral leishmaniasis.  
 
Despite some ambiguity as to whether ERK is always activated in APCs as a result of 
interaction with Leishmania spp and the currently unclear nature of the PRR engaged by 
L. donovani, ERK-dependent modulation of cytokine responses in DCs after infection 
allows the generation of a hypothetical model which may go some way toward 
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explaining the impaired IL-12p40 production and enhanced IL-10 expression by cDCs 
observed in this study (3.11). However, as many of the previous studies were based 
upon direct infection of APCs in vitro, further studies directly assessing the state of 
ERK activation in defined ex vivo cDC populations during chronic infection with L. 
donovani would be required to more fully support this proposed mechanism.  
 
Co-culture of sorted cDC subsets and naïve OTII TCR transgenic T cells allowed an 
assessment to be made of the priming and polarising capacity of cDCs during chronic 
infection. All cDC subsets were capable of priming naïve T cells, with those isolated 
from chronically infected mice no better at inducing proliferation of CFSE-labelled T 
cells than those from naïve animals. This was despite the fact that they had enhanced 
expression of some costimulatory molecules. The fact that cDCs were not more 
impaired in their capacity to generate T cell proliferation may be influenced by the fact 
that cultures contained the peptide epitope of OVA recognised by the OTII TCR and so 
no antigen processing was required for presentation. Therefore any alterations in antigen 
processing and presentation, which may have affected the ability of cDCs to prime T 
cells during infection, would be missed. Future studies using whole OVA for co-
cultures or making an assessment of any defect in antigen processing in cDCs using 
fluorescently labelled DQ-OVA could address this issue.  
 
The limited polarisation of a Th1 response by cDCs at day 28 of infection was 
consistent with that seen previously [108], with both studies showing levels of TCR-
transgenic T cell IFNγ production induced by cDC subsets isolated from chronically 
infected mice only marginally higher than that induced by cDC subsets from naïve 
animals. In both studies, cDC subsets have a significantly impaired capacity for IL-
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12p40 (this study) and IL-12p70 [108] protein production by day 28 of infection; a 
defect which is likely to underlie the modest capacity for cDCs to generate functional 
Th1 responses by this stage of infection.  
 
The assessment of the defect in cDC Th1 polarisation in this study was extended by 
including cDC / OTII cultures with the addition of a high dose of LPS. Naïve cDCs 
were capable of inducing a highly polarised Th1 response by OTII in the presence of 
LPS, whereas cDCs from chronically infected mice were unable to do so. This is 
consistent with the reduced ability of cDCs from day 28 infected mice to increase their 
production of IL-12p40 in response to LPS, resulting in far lower concentrations of IL-
12 in supernatants from cDC cultures isolated from chronically infected mice and 
presumably far lower amounts of IL-12 available for Th1 polarisation in the co-cultures 
containing OTII.  
 
In light of the dominant role for IL-27 in the generation of IL-10 producing CD4+ T 
cells [254-257, 260, 262, 486] and the ability for cDC subsets to produce IL-27p28 
protein during chronic infection determined in this study, it was surprising that cDC 
subsets from infected mice did not generate OTII cells capable of IL-10 production in 
vitro. A major factor in this observation could be due to dramatic differences in the 
amount of recombinant IL-27 used during T cell polarisation in previous studies. In this 
study, analysis by ELISA revealed that between 200-300 pg/ml of IL-27p28 was present 
in culture supernatant of cDCs isolated from chronically infected mice. This is in 
contrast to previous in vitro studies which utilised recombinant IL-27 at concentrations 
of 20ng/ml [255, 262, 486], 25ng/ml [259, 260], 50ng/ml [256] and 100ng/ml [254, 
257], often in combination with T cell stimulation by plate-bound αCD3 and αCD28. 
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Such concentrations are 100 - 500 fold higher than that determined ex vivo. Thus it is 
possible that the in vitro polarisation assay in this study, containing physiological levels 
of DC-produced IL-27, were simply lacking in sufficient IL-27 to replicate the 
dominant polarising effect seen previously. However, High doses of IL-27 applied to 
cultured OTII T cells also failed to replicate the published data indicating a role for IL-
27 in instructing IL-10 production, so it is possible that OTII T cells do not express 
sufficient WSX-1 and are thus insensitive to IL-27 signalling. Further work will be 
required to address this. 
 
Although IL-10 has been shown to be a requirement for IL-10-producing regulatory 
‘Tr1’ cell development (for example see [487]), IFNγ and IL-10 co-producing CD4+ T 
cells of a similar phenotype to that identified here have been shown to develop via a 
mechanism independent of IL-10 [162]. As such the IL-10 production by cDCs may be 
a bigger contributor to systemic IL-10 levels during chronic infection, rather than 
having a role in shaping the T cell phenotype that is observed ex vivo. The potential role 
for IL-10 in directly modulating cDC function is discussed further in chapter 4 of this 
study. 
 
Recent in vitro data has revealed key roles for IL-12 and repeated, high dose antigen 
stimulation in the generation of effector CD4+ T cells co-producing IFNγ and IL-10 
[488]. This is supported by in vivo studies showing that repeated exposure to antigen 
during chronic infection [162] and therapeutic intervention for autoimmunity [489] are 
required for the generation of CD4+Foxp3- T cells capable of co-producing IFNγ and 
IL-10. As all cDC subsets showed severely impaired production of IL-12p40 as a result 
of infection, it is possible that without the production of this cytokine, OTII T cells 
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cannot be driven toward an IFNγ and IL-10-producing phenotype by cDCs isolated 
from chronically infected mice. Furthermore, antigen exposure is likely to be far higher 
in vivo than in vitro, suggesting that the co-cultures established in this study may have 
also been lacking in the required number of antigen encounters to generate IFNγ and IL-
10 dual producers as seen ex vivo.  
 
As there was no evidence from the co-cultures that cDCs producing IL-10 and IL-27 
could generate populations of IL-10+ T cells, the impact of these cytokines on T cell 
polarisation was determined by neutralising the function of IL-10 and IL-27 during T 
cell activation by cDCs in vitro. Blockade of IL-27 alone had very little effect on co-
cultures containing cDC subsets isolated from either naive or chronically infected mice. 
In contrast, neutralisation of IL-10 signalling by blockade of the IL-10 receptor (IL-
10R) had a marked effect. Although this was evident in co-cultures containing cDCs 
from naïve mice, the effect were far more limited, with neutralisation of IL-10 
signalling only modestly enhancing the Th1 polarising capacity of this subset. In 
contrast, blockade of IL-10 signalling allowed cDC subsets from chronically infected 
mice to much more efficiently polarise OTII T cells toward an IFNγ+ phenotype. This 
was accompanied by an augmented improvement in Th1 polarising capacity when IL-27 
was neutralised alongside IL-10R blockade, the potential significance of which will be 
addressed in the next chapter.  
  
In conclusion, the data presented in this chapter yield greater insight into the functional 
alterations within the CD4+ T cell and cDC compartments as a result of chronic 
Leishmania donovani infection. The potential mechanisms by which the novel pattern 
of cDC cytokine production mediate the effects of chronic infection, as well as the role 
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of cDC subsets in the establishment and maintenance of chronic disease in vivo, will be 
addressed in the subsequent chapter 
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Figure 3.1 Progressive experimental visceral leishmaniasis is associated with impaired splenic IFNγ 
production. Female C57BL/6 mice were infected i.v with 3x107 Leishmania donovani LV9 amastigotes. 
At the indicated time point post infection, mice were killed by cervical dislocation and organs isolated. A, 
C. Hepatosplenomegaly was assessed by expressing spleen and liver mass as a percentage of total body 
weight. B, D. Splenic and hepatic parasite burdens were determined from Giemsa stained impression 
smears. Parasite burden is expressed as Leishman-Donovan Units (LDU). Splenocytes were isolated at 
each time point and cultured for 72 hours with1µg/ml αCD3ε (E) or 2x106 fixed LV9 amastigotes (F). 
Supernantants were assessed by ELISA for presence of IFNγ. Data are expressed as mean ± SEM of IFNγ 
production (pg/ml) from total n=8 (naïve mice) or n=4 (infected mice per timepoint). Splenomegaly and 
parasite burden from n=4 mice per timepoint (naïve and infected) ND = not detectable. n.s. = not 
significant, **= p<0.01, ***=p<0.001 for indicated day p.i compared to naïve (αCD3ε-stimulated) or day 
7 infected (LV9-stimulated) mice. Or infected vs naïve groups (hepatosplenomegaly). Triangles = 
infected mice, circles = naïve mice. 
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Figure 3.2 IL-10 producing CD4+ T cells expand in frequency and number during chronic 
Leishmania donovani infection. Female C57BL/6 mice were infected i.v with 3x107 Leishmania 
donovani LV9 amastigotes and disease allowed to develop for 28 days. A –F. Splenocytes from infected 
or naïve age-matched control mice were restimulated for 2 hours with PMA and Ionomycin (A-C) or for 
3 hours with LV9-pulsed BMDC (D-F) and subsequently assessed by intracellular cytokine staining for 
alterations in CD4+ T cell phenotype. A and D show representative FACS plots, gated on CD3ε+CD4+ 
cells. B and E show the mean frequency of CD3ε+CD4+ T cells ± SEM with the indicated cytokine 
phenotype. C and F show the mean number of CD3ε+CD4+ T cells ± SEM with the indicated cytokine 
phenotype. Splenocytes from naïve (open bars) or day 28 infected mice (closed bars) are shown. Data are 
from n=4 mice and representative of 3 individual experiments. *=p<0.05, **=p<0.01, ***=p<0.001 for 
infected vs naïve mice.  
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Figure 3.3 T-bet+ Th1 cells are the predominant IL-10-producing T cell population during chronic 
infection. A. CD3ε+CD4+ T cells are capable of producing IL-10 and IFNγ during chronic infection. B. 
Populations of Th1 (IFNγ+, blue), Th1 + IL-10 (IFNγ+IL-10+, turquoise), Th0 (no cytokine production, 
red) and IL-10+ (grey) were assessed by flow cytometry for intracellular expression of T-bet and Foxp3 
and surface expression of CD127. C. The frequency of splenic CD4+Foxp3+ natural Tregs were 
determined by flow cytometry in naïve and day 28-infected mice. D. MFI of Foxp3 expression in natural 
Tregs. Data shown are representative flow plots and histograms and mean frequency (±SEM) from n=3 
mice. Representative of 2 experiments. *=p<0.05 for infected vs naïve mice.  
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Figure 3.4 Altered composition and phenotypic analysis of the CD11chi cDC compartment during 
chronic infection. A, B. CD11chiMHCIIhi conventional DC can be phenotypically divided into three 
subsets based upon surface expression of CD4, CD8α or neither. C. The frequency of each cDC subset 
was quantified in naïve and day 28-infected mice. D-F cDC subset expression of CD11b, Ly6C and 
CD103 was determined in mice at day 28 of infection. Red line indicates specific staining, grey histogram 
isotype control.  Data show representative dot plots or histograms, and the mean frequency of each 
splenic cDC subset ±SEM from n=4 mice. Representative of 2 (D – F) or 4 (A – C) individual 
experiments. *=p<0.05, ***=p<0.001 for infected vs naïve mice. Filled grey histogram- Isotype control, 
open red line- specific staining. 
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Figure 3.5 Subset-specific alterations in costimulatory molecule and TLR2 expression by splenic 
cDCs during chronic infection. cDC subsets from naïve or day 28 infected mice were assessed by flow 
cytometry for surface expression of CD40 (A), CD80 (B), CD86 (C), CD70 (D), B7-H1 (E) and TLR2 
(F). Charts show mean fold increase ±SEM of surface protein expression (MFI) on the indicated CD11chi 
MHCIIhi cDC subset from infected mice over cDC from naïve, age matched control animals. Data are 
representative of 2 individual experiments, n=3-4 mice per experiment. *=p<0.05, **=p<0.01, ns = not 
significant for differences between cDC subsets 
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Figure 3.6 cDC subsets sorted to high purity from spleens of naïve and chronically infected mice. 
Conventional splenic DC were characterised by flow cytometry as CD11chi MHCIIhi (A) DX5- (B) and 
defined as three discrete subsets based upon surface expression of CD4, CD8α or neither (C). CD11c+ 
cells were isolated by positive selection using CD11c-specific magnetic beads. cDC subsets were then 
flow sorted based on expression of CD4 (D), CD8α (E) or a lack of expression of both (F). A - C show 
representative FACS plots used to define parameters for sorting. D - F show representative plots of sorted 
populations assessed for purity by subsequent flow cytometric analysis. All cDC subset populations were 
routinely 98-99% pure when used for downstream analysis.  
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Figure 3.7 cDC subsets accumulate immunoregulatory cytokine mRNA during chronic infection. 
Splenic cDC subsets were sorted from individual naïve or day 28 infected mice and frozen immediately in 
RLT lysis and RNA stabilisation buffer. Changes in the relative expression of mRNA encoding the 
indicated genes between cDC from naïve or day 28-infected mice was determined by qRT-PCR, using 
HPRT as an endogenous control. A - E show fold increase in accumulation of the indicated mRNA in 
cDC subsets isolated from 4 individual mice at day 28 p.i, compared to cDC isolated from 4 individual 
naïve mice, ±SEM. Representative of two individual experiments. 
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Figure 3.8 Impaired production of IL-12p40 accompanies the acquisition of an immunoregulatory 
cytokine profile by cDCs during chronic infection. Splenic cDC subsets were sorted from pooled naïve 
or individual day 28 infected mice. A-E. 1x105 of each subset was plated, in triplicate, in complete RPMI. 
Cells were cultured for 24 hours at 37oC and resultant cell supernatants assessed for the presence of IL-
12p40 (A&B), IL-27p28 (C) or IL-10 (D&E) by sandwich ELISA, according to the manufacturer’s 
instructions. Where indicated, cDC subsets were cultured in the presence of 1µg/ml ultrapure 
Lipopolysaccharide (LPS) or 1.3µg/ml anti-mouse IL-10 receptor (αIL-10R). Data shows mean 
production of indicated cytokine from triplicate wells of sorted cDC subsets of 6-8 pooled naïve mice (per 
cytokine) and sorted cDC from 3-4 individual mice at day 28 p.i. ± SEM. * = p<0.05, **= p<0.01, 
***=p<0.001 
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Figure 3.9 Effective CD4+ T cell priming and weak Th1 polarisation by cDC subsets isolated during 
chronic infection. cDC subsets were sorted as previously. cDC were cultured at a 1:5 ratio with 
TCRβ+CD44loCD62Lhi CFSE-labelled OTII.Rag2-/- T cells, in the presence of 5nM OVA(323-339) peptide. 
After 5 days, cells were restimulated with PMA and Ionomycin for 2 hours. A-D. CD3ε+CD4+ T cells 
were assessed by flow cytometry for proliferation and IFNγ production. A shows representative FACS 
plots indicating CFSE dilution and IFNγ production by CD3+CD4+ cells induced by cDC subsets from 
naïve (upper panel) or day 28 infected (lower panel) mice. B shows the mean level of OTII proliferation 
induced by the indicated cDC subset from naïve or day 28 infected mice ±SEM. C shows the mean fold 
increase in Th1 polarising capacity of cDC from chronically infected mice, when compared to cDC from 
naïve animals ±SEM. D and E show the capacity for LPS-stimulated cDC subsets from naïve (D) or day 
28 infected (E) mice to instruct Th1 commitment in OTII T cells. Data are from 3-5 replicate wells per 
cDC subset and are representative of 2 individual experiments.  *=p<0.05 **= p<0.01, for LPS-
stimulated cultures compared to media only control wells.  
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Figure 3.10 Coordinate inhibition of IL-10 and IL-27 signalling improves the Th1 polarising 
capacity of cDC subsets isolated from chronically infected mice. A-E. cDC subsets from naïve (A–C) 
or day 28 infected (D-E) mice and naïve OTII T cells were sorted and cultured as described, in the 
presence of control IgG, αIL-27p28, αIL-10R or both. Data show mean fold change in capacity for Th1 
induction, determined by dividing the frequency of IFNγ+ OTII T cells in triplicate cDC-T cell co-cultures 
with the indicated treatment by the frequency in triplicate cultures containing RPMI and OVA(323-339) 
only. Data are mean ±SEM, and are from one experiment. * = p<0.05, **= p<0.01 
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Figure 3.11 Potential mechanisms of altered cDC cytokine production due to chronic infection 
Several signalling pathways may be implicated in the simultaneous enhanced IL-10 production and 
repressed IL-12 production by splenic cDCs observed in this study. These include i) direct recognition of 
L. donovani by TLR2 and/or DC-SIGN, leading to ERK activation and IL-10 production; ii) formation of 
a TRAF6 and Syk-containing signalosome downstream of CD40; iii) metabolism of retinoic acid and 
autocrine induction of SOCS3 and iv) autocrine uptake up of IL-10 and suppression of IL-12p40 gene 
induction. Adapted from [490], original literature cited in text.  
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Chapter 4: CD11chi cDCs facilitate the expansion of IFNγ+ IL-10+ CD4+ 
T cells in vivo and help maintain chronic infection with L. donovani 
 
4.1 Introduction 
The altered cytokine profile of splenic cDCs identified in the previous chapter 
suggested a potential auto-regulatory role for IL-10 and IL-27 in modulating production 
of IL-12 by these cells during infection. Such autocrine IL-10 signalling is known to 
suppress IL-12 production by DCs as a result of Mycobacterium tuberculosis infection 
[491], as well as inhibiting IL-12p70 production by splenic cDCs after TLR stimulation 
in vitro [492]. Suppression of TLR-induced IL-12 expression via activation of ERK 
occurs due to autocrine uptake of IL-10 by BMDCs [493] and the functional exhaustion 
of DCs is purportedly mediated by a similar mechanism [494]. There is no direct 
evidence for the inhibition of IL-12 production by DCs as a result of IL-27 signalling; 
however, enhanced activation of DCs from IL-27R-deficient mice [495] and the 
inhibition of macrophage IL-12 production by IL-27 in vitro [496] suggest a potential 
regulatory role for this cytokine at the level of the APC. To date, no study has addressed 
the role for autocrine IL-10 or IL-27 signalling in modulating the cytokine profile of 
splenic cDCs isolated during chronic parasitic infection in vivo. 
 
IL-27 production by DCs and macrophages is known to be dependent on several 
elements of the type I interferon (IFN) pathway. IFNα is critically required for 
expression of the IL-27p28 subunit in TLR3, 4 or 7/8-stimulated human macrophages, 
as a direct result of IRF1 induction and subsequent binding to an ISRE in the p28 gene 
promoter [497]. Confirming this crucial role for IRF1, stimulation of human monocyte-
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derived DCs with another type I IFN, IFNβ, either alone or in conjunction with LPS, 
leads to enhanced IL-27p28 expression, again as a result of IRF1 activation [498]. IRF3 
has been proposed as a ‘master switch’ for IL-27 expression, with Irf3-/- BMDCs 
showing reduced IL-27p28 production in response to LPS, Irf3-/- mice having lower 
concentrations of serum IL-27 in response to LPS administration  and the existence of 
an IRF3-specific binding site within the human IL-27p28 promoter [499].  
 
More recently, a sequential process leading to IL-27p28 expression has been proposed, 
whereby in response to TLR3 or TLR4 stimulation, initial IL-27p28 expression is 
induced by IRF1 and IRF3 and the subsequent amplification of expression is dependent 
upon recruitment of an IRF9-containing IFN-stimulated gene factor 3 complex [500]. 
This is further complicated by a role for IRF8 in enhancing IL-27 production by 
macrophages as a result of direct interaction with the p28 promoter at a binding site 
which overlaps with that of IRF1 [501]. Although BMDCs from B6.Irf7-/- mice show 
normal IL-27 production in response to LPS [500], it is not known whether IRF7 is 
required for production of IL-27 by splenic cDCs in response to infection in vivo. In 
addition, as studies addressing a function for IRF7 in the response to Leishmania 
donovani infection in vivo have been restricted to the acute stages of parasitisation [502] 
and chronic infection of the liver (Beattie et al, in press), little is known about the role 
for this transcription factor in the establishment of chronic disease in the spleen. 
 
The ability to selectively deplete CD11c-expressing dendritic cells was first established 
using transgenic animals carrying a simian diphtheria toxin receptor (DTR) under 
control of the CD11c promoter [503]. This system allowed for conditional ablation of 
dendritic cells in an otherwise intact animal after administration of diphtheria toxin 
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(DTx). However, toxicity as a result of repeated DTx treatment limited studies with this 
original line of mice to short-term DC ablation, unless bone marrow radiation chimeras 
were generated [504]. 
 
In addition, new strains of mice have been developed that allow for multiple injections 
of DTx, and therefore sustained DC ablation, including CD11c.DOG mice bearing a 
human DTR under the control of the CD11c promoter [505]. Studies using this line of 
mice established the feasibility of sustained depletion of splenic CD11c+ cells for up to 
11 days during Schistosoma mansoni infection [506]; a chronic disease associated with 
splenic enlargement of a similar order of magnitude to that seen in L. donovani-infected 
C57BL/6 mice.  
 
In order to avoid issues with DTx toxicity, a novel strategy for CD11c-depletion during 
chronic infection was employed in this study, using mice in which Cre recombinase is 
expressed under control of the CD11c promoter [507], crossed with mice bearing a 
loxP-flanked STOP cassette upstream of a simian DTR sequence [508]. As such, the 
resulting strain has DTR expression restricted to cells in which CD11c promoter activity 
has occurred. Very few studies have attempted to address the role of DCs in Leishmania 
infection by such conditional ablation approaches. These have been limited to short-
term DC depletion after acute infection with L. infantum promastigotes [353]; transient 
ablation of DCs during L. donovani and Streptococcus pneumoniae co-infection [509]; 
and depletion of langerin-expressing cutaneous DC populations during L. major 
infection using a langerin-DTR ablation system [510].  
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This chapter therefore aims to elucidate the mechanisms behind the dysregulated 
cytokine profile of cDCs, to assess any role for IRF7 in IL-27 production and pathology 
during infection and for the first time determine the impact of in vivo dendritic cell 
ablation on disease progression and pathology during chronic infection with L. 
donovani.  
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4.2 Results 
4.2.1 Autocrine IL-10 signalling inhibits IL-12p70 production by cDCs  
In order to gain an insight into the potential mechanisms responsible for the altered cDC 
cytokine profile of identified during chronic infection, total CD11chiMHCIIhi splenic 
cDCs were sorted from groups of naïve and day 28 infected C57BL/6 mice and cultured 
for 24 hours in the presence of LPS, control IgG, αIL-27p28 and αIL-10R, or 
combinations thereof, before levels of IL-12p70 (4.1A&B) and IL-10 (4.1C&D) in 
culture supernatants were determined by ELISA.  
 
cDCs isolated from naïve and infected mice showed very low levels of IL-12p70 
production when cultured in the absence of exogenous stimulation. Upon LPS 
stimulation, cDCs from naïve mice produced significantly more IL-12p70, increasing 
from 2.54 ±0.47pg/ml from unstimulated cDCs to 28.36 ±5.59 pg/ml (p<0.05) in the 
presence of LPS. Although barely detectable ex vivo, IL-12p70 production by cDCs 
from day 28 infected mice increased to 12.26 ±1.65 pg/ml (p<0.01) when cultured with 
LPS. Adding Isotype control (IgG) or αIL-27p28 antibodies in the presence or absence 
of LPS during culture had no effect on IL-12p70 production by cDCs from naïve or 
infected mice, with levels of IL-12p70 in supernatant not significantly altered at 3.54 
±0.22 and 3.77 ±0.13 pg/ml, respectively. In contrast, inhibition of IL-10 signalling by 
culture with an IL-10R blocking antibody had a profound effect on cDC production of 
IL-12p70, particularly by cDCs isolated from chronically infected mice.  
 
IL-10R blockade in isolation had a small but significant effect on IL-12p70 production 
by cDCs isolated from naïve mice, with levels in supernatant increasing to 7.16 ±1.04 
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pg/ml (p<0.05) after culture. Similarly, addition of αIL-10R to cDCs isolated from mice 
at day 28 of infection led to an increase in IL-12p70 production to 9.05 ±0.83 pg/ml 
(p<0.01) after 24 hours of culture.  When inhibition of IL-10 signalling was combined 
with LPS stimulation, IL-12p70 production by cDCs from both naïve and infected mice 
was dramatically increased. This was represented by increases to 101.41 ±20.37 pg/ml 
(p<0.01) and 266.11 ±7.79 pg/ml (p<0.0001) of IL-12p70 in culture supernatant of 
cDCs from naïve and day 28 infected mice, respectively when compared to cDCs 
cultured in the presence of LPS and IgG. Blockade of IL-10R alongside neutralisation 
of IL-27p28 during culture led to significantly higher production of IL-12p70 by cDCs 
isolated from both naïve and infected mice, when compared to those cultured with IgG, 
at 6.14 ±0.74 (p<0.05) and 7.03 ±0.89 pg/ml (p<0.01), respectively. However, the 
combined inhibition of IL-10 and IL-27 signalling did not have a supplementary effect 
on IL-12p70 production by cDCs with levels similar to those observed when IL-10 
signalling was blocked in isolation.  A similarly enhanced response was observed when 
cDCs were cultured with IL-10R blocking and IL-27p28 neutralising antibodies in the 
presence of LPS. This was reflected by highly significant increases in IL-12p70 
production, reaching 87.83 ±6.25 and 269.53 ±8.21pg/ml in culture supernatants of 
cDCs isolated from naïve and chronically infected mice respectively. Again, enhanced 
production of IL-12p70 by cDC when IL-10 and IL-27 signalling were both inhibited 
was not significantly greater than that observed when IL-10R was blocked in isolation. 
 
A similar approach was taken to assess whether IL-10 production by cDCs isolated 
from naïve or chronically infected mice was affected by IL-10R blockade and IL-27p28 
neutralisation. After 24 hours in culture, culture supernatant from cDCs isolated from 
naïve animals had very low levels of IL-10 (4.1C). IL-10 was only detectable in culture 
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supernatant when cDCs were cultured in the presence of αIL-10R and LPS or αIL-10R, 
αIL-27p28 and LPS (62.23 ±9.2 and 55.07 ±4.55 pg/ml, respectively). 
 
 In contrast to those isolated from naïve mice, cDCs sorted from mice at day 28 of 
infection were capable of IL-10 production even in the absence of exogenous 
stimulation (4.1D). The addition of LPS augmented this IL-10-producing capacity, with 
levels increasing from 324.29 ± 19.54 pg/ml in supernatant of cDCs cultured in media 
alone to 583.48 ±32.84 pg/ml (p<0.01) when cultured in the presence of LPS. Addition 
of control IgG or αIL-27p8, alone or in combination with LPS, had no significant effect 
on levels of IL-10 production by cDCs, when compared with respective control 
treatments. However, culture with an IL-10R blocking antibody enhanced IL-10 
production by cDCs, reflected by an increase in IL-10 from 345.15 ±55.50 pg/ml in 
supernatant of cDCs cultured with IgG to 889.11 ±60.36 pg/ml (p<0.01) when cultured 
with αIL-10R. Similarly, addition of αIL-10R to cDC cultures in the presence of LPS 
dramatically augmented the IL-10-producing capacity of cDCs, with levels increasing to 
1953.93 ±118.60 pg/ml in culture supernatant after 24 hours. Combined inhibition of 
IL-10 and Il-27 signalling, in the presence or absence of LPS, had a very similar effect 
on cDC IL-10 production as IL-10R blockade alone. In the absence of LPS, cDC IL-10 
production increased to 760.52 ±97.58 pg/ml (p<0.05) and when LPS was added IL-10 
levels in culture supernatant reached 1904.02 ±31.92 pg/ml (p<0.01). Collectively, this 
confirmed that IL-10 is produced and taken up by cDCs as a result of chronic infection 
and suggests that this IL-10 may contribute to the inhibition of IL-12p70 production by 
cDCs at this stage of infection.  
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4.2.2 IL-27 inhibits IL-12 mediated Th1 induction in vitro by an IL-10-dependent 
mechanism 
As a negative effect of cDC-derived IL-27 on in vitro T cell polarisation had been 
suggested by earlier data (cf. Chapter 3) and neutralisation of IL-27p28 had little effect 
on cDC cytokine production (4.1), to address the potential role of IL-27 production by 
cDCs, the impact of exogenous IL-27 on CD4+ T cell polarisation was determined in 
vitro.  
 
Total splenic CD11chi cDCs were sorted from naïve C57BL/6 mice and cultured with 
sorted naïve OTII.Rag2-/- T cells, in the presence of OVA(323-339) and combinations of 
the indicated cytokines (4.2A&B). After 5 days of culture, cells were restimulated and 
CD3ε+CD4+ OTII T cells assessed for functional polarisation by intracellular cytokine 
staining and flow cytometry. Restimulation with PMA and Ionomycin revealed that 
OTII T cells were solely capable of IFNγ production (4.2A). In the absence of 
exogenous cytokines, cDCs induced 7.34 ±0.89% of OTII to become IFNγ+ (4.2B), 
presumably due to spontaneous activation of splenic cDCs after isolation and culture 
(Owens, unpublished observations and [511]). This level of polarisation was 
significantly reduced to 4.5 ±0.22% (p<0.05) when OTII were polarised in the presence 
of IL-27. As expected, addition of IL-12 to the cultures generated a potent Th1 
response, with IFNγ+ OTII cells increasing in frequency to 17.91 ±0.29% after 
restimulation. Co-culture of cDCs and OTII in the presence of both IL-12 and IL-27 
significantly impaired IL-12-induced Th1 polarisation, with the frequency of IFNγ+ 
OTII T cells generated  reduced to 7.96 ±0.45% (p<0.0001).  
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In order to determine a potential mechanism for the observed inhibition of Th1 
polarisation by IL-27, total splenic cDCs were sorted from naïve C57BL/6 and B6.Il10-/- 
mice and co-cultured with sorted naïve OTII T cells in the presence of cytokines as 
before (4.2C). Although frequencies of viable cells as a whole were slightly lower in 
this experiment, activation of OTII with C57BL/6 cDCs in the presence of IL-27 again 
led to a significant decrease in the percentage of IFNγ+ OTII cells from 2.36 ±0.12% 
when activated in media alone to 1.68 ±0.08% (p<0.01) when supplemented with IL-27. 
The addition of IL-12 again led to enhanced Th1 polarisation, with 6.50 ±0.19% 
(p<0.0001) OTII expressing IFNγ after culture. Addition of IL-27 suppressed this Th1 
induction, with IFNγ+ OTII significantly reduced in frequency to 4.08 ±0.35% (p<0.01) 
when these cytokines were combined.  
 
In contrast, co-cultures containing splenic cDCs from IL-10-deficient mice did not 
contain a lower frequency of IFNγ+ OTII when cultured with IL-27, with equivalent 
frequencies of  IFNγ+ OTII at 2.89 ±0.37% with media alone and 2.52 ±0.27% in the 
presence of IL-27. The IL-12-induced polarisation of OTII cells by Il10-/- cDCs was 
slightly enhanced compared to wildtype cDCs, with 7.95 ±0.73% of OTII capable of 
IFNγ+ production after restimulation. However, the ability for IL-27 to inhibit IL-12-
induced IFNγ production by OTII was abolished when Il10-/- cDCs were used as APCs, 
as reflected in a frequency of IFNγ+ OTII generated in the presence of IL-12 and IL-27 
of 7.22 ±0.34%, not significantly altered from the frequency when stimulated with IL-
12 alone. This therefore suggests that the capacity for IL-27 to impair IL-12-induced 
Th1 polarisation is, at least in part, dependent on cDC-derived IL-10.  
 
131 
 
4.2.3 IRF7 is not required for cDC IL-27 production in vitro or in vivo and splenic 
responses to chronic L. donovani infection are unaffected in B6.Irf7-/- hosts 
Female C57BL/6 and B6.Irf7-/- mice were infected with L. donovani as described above. 
Chronic infection was allowed to establish and mice were killed at day 28. C57BL/6 
and B6.Irf7-/- animals showed equivalent alterations in spleen mass as a result of 
infection, with spleens comprising 3.94 ±0.52% and 4.04 ±0.27% of body weight in day 
28-infected wildtype and IRF7- deficient mice, respectively (4.3A). Parasite burdens in 
spleens of chronically infected mice were also equivalent, at 105.7 ±18.7 and 121.3 
±14.7 (p=ns) LDUs in C57BL/6 and B6.Irf7-/- animals (4.3B) 
 
Levels of CD40 (4.3C) and CD86 (4.3D) expression on cDC subsets were equivalent in 
steady state C57BL/6 and B6.Irf7-/- mice, with the MFI of CD40 expression on CD4+, 
DN and CD8α+ cDC subsets at 48.19 ±0.93, 37.41 ±0.55 and 63.03 ±0.82 units in 
C57BL/6 mice and at 54.34 ±2.69, 38.79 ±2.04 and 70.46 ±4.62 in mice deficient in 
IRF7. Similarly, the MFI of surface CD86 expression on cDCs were comparable, with 
the CD4+, DN and CD8α+ subsets having surface levels of 14.89 ±1.95, 17.00 ±0.44 
and 22.37 ± 3.78 fluorescence units when assessed in C57BL/6 mice and 14.63 ±0.51, 
10.29 ±1.93 and 18.21 ±2.37 when splenic cDCs from B6.Irf7-/- mice were assessed by 
flow cytometry.  
 
Showing similar patterns to those previously observed (3.5), cDC subset costimulatory 
molecule expression on cDC subsets, particularly apparent with CD86 and on CD8α+ 
cDCs, was only modestly increased after infection. Reflecting the comparable 
expression levels seen in naïve mice, there were also no major differences in 
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costimulatory molecule expression on cDCs in chronically infected wildtype or IRF7-
deficient animals. This was reflected by CD40 expression levels on CD4+, DN and 
CD8α+ cDC subsets from infected wildtype mice of 126.13 ±7.42, 106.48 ±5.64 and 
103.05 ±6.44 fluorescence units and 106.90 ±6.48, 118.14 ±9.50 and 107.70 ±7.92 units 
on the surface of cDC subsets in spleens of B6.Irf7-/- animals.  Similarly, CD86 
expression on cDC subsets during chronic infection was equivalent in C57BL/6 and 
B6.Irf7-/- mice. CD4+, DN and CD8α+ cDCs expressed CD86 at 30.01 ±2.40, 21.22 
±0.90 and 19.00 ±0.84 units in C57BL/6 mice and 28.60 ±2.44, 20.35 ±0.54 and 
19.19±1.28 in spleens of B6.Irf7-/- mice chronically infected with L. donovani, 
indicating that IRF7 deficiency does not substantially alter the regulation of 
costimulatory molecule expression on cDCs in the steady state or during inflammation.  
 
As various members of the IRF family have been implicated in the regulation of IL-27 
production [497-501], it was of interest to determine whether cDCs deficient in IRF7 
were impaired in their capacity to produce IL-27 as a result of chronic of infection 
(4.3E). Total cDCs were sorted from spleens of naïve and day 28 infected C57BL/6 and 
B6.Irf7-/- mice and cultured for 24 hours in the absence of exogenous stimulation. In 
agreement with previous data obtained from sorted cDC subsets (cf. Chapter 3), chronic 
infection of C57BL/6 mice resulted in significantly enhanced levels of IL-27 production 
by cDCs, with mean IL-27 levels in culture supernatant of 43.54 ±33.33 pg/ml after 
culture of cDCs from naïve mice and 403.80 ±23.90 pg/ml (p<0.0001) after culture of 
cDCs sorted from day 28 infected mice. Chronic infection of IRF7-deficient mice also 
led to a significantly enhanced level of IL-27 production by cDCs, with IL-27p28 in 
culture supernatant at 26.56 ±12.40 pg/ml and 283.84 ±37.08 pg/ml in culture 
supernatant of cDCs isolated from naïve and day 28 infected mice, respectively. 
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Although slightly lower than cDCs isolated from C57BL/6 mice, a lack of IRF7 did not 
impact significantly upon the ability of cDCs to produce IL-27 as a result of chronic 
infection.  
 
To establish whether IRF7 deficiency impacted on systemic immune responses in 
chronically infected mice, serum was isolated from peripheral blood of naïve and day 
28 infected C57BL/6 and B6.Irf7-/- mice. Levels of IL-12p70 (4.3F) and IL-27p28 
(4.3G) were determined by ELISA. Although elevated in infected mice of both strains, 
serum IL-12p70 levels were significantly increased only in B6.Irf7-/- mice as a result of 
chronic infection (3.95 ±0.48pg/ml vs 9.97 ±1.78pg/ml (p<0.05) in sera from naïve and 
infected B6.Irf7-/- mice, respectively). IL-27p28 was barely detectable in sera from 
naïve mice of either strain. Chronic infection led to a significant increase in serum IL-
27p28 levels from 2.60± 1.50 to 341.85 ±96.40pg/ml (p<0.05) in wildtype mice and 
6.78 ±1.68 to 272.82 ±16.98 pg/ml (p<0.001) in IRF7-deficient animals. Although 
slightly lower in B6.Irf7-/- mice, there was no significant difference between serum IL-
27p28 levels between the two strains at day 28 of infection.  
 
Finally, to investigate any potential role for IRF7 in IL-27p28 production by cDCs in 
response to other stimuli, cDCs were sorted from naïve C57BL/6 and B6.Irf7-/- mice and 
cultured for 24 hours in the presence of LPS or IFNα, before IL-27p28 levels in culture 
supernatant were determined by ELISA (4.3H).  cDCs from both strains produced very 
little IL-27p28 when cultured for 24 hours in the absence of exogenous stimulation. 
Addition of LPS increased IL-27 production to 61.23 ±3.29pg/ml by wildtype cDCs and 
59.00 ±0.75pg/ml by B6.Irf7-/- cDCs, with no significant difference in levels between 
the strains. Addition of IFNα strongly enhanced IL-27p28 production by cDCs from 
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both strains, with levels of IL-27 production significantly higher (216.92 ±5.60pg/ml) in 
culture supernatant from IRF7-deficient cDCs compared to those from wildtype mice 
(124.18 ±4.79pg/ml; p<0.001). These data indicate that IRF7 is not essential for IL-27 
production by splenic cDCs in vitro or in vivo, and that IRF7 may regulate production 
of IL-27 in response to exogenous IFNα.  
 
4.2.4 Equivalent T cell responses in chronically infected mice deficient in IRF7 
To determine whether IRF7 deficiency impacted upon T cell polarisation during chronic 
infection, splenocytes from naïve and infected C57BL/6 and B6.Irf7-/- mice were 
restimulated in vitro in the presence of PMA, Ionomycin and Brefeldin A (4.4). After 
restimulation, cytokine production by T cells was assessed by ICS and flow cytometry, 
with T cells gated as viable, CD3ε+ and expressing either CD4 or CD8α (4.4A). The 
frequency of CD4+ and CD8α+ T cells was equivalent in both strains (See chapter 5.1 
for details).  CD8α+ (4.4B&D) and CD4+ (4.4C&E) T cells were assessed for 
expression of intracellular IFNγ and IL-10. Production of IFNγ by CD8α+ T cells after 
PMA and Ionomycin stimulation of naïve splenocytes was equivalent in both strains at 
17.03 ±0.81 and 14.45 ±0.35% in C57BL/6 and B6.Irf7-/- mice, respectively (4.4D). 
IFNγ production by CD8α+ T cells increased as a result of chronic infection, but there 
was no significant difference in the frequency of these cells at 50.64 ±4.36 and 42.3 
±1.53% in spleens of chronically infected wildtype and IRF7-deficient mice.  
 
The frequency of CD4+IFNγ+ T cells in naïve B6.Irf7-/- mice was significantly elevated 
compared to wildtype animals, at 3.36 ±0.34% of splenocytes compared to 1.45 ±0.10% 
(p<0.01) in spleens of C57BL/6 mice (4.4E). CD4+IL-10+ T cells were at an equivalent 
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frequency in steady state B6.Irf7-/- and C57BL/6 mice, at 0.70 ±0.07 and 1.33 ±0.26%, 
respectively. CD4+ T cells producing both IFNγ and IL-10 were at very low and 
equivalent levels of 0.20 ±0.01 and 0.40 ±0.10% in wildtype and B6.Irf7-/- mice.  
 
Consistent with previous observations, infection with L. donovani led to the expansion 
of CD4+ T cell populations expressing IFNγ, IL-10 or both. A lack of IRF7 did not 
significantly affect the frequency of CD4+ T cells capable of IFNγ production, with 
20.06 ±5.31 and 17.96 ±2.19% of CD3ε+CD4+IFNγ+ cells in spleens of C57BL/6 and 
B6.Irf7-/- mice by day 28 of infection. Splenic CD4+IL-10+ T cells were at a 
significantly higher frequency in chronically infected B6.Irf7-/- mice, representing 2.70 
±0.34% of splenocytes in these animals, compared to 1.17 ±0.09% (p<0.05)  in 
chronically infected C57BL/6 mice. CD4+IFNγ+IL-10+ T cells expanded dramatically in 
frequency as a result of infection, comprising 4.16 ±1.54% in wildtype mice and 4.78 
±0.50% (p=ns) in IRF7-deficient mice by day 28 of infection.  Taken together, IRF7 
deficiency did not significantly alter the splenic effector T cell response during chronic 
infection, with only a slight, albeit significant, enhancement in T cell IL-10 production 
being observed in these mice.  
 
4.2.5 Efficient conditional ablation of CD11c+ cells in CD11c.iDTR mice 
To assess the functional impact of the altered dendritic cell phenotype characterised in 
chapter 3, studies were performed with mice in which the conditional ablation of 
CD11c-expressing cells is facilitated by injection of Diptheria Toxin (DTx) (4.5). Mice 
in which expression of Cre recombinase is dependent on CD11c-promoter activity 
(4.5Ai) were crossed with mice in which a construct containing a loxP-flanked STOP 
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cassette upstream of a simian DTR sequence is inserted into the ubiquitously expressed 
ROSA26 locus (4.5Aii). Past or current expression of Cre within CD11c+ cells results in 
cleavage at loxP sites flanking the STOP cassette, leading to expression of DTR on the 
cell surface, effectively resulting in CD11c-dependent DTR expression (4.5Aiii). Such 
mice, designated hereafter as CD11c.iDTR, enable depletion of CD11c-expressing cells 
and cells with past expression of CD11c by administration of DTx by i.p injection.  
 
To confirm the utility of these mice, the effects of DTx administration to naïve mice 
was determined by flow cytometry. Importantly, despite injection of multiple (4) doses 
of DTx at 48hr intervals over a 7 day period, no lethal toxicity was observed in any 
group of CD11c.iDTR mice, as has been reported for certain original strains of CD11c-
DTR animals [512]. Administration of DTx to naïve animals led to substantial decreases 
in the number of splenic CD11c-expressing cells (4.5B-C). This included i) a slight 
reduction in the number of CD11intMHCII- cells, from 1.32x106 ±2.33x104 in PBS 
treated animals to 1.01x106 ±1.23x105 after DTx administration; ii) a significant loss of 
CD11cintMHCIIhi cells, decreasing in number from 9.33x105 ±4.97x104 in PBS treated 
mice to 4.98x105 ±8.51x104 (p<0.05) cells after administration of DTx; and iii) highly 
significant ablation of CD11chiMHCIIhi cDCs, with depletion of almost 90% of these 
cells. cDC numbers dropped from 1.29x106 ±8.51x104 in PBS-treated animals to 
1.40x105 ±1.49x104 when assessed after four injections of toxin.  
 
DTx administration to naïve CD11c.iDTR mice led to a significant ablation of all cDC 
subsets, with remaining CD11chiMHCIIhi cells almost entirely restricted to the DN 
subset (4.5E). CD4+ cDCs decreased in number from 5.72x105 ±5.60x104 in PBS 
treated, naïve animals to 9.85x103 ±5.30x102 (p<0.001) after DTx treatment (4.5F).  
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CD8α+ cDCs were depleted to a similar efficiency, decreasing from 1.47x105 ±1.19x104 
to 1.43x103 ±5.29x102 (p<0.001) after administration of DTx. Although highly 
significant, depletion of DN cDCs was less effective, with 1.20 x105 ±1.32x104 cells 
from this subset remaining in DTx treated mice, compared with 5.01x105 ±3.15x104 
cells (p<0.001)  in PBS-treated control animals. CD11c.iDTR mice should therefore 
provide an effective tool to address the impact of conventional cDC subset depletion in 
the chronic stages of infection with Leishmania donovani.  
 
4.2.6 Effects of DTx administration on spleen cell composition in CD11c.iDTR 
mice 
Although administration of DTx should have a limited effect on non-CD11c expressing 
cells, evidence for promiscuous activity of the CD11c promoter required an assessment 
of the impact of DTx administration on other splenic immune cell compartments. The 
frequencies (4.6A) and numbers (4.6B) of splenic CD3ε+ T cells and B220+ B cells 
were unaffected by administration of DTx, with T cells at a frequency of 27.75 ±0.87% 
and number of 6.02x107 ±3.29x106 in PBS-treated CD11c.iDTR mice, in contrast to 
26.46 ±2.13% and 4.44x107 ±5.61x106 in spleens after DTx administration. B220+ cells 
represented 57.80 ±1.12% of splenocytes in PBS-treated mice, representing a total of 
2.88x107 ±1.53x105 cells with this phenotype. Injection of DTx did not significantly 
alter the frequency or number of these cells, with spleens of treated mice containing 
2.03x107 ±2.66x106 B220+ cells, making up 57.70 ±1.17% of splenocytes after DTx 
injection. 
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 CD4+ and CD8α+ T cell frequency (4.6C) and number (4.6D) were similarly unaffected 
by DTx administration, with only slight, but non-significant, reductions in splenic T cell 
numbers - probably as a result of decreases in total spleen cellularity. Frequencies of 
splenic CD4+ T cells were equivalent in PBS and DTx treated mice, at 16.02 ±0.40 and 
15.31 ±0.84%, respectively. Numbers of these cells were also equivalent in both groups, 
at 4.61x106 ±8.62x104 and 3.17x106 ±6.14x105 in PBS and DTx treated mice. 
Administration of DTx led to a slight decrease in the frequency of NK1.1+CD11b+ NK 
cells from 5.04 ±0.07% in PBS treated mice to 4.33 ±0.36% after DTx injection (4.6E). 
This was reflected by a significant decrease in the number of these cells, dropping from 
5.24x106 ±1.92x105 in PBS treated animals to 3.31x106 ±4.67x105 (p<0.05) after DTx 
treatment (4.6F). A slight, but insignificant, decrease in the frequency of splenic 
NK1.1+ cells, from 1.91 ±0.15 to 1.74 ±0.23% was also seen after DTx administration, 
represented by a drop in the number of these cells from 1.97x106 ±1.21x105 in spleens 
of PBS treated mice to 1.29x106 ±8.25x104 after injection of the toxin.  
 
The frequency (4.6G) and number (4.6H) of Gr-1hi cells in CD11c.iDTR mice treated 
with DTx decreased to 1.83 ±0.14% of splenocytes, or 1.40x106 ±1.92x105 cells, from 
3.15 ±0.20% and 3.26x106 ±1.04x105 cells (p=ns) in PBS treated animals. This was 
accompanied by a reciprocal increase in the frequency of Gr-1hiCD11bhi cells, from 3.88 
±0.28% to 10.09 ±1.49% (p<0.05) of splenocytes and in cell number from 4.04x106 
±3.16x105 to 7.73 ±1.45x106 (p<0.05) after DTx administration. Therefore, 
administration of four doses of DTx to naïve CD11c.iDTR mice led to a significant 
reduction in the number of splenic NK1.1+CD11b+ cells, in addition to a significant 
expansion in the number of Gr-1hiCD11bhi neutrophils in the spleen.  
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4.2.7 Conditional ablation of CD11c+ cells during chronic infection reduces splenic 
pathology, enhances nitric oxide production and initiates parasite clearance 
In order to assess the impact of CD11c-depletion on parameters of disease, 
CD11c.iDTR mice infected with L. donovani, or age-matched naïve controls, were 
treated with PBS or 4ng/g DTx every 48 hours from day 21 of infection (4.7A). At day 
28 mice were killed and effects on spleen cell composition determined by flow 
cytometry. The effects of DTx administration to chronically infected mice were broadly 
equivalent to those seen after DTx administration to naïve CD11c.iDTR animals (data 
not shown, cf. 4.6). The frequencies of splenic Gr-1hi cells were equivalent, at 0.74 
±0.07% vs 0.94 ±0.02%, in PBS and DTx treated mice respectively (4.7B), with Gr-
1hiCD11bhi cells increasing significantly in frequency from 1.46 ±0.18% to 2.38 ±0.29% 
(p<0.05) after DTx administration. In contrast, treating infected CD11c.iDTR mice with 
DTx led to a decrease in the number of Gr-1hi cells from 5.59x106 ±5.10x105 to 3.04 
x106 ±3.42x105 after treatment (4.7C). This was accompanied by a slight decrease in the 
number of Gr-1hiCD11bhi cells from 1.15x107 ±2.22x106 in PBS treated mice to 
7.33x106 ±5.26x105 after DTx administration.   
 
Administration of DTx to chronically infected CD11c.iDTR mice also allowed for the 
efficient ablation of splenic CD11c-expressing cells (4.7D-F). This was represented by 
depletion levels in infected mice across two pooled experiments (n=8) of 31.22 ±4.74% 
for CD11cintMHCII- cells, 52.99 ±5.00% for CD11cintMHCIIhi cells and 78.39 ±5.07% 
from CD11chiMHCIIhi cells (4.7E). As in naïve CD11c.iDTR mice treated with DTx, 
cDC subsets were also depleted to high efficiency in infected mice, with 98.23 ±0.25%, 
75.56 ±3.88% and 99.08 ±0.30% of CD4+, DN and CD8α+ cDC subsets depleted 
respectively, after DTx administration (4.7F).  
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Depletion of CD11c+ cells in chronically infected CD11c.iDTR mice had a profound 
impact on splenic pathology, reflected by dramatically reduced spleen size in these 
animals, from 3.94 ±0.22% of total body weight in PBS-treated, infected CD11c.iDTR 
mice, to 2.14 ±0.14% (p<0.0001) of body weight in DTx treated animals (4.7G). 
Treatment of naïve mice with DTx had no impact on spleen size, with spleens of naïve, 
PBS treated animals at 0.35 ±0.02% of body weight compared to 0.37 ±0.04% of body 
weight after injection of DTx. Reduced splenic pathology was accompanied by 
significantly enhanced production of Nitric Oxide by adherent splenocytes, with NO2- 
levels in culture supernatant increasing from 23.04 ±2.51 µM in PBS-treated, infected 
mice to 92.36 ±21.89 µM (p<0.05) after culture of adherent splenocytes from DTx-
treated animals (4.7H). NO2- was not detectable in culture supernatants of adherent 
splenocytes isolated from naïve animals treated with either PBS or DTx. Ablation of 
CD11c+ cells also had a significant effect on splenic parasite burden, represented by a 
decrease in LDUs from 101.54 ±23.02 in PBS-treated animals to 26.98 ±9.45 (p<0.05)  
after ablation of CD11c+ cells (4.7I). Levels of circulating IL-27 were dramatically 
enhanced as a result of infection, with PBS-treated CD11c.iDTR serum containing 
287.45 ±23.05pg/ml of IL-27p28 protein, up from a baseline of 5.85 ±1.15pg/ml 
(p<0.0001) in naïve PBS-treated animals (4.7J). Levels of serum IL-27p28 were 
similarly elevated in DTx-treated infected mice, but this was not significantly changed 
from PBS-treated animals at 336.96 ±20.68 pg/ml.  
 
4.2.8 Effects of DTx administration on splenic architecture in naïve and 
chronically infected CD11c.iDTR mice  
In order to determine any impact of DTx administration on the splenic architecture of 
naïve and infected CD11c.iDTR mice, cryosections of splenic tissue were assessed by 
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confocal microscopy for expression of CD169, CD3ε and B220 (4.8A). DTx 
administration to naïve CD11c.iDTR mice had a minor effect on populations of CD169+ 
marginal zone macrophages located in the marginal zone, whilst in infected mice, DTx 
treatment resulted in a significant ablation of these cells.    
 
4.2.9 Ablation of CD11c+ cells during chronic infection impairs the generation of 
IL-10+ and IFNγ+IL-10+ antigen-specific CD4+ T cells in vivo 
To further examine the mechanisms behind the dramatic improvement in pathology and 
disease progression after CD11c+ cell ablation, splenocytes from naïve and infected 
PBS and DTx-treated animals were assessed for antigen-specific cytokine producing 
capacity (4.9). Using L. donovani-pulsed BMDCs as a source of antigen during 
restimulation, intracellular cytokine staining revealed populations of splenic 
CD3ε+CD4+ T cells capable of producing IFNγ, IL-10 or both, with responding cells 
restricted to splenocytes isolated from infected hosts (4.9A). Ablation of CD11c+ cells 
did not affect the frequency of antigen-specific IFNγ+ T cells (35.78 ±4.18% in PBS-
treated mice vs 30.33 ±5.32% after DTx administration; 4.9B). Splenocytes from naïve 
mice did not respond above the background of the assay.  The frequency of antigen 
specific CD3ε+CD4+ T cells capable of IL-10 production decreased as a result of 
CD11c+ cell depletion, from 0.93 ±0.28% to 0.39 ±0.07% (p=0.07, ns) (4.9C). Antigen 
specific CD4+ T cells capable of the simultaneous production of IFNγ and IL-10 were 
significantly affected by depletion of CD11c-expressing cells, reduced by 50% in 
frequency from 2.62 ±0.31% to 1.28 ±0.11% (p=0.0009) of viable CD4+ T cells after 
administration of DTx to infected CD11c.iDTR animals (4.9D). Therefore, depletion of 
CD11c+ cells during chronic infection impairs the generation, survival, maintenance or 
recruitment of antigen-specific CD3ε+CD4+ T cells capable of IL-10 production, either 
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alone or in conjunction with IFNγ, but leaves effector cytokine production by these cells 
largely intact. Administration of DTx to chronically infected, Cre-ve littermates failed to 
ablate splenic DCs and had no discernable impact upon any of the parameters discussed 
above (data not shown).  
 
4.2.10 Neutrophil influx due to DTx administration does not account for the 
altered CD4+ T cell phenotype after ablation of CD11c+ cells  
As administration of DTx to naïve or infected CD11c.iDTR mice led to an increase in 
neutrophils in the spleen, it was important to determine whether enhanced neutrophil 
numbers contributed to the altered CD4+ T cell phenotype observed as a result of 
CD11c+ cell ablation. 1A8 is an antibody that recognises Ly6G [513] and enables the 
specific depletion of neutrophils in vivo. Neutrophil depletion was carried out in 
chronically infected CD11c.iDTR mice having received DTx, in addition to chronically 
infected C57BL/6 mice in order to control for any effects of neutrophil depletion on 
CD4+ T cell cytokine phenotype in CD11c-sufficient animals. Mice received 1A8 or 
2A3, an isotype control antibody, intraperitoneally at days 20, 23 and 26 post-infection.  
 
Administration of 1A8 to chronically infected CD11c.iDTR or C57BL/6 mice resulted 
in the efficient depletion of CD11b+Ly6G+ neutrophils, with limited or no depletion of 
CD11b+Ly6C+ cells (4.10). This was reflected by a highly significant decrease in the 
frequency of neutrophils from 11.55 ±1.05% of CD11b+ cells in CD11c.iDTR mice 
receiving 2A3 to 3.02 ±0.64% (p<0.001) in animals after 1A8 administration 
(4.10A&C). CD11b+Ly6C+ cells were consequently increased in frequency, from 14.02 
±1.66 to 25.52 ±0.87% as a result of 1A8 injection (p<0.001). Levels of CD11c+ cell 
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ablation were consistent with that observed in the absence of either antibody, as well as 
between the 2A3 and 1A8-treated groups (data not shown). Depletion of CD11b+Ly6G+ 
neutrophils was also evident after 1A8 administration to infected C57BL/6 mice, with 
these cells decreasing significantly in frequency from 14.80 ±3.27 to 1.47 ±0.54% 
(p<0.05) after treatment with 1A8. Similar to CD11c.iDTR mice, the decrease in 
neutrophil frequency was associated with a concomitant increase in the frequency of 
CD11b+Ly6C+ cells, from 12.03 ±1.54 to 27.64 ±2.49% (p<0.01) after 1A8 
administration.  
 
In order to address any impact of neutrophil influx upon the altered CD4+ T cell 
phenotype observed after depletion of CD11c+ cells, CD3ε+CD4+ T cells from DTx-
treated infected CD11c.iDTR mice, having received either 2A3 or 1A8, were 
restimulated with PMA and Ionomycin and assessed by flow cytometry for expression 
of IFNγ and IL-10 (4.10E&G). Levels of cytokine production were broadly equivalent 
in infected, CD11c+ cell-depleted mice in the presence or absence of neutrophils. This 
was the case for both effector and regulatory cytokine production, with IFNγ+ T cells at 
43.68 ±1.17 and 35.12 ±2.22%, IL-10+ T cells at 0.94 ±0.06 and 0.98 ±0.16% and 
IFNγ+IL-10+ T cells at 1.69 ±0.37 and 1.89 ±0.40% after 2A3 or 1A8 administration, 
respectively.    
 
In order to confirm whether neutrophil depletion in itself impacted upon CD4+ T cell 
polarisation during chronic infection, CD3ε+CD4+ T cells from chronically infected 
C57BL/6 mice treated with 2A3 or 1A8 were assessed for cytokine production after 
restimulation in the same way. Ablation of neutrophils had a similarly limited effect on 
T cell phenotype in mice with an intact CD11c+ compartment, with IFNγ+ T cells at 
144 
 
36.74 ±16.43 and 41.01 ±18.34%, IL-10+ T cells at 0.51 ±0.23 and 0.50 ±0.22% and 
IFNγ+IL-10+ T cells at 3.94 ±1.76 and 5.21 ±2.33% after treatment with 2A3 or 1A8, 
respectively. Therefore the reduced frequency of IFNγ+IL-10+ T cells in chronically 
infected CD11c.iDTR mice after ablation of CD11c+ cells is unlikely to be as a 
consequence of the splenic neutrophil influx associated with DTx administration.   
 
4.2.11 Adoptive transfer of CD11c+ cells from chronically-infected mice confirms 
their key contribution to the maintenance of chronic disease  
 The previous ablation studies had suggested a role for CD11c+ cells, including CD11chi 
cDCs, in the establishment of chronic infection in the spleen. Although leading to the 
depletion of ~80% of CD11chiMHCIIhi cDCs, DTx administration to infected 
CD11c.iDTR mice also led to ablation of other CD11c-expressing populations, albeit at 
lower levels, thus making an association between chronic infection and a particular 
CD11c-expressing cell type difficult. Therefore, CD11c ablation and subsequent 
adoptive transfer approaches were used to assess the relative contribution of CD11chi 
cDCs and CD11cint cells to the establishment of chronic disease (4.11). 
 
Groups of CD11c.iDTR mice were infected with Leishmania donovani and disease 
allowed to progress for 21 days. At day 21 of infection, mice received PBS or DTx, 
with some DTx-treated groups also receiving splenic CD11chiMHCIIhi cDCs and/or 
CD11cint cells sorted from day 21-infected CD45.1+ congenic wildtype donors. CD11c+ 
cell transfers were performed ~12hrs after initial DTx treatment. DTx administration on 
days 23, 25 and 27 was then performed as previously, before the end of the experiment 
at day 28 (4.11A). Transferred cell populations were sorted to high purity, with CD11chi 
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cDCs at >98% and CD11cint cells at >97% purity when isolated from infected 
B6J.CD45.1 mice at day 21 of infection (4.11B).  
 
As the transferred cells were from congenic CD45.1+ hosts, it was possible to track 
them after injection by flow cytometry (4.11C). However when assessed, the few cells 
remaining in the CD11chiMHCIIhi gate after 4 doses of DTx were exclusively CD45.2+ 
and at frequencies consistent with that previously observed after CD11c ablation. 
CD11cint cells were also entirely derived from the endogenous CD45.2+ population, 
suggesting that very few of the transferred cells, of either population, remained or had 
engrafted 7 days after transfer.    
 
Despite the lack of detectable transferred cells at day 28, transfer of CD11c+ cells from 
chronically infected mice into infected, CD11c-depleted animals substantially altered 
the splenic response to Leishmania donovani (4.11D-F). Whereas ablation of CD11c+ 
cells reduced spleen size from 2.92 ±0.53% of body weight in CD11c-sufficient mice to 
1.11 ±0.09% after DTx administration (p<0.05), adoptive transfer of CD11c-expressing 
cells from infected mice significantly restored splenomegaly. One week post-transfer, 
spleen size was 2.47 ±0.24%, 2.44 ±0.24% and 2.29 ±0.16% (all p<0.01) in CD11c-
depleted mice receiving CD11chi, CD11cint or both populations of cells, respectively 
(4.11D). Therefore, all CD11c+ cell populations restored splenomegaly after adoptive 
transfer to CD11c-depleted mice.  
 
Alongside the substantial effects on splenomegaly, CD11c ablation and subsequent 
adoptive transfer also impacted upon splenic parasite burden (4.11E). Consistent with 
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previous observations (4.7), ablation of CD11c+ cells during chronic infection led to a 
significant decrease in splenic parasite burden (116.39 ±24.15 vs 42.52 ±12.21 LDUs in 
PBS treated vs DTx treated mice, respectively; p<0.05). Transfer of CD11chi cells from 
infected mice significantly restored the splenic parasite burden (115.11 ±25.20 LDUs; 
p<0.05). Although not significantly so, CD11cint and mixed CD11chi/CD11cint transfers 
showed a similar trend and increased parasite burden in the spleen.  
 
Ablation and subsequent transfer of CD11c+ cells during infection also had an impact 
on the systemic response to L. donovani (4.11F). Although not significantly altered, 
ablation of CD11c+ cells led to a trend toward decreased levels of IL-10 in sera from 
infected CD11c.iDTR mice. However, transfer of CD11c+ cells from infected mice 
significantly augmented levels of serum IL-10, with transfer of CD11chi cDCs 
increasing levels of IL-10 to 64.50 ±12.23 pg/ml (p<0.05), CD11cint cells to 58.80 ±7.53 
pg/ml (p<0.01) and both populations to 40.00 ±5.03 pg/ml (p<0.05) 7 days after 
transfer. Therefore, transfer of CD11c+ cells significantly enhanced systemic levels of 
IL-10 after CD11c depletion.  
 
4.2.12 CD11chi cDCs are the major cell type facilitating expansion of splenic 
CD4+IFNγ+IL-10+ T cells during chronic infection in vivo.  
The previous data supported a role for CD11c-expressing cells in the maintenance of 
chronic infection. However, it appeared that CD11chi cDCs and CD11cint cells both had 
the capacity to mediate these pathological processes. To further investigate any 
differences in the function of these cell populations during infection, CD3ε+CD4+ cells 
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from each experimental group were assessed by flow cytometry for expression of IFNγ 
and IL-10 after restimulation with PMA & Ionomycin (4.12).  
 
Ablation of CD11c+ cells during infection and the subsequent adoptive transfer of 
CD11c-expressing cells from chronically infected mice altered the cytokine producing 
capacity of CD4+ T cells during infection (4.12A). CD4+ T cells producing IFNγ alone 
were not significantly affected by CD11c depletion. However, the adoptive transfer of 
CD11chi, CD11cint or both populations of cells significantly increased the frequency of 
CD4+IFNγ+ cells to 27.42 ±1.92, 27.16 ±1.92 and 23.54 ±0.75% (all p<0.01), 
respectively, by day 28 of infection (4.12B). There were no differences in the capacity 
for either cell population to affect IFNγ-producing T cell frequencies. IL-10+ T cells 
were slightly reduced in frequency by CD11c ablation, from 2.74 ±0.55 to 2.01 ±0.31% 
after DTx administration (4.12C). Adoptive transfer of either population into CD11c-
depleted animals had little effect on the polarisation of IL-10-producing T cells, 
reflected in frequencies of 2.05 ±0.15, 2.39 ±0.10 and 2.11 ±0.08% after transfer of 
CD11chi, CD11cint or both populations.  
 
In contrast to the relatively modest changes in IFNγ and IL-10 single producing cells, 
CD4+ T cells capable of simultaneous IFNγ and IL-10 production were substantially 
affected by CD11c ablation and subsequent adoptive transfer of CD11c-expressing cells 
during infection. CD4+IFNγ+IL-10+ T cells decreased in frequency from 8.21 ±1.97 to 
2.76 ±0.87% after DTx administration, with this population being substantially restored 
after adoptive transfer of CD11chi cells, to 7.21 ±0.59% (p<0.01). In contrast, adoptive 
transfer of CD11cint or both populations of cells only slightly increased the frequency of 
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splenic CD4+ T cells with this phenotype, at 4.34 ±0.80 and 4.81 ±0.43% after transfer 
(p=ns), significantly less than that generated after transfer of CD11chi cells (both 
p<0.05).  
 
Therefore, CD11chiMHCIIhi cells are the major cell type responsible for the generation 
of CD4+IFNγ+IL-10+ T cells as a result of chronic Leishmania donovani infection in 
vivo. 
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4.3 Discussion 
The data presented here further elucidate the mechanistic basis for impaired IL-12 
production by splenic cDCs during chronic infection by identifying an auto-regulatory 
loop in which IL-10 and IL-27 production by cDCs modulates their function and thus 
contributes to their limited capacity for T cell activation in vitro. Furthermore, a 
fundamental role for altered dendritic cell function in the maintenance of chronic 
infection was established by conditional ablation and subsequent adoptive transfer of 
these cells in vivo, highlighting the paradoxical role that cDCs play by impairing 
effective immune responses during experimental Leishmania donovani infection.  
 
Extending observations on cytokine dysregulation from the previous chapter, cDCs 
isolated from chronically infected mice showed an impaired capacity to produce IL-
12p70 directly ex vivo or after LPS stimulation. This is in accordance with previous data 
indicating that  ex vivo IL-12p70 production by cDC subsets is completely abolished in 
day 28-infected BALB/c mice [108]. IL-10 receptor blockade initiated enhanced 
production of IL-12p70 by cDCs from both naïve and infected mice, but this effect was 
most pronounced upon cDCs from chronically infected animals. cDCs isolated from 
chronically infected mice also produced significant amounts of IL-10, levels of which 
were increased dramatically when IL-10 uptake by cDCs was prevented after culture 
with an αIL-10R antibody, confirming observations from the previous chapter that 
suggest autocrine uptake of IL-10 by cDCs occurs as a result of infection.  
 
IL-10 has long been known as a potent suppressor of IL-12 production by APCs [514-
516], and a growing body of evidence suggests that autocrine IL-10 signalling in DC 
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regulates their functional activation, including costimulatory molecule expression and 
pro-inflammatory cytokine production [517]. Autocrine IL-10 signalling plays a role in 
mediating the IL-12-inhibiting effects of the chemoattractants MCP1-4 [518], in 
addition to regulating the differentiation, IL-12 production and T cell polarising 
capacity of human monocytes [519, 520] and mouse BMDCs [521] in vitro. However, 
IL-12p70 production by DCs can be inhibited independently of autocrine IL-10 
signalling [522] and so other mechanisms may also be involved in the cytokine 
dysregulation observed in this study. Interestingly, suppression of IL-12p70 production 
by endogenous IL-10 after TLR ligation is more pronounced in murine splenic cDCs 
than either macrophages or BMDCs [492], suggesting a particular sensitivity of these 
cells to this process of self-regulation. 
 
Although only capable of producing very little IL-10, preventing IL-10 uptake by naïve 
cDCs in culture also significantly increased their capacity for IL-12p70 secretion, 
indicating that IL-10 is highly efficient at regulating pro-inflammatory cytokine 
production by cDCs, even at low levels. This process is thought to be mediated by Stat3 
activation, as ablation of Stat3 specifically in cDCs leads to enhanced IL-12 production 
and resistance to inhibition of DC activation by IL-10 in vivo [523], with suppressor of 
cytokine signalling (SOCS)-3 also playing a role in vitro [524]. An additional 
mechanism by which autocrine IL-10 signalling in DCs impairs IL-12 production 
through Mammalian target of rapamycin (mTOR) has also been proposed [217], so 
further work will be required to elucidate the molecular mechanisms underlying the 
cytokine dysregulation described in this study. Of relevance to the enhanced expression 
of TLR2 on cDCs during infection described in Chapter 3, in addition to the potential 
recognition of Leishmania spp by this receptor [338, 342, 481-483, 485], TLR2 
signalling has been shown to induce IL-10 and result in the autocrine suppression of IL-
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12p35 mRNA in human DCs [525], suggesting a potential link between TLR2 
signalling and the suppression of IL-12 production by autocrine IL-10 in cDCs 
identified here.  
 
Studies identifying such an autocrine regulatory network during infection are more 
limited, but preventing endogenous IL-10 production by DCs initiates more effective 
Th1 responses after vaccination against Chlamydia infection [526], autocrine IL-10 
signalling prevents IL-12 production by BMDCs in response to BCG infection in vitro 
[491] and human DC production of IL-12p70 is prevented as a result of autocrine IL-10 
signalling after Neisseria meningitidis infection in vitro [527]. Furthermore, autocrine 
IL-10 production by splenic DCs in response to yeast zymosan inhibits pro-
inflammatory cytokine production in vitro [209] and IL-10 production by innate cells 
inhibits DC-derived IL-12 production after vaccination against L. major [528], 
suggesting that autocrine regulation of IL-12 production also occurs in other in vivo 
systems. In addition, endogenous IL-10 attenuates BMDC maturation and IL-12 
production in response to Streptococcus pneumoniae, as well as limiting apoptosis of 
these cells after activation [529]. However, autocrine IL-10 signalling has also been 
shown to inhibit expression of Bcl-2 family members in BMDCs, thus increasing their 
apoptotic potential [530], indicating that further work is required to address whether  
autocrine IL-10 may also impact upon splenic cDC lifespan as a result of infection in 
vivo.  
 
Despite the beneficial effect of combined IL-10R blockade and IL-27p28 neutralisation 
on in vitro Th1 polarisation by cDCs from infected mice described in Chapter 3, 
neutralisation of IL-27 during ex vivo cDC culture had a limited impact on cytokine 
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production by these cells. As cDCs from naïve mice produced very little IL-27 ex vivo, 
it was unsurprising that neutralisation of this cytokine had no effect on IL-12p70 
production by these cells, alone, in conjunction with αIL-10R, or in the presence of 
LPS. However, culture with αIL-27p28 had a similarly limited impact on IL-12p70 
production by cDCs which were previously determined as significant producers of 
elevated levels of IL-27 when isolated during chronic infection. This was unexpected, 
as rIL-27 has been reported to suppress IL-12 production by macrophages in vitro [496, 
531] and BMDCs generated from WSX-1 (IL-27Rα)-/- mice show enhanced production 
of IL-12p40 and p70, as well as augmented costimulatory molecule expression, in 
response to TLR ligation in vitro [495]. 
 
 It is possible that the autocrine suppression of IL-12p70 production by IL-10 overrides 
any inhibitory effect of IL-27 on IL-12 production; however, combined inhibition of IL-
10 and IL-27 signalling did not result in an additive effect on the rescue of IL-12p70 
production by cDCs, indicating a limited role for IL-27 in suppressing IL-12p70 in this 
situation.  Neutralisation of IL-27 actually led to slightly enhanced IL-10 production by 
cDCs after LPS stimulation, indicating a potential negative regulation of IL-10 
expression by IL-27- an effect reported in human monocytes [532]. If this is indeed 
occurring, then the enhanced IL-10 production by cDCs in the presence of αIL-27p28 
alone may explain the limited capacity for neutralisation of IL-27 to enhance IL-12 
production by cDCs; however, a recent study showing that IL-27 production by 
macrophages is required for optimum IL-10 production suggests that the opposite may 
be the case [533]. Further work will be required to more fully elucidate the mechanisms, 
but the data presented here indicate that autocrine IL-10 signalling plays a dominant 
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role in modulating pro-inflammatory cDC cytokine production during chronic L. 
donovani infection.  
 
As there appeared to be a limited role for IL-27 in directly regulating cytokine 
production by cDCs, the impact of exogenous IL-27 on the polarisation of OTII.Rag2-/- 
TCR transgenic T cells was assessed in vitro. As previously discussed, IL-27 has a 
documented role in the generation of IFNγ+IL-10+ CD4+ T cells. Despite this, five day 
cultures with cDCs in the presence of exogenous recombinant IL-27 did not lead to IL-
10 production by OTII T cells after restimulation with PMA and Ionomycin. Instead the 
contribution of IL-27 to the negative regulation of IL-12-induced Th1 polarisation, 
partially dependent upon APC-derived IL-10, was apparent.  
 
As discussed in Chapter 3, such a lack of IL-10 production by OTII T cells after culture 
with IL-27 could be due to variations in the in vitro systems used for assessing its 
function. This study utilised recombinant IL-27 at a concentration shown to induce 
IFNγ+IL-10+ cells from draining LN of mice infected with L. major [486], suggesting 
that the availability of IL-27 is unlikely to be a reason for the lack of CD4+IL-10+ T 
cells generated after in vitro culture. Other components of the culture system may 
however be playing a role; the vast majority of previous studies describing IL-27’s role 
in T cell IL-10 production utilised a much ‘stronger’ stimuli of αCD28 and/or αCD3, in 
many cases in an APC-free system, than the cDCs plus PMA and Ionomycin used here 
[254, 255, 259, 260, 262]. However the part played by IL-27 in the polarisation of CD4+ 
T cells to an IFNγ+IL-10+ phenotype has been reported in a system involving CD11c+ 
APCs in conjunction with PMA and Ionomycin restimulation [486], so there is some 
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evidence that both culture / restimulation methods are permissive to the generation of T 
cells with this phenotype.  
 
Previous studies showing co-expression of IL-10 and IFNγ by T cells in vitro, 
irrespective of whether the role of IL-27 was addressed, have been restricted to using 
non-TCR transgenic T cells [486, 534], T cells bearing auto-antigen specific TCRs 
[254] or an OVA-specific DO11.10 TCR from mice on a BALB/c background [262, 
488]. Therefore it is possible that the nature of the TCR transgenic T cell system used in 
this study had specific differences which impacted upon the potential for IFNγ+IL-10+ T 
cell generation by cDCs in vitro. Further work will be required to determine if the lack 
of any co-expression of IFNγ and IL-10 in this study was due to an intrinsic incapacity 
of OTII.Rag2-/- T cells to acquire this phenotype after stimulation.  
 
Interestingly, IL-27 partially inhibited the IL-12-induced Th1 polarisation of OTII T 
cells after culture. A capacity for IL-27 to affect Th1 polarisation has been reported in a 
wide range of relevant experimental infections. Mice deficient in WSX-1 and thus 
unable to respond to IL-27 show exacerbated Th1 responses, pro-inflammatory cytokine 
production and severe liver pathology when infected with Leishmania donovani [535], 
Plasmodium berghei [536], Trypanosoma cruzi [239] or Toxoplasma gondii [238]. A 
very similar pathology is observed in WSX-1-/- mice infected with Mycobacterium 
tuberculosis, where exacerbated IFNγ production and T cell activation leads to 
enhanced macrophage activity and bacterial clearance, but severe immunopathology and 
early death [496]. However, IL-27R deficiency does not affect IFNγ production by T 
cells in mice infected with Listeria monocytogenes [262], indicating that the effects of 
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IL-27 signalling on IFNγ+ T cell polarisation may be dependent upon the nature of 
infection.  
 
Such a dramatic impact of IL-27 on IFNγ-production by CD4+ T cells may be due to 
mechanisms independent of IL-10, as serum and splenocyte production of IL-10 is 
equivalent to that of wildtype animals at day 30 during L. donovani infection of WSX-1-
/- mice [535]; IL-10 levels are equivalent in liver mononuclear cells from wildtype and 
WSX-1-/- mice infected with T. cruzi [239]; and administration of recombinant IL-10 to 
P. berghei infected IL-27R-deficient mice is unable to prevent immunopathology [536]. 
Although IL-12 expression is enhanced at the mRNA and protein level during infections 
of WSX-1-/- mice, [496, 535, 536], no study has addressed whether DCs are the source 
of enhanced IL-12; assays in previous studies were performed on whole tissue or serum. 
However the exacerbated T cell IFNγ production during T. gondii infection of WSX-1-/- 
mice is thought to be independent of the regulation of IL-12 in DCs [238], therefore 
suggesting that IL-27 can modulate T cell IFNγ production independently of DC-
derived IL-10 and IL-12, consistent with the observations that IL-27 blockade had little 
effect on production of these cytokines by cDCs in this study. 
 
Perhaps the most convincing evidence of a role for IL-27 in directly regulating IL-12-
induced Th1 induction, similar to that described here, comes from recent work 
describing the function of liver myeloid DCs (mDCs) [537]. These cells preferentially 
express IL-10 and IL-27 after activation, have a higher threshold for LPS stimulation 
and a reduced capacity for T cell polarisation, in part due to their low levels of IL-12 
production. Crucially, culture of liver mDCs with wildtype or WSX-1-/- T cells in the 
presence of exogenous IL-12 revealed significantly augmented IFNγ production from T 
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cells which could not respond to the IL-27 produced by mDCs, strongly indicating that 
IL-27 is able to regulate Th1 polarisation induced by IL-12 in vitro.  
 
As these cells co-express IL-10, similar to the splenic cDCs described in this study, it is 
not possible to segregate the respective roles for IL-10 and IL-27 in this process. 
However, the data presented in this study indicates that the inhibition of IL-12-induced 
IFNγ from OTII T cells by IL-27 is at least partially dependent upon IL-10, as cultures 
utilising B6.Il10-/- cDCs as APCs revealed a more limited capacity for IL-27 to affect 
Th1 polarisation when compared to IL-10-sufficient cDCs. It is unclear whether this is 
due to a requirement for synergy between IL-10 and IL-27 to fully suppress Th1 
polarisation, but as IL-27 has been recently reported to modulate other effector 
functions of IL-12 [538] and antagonise gp130-mediated pro-inflammatory cytokine 
signalling [539], further work is warranted to elucidate the mechanism behind this 
observation. Nevertheless, the regulation of IL-12 function by IL-27 suggested by this 
data allows the creation of a model by which autocrine IL-10 signalling as a result of 
chronic infection limits IL-12 production by cDCs, with the effector function of the low 
levels of IL-12 remaining being modulated by IL-27 produced by the same cells (cf. 
Chapter 6). This goes some way to explaining the observed synergy between IL-10R 
blockade and IL-27p28 neutralisation in improving the Th1 polarising capacity of cDCs 
described in the previous chapter.  
 
In summary, the data presented here are the first evidence that the profound suppression 
of IL-12 production by splenic cDCs as a result of L. donovani infection in vivo is, at 
least in part, mediated by autocrine uptake of IL-10. In addition, IL-27 contributes to the 
impaired T cell polarising capacity of these cells by modulating IL-12-induced IFNγ 
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production by CD4+ T cells in vitro. As both T cells and APCs express the IL-27 
receptor [218, 540, 541], determining whether sensitivity to IL-27 and/or IL-10 is 
required by cDCs and/or T cells is necessary. To this end, the use of cell-specific Cre 
recombinase-expressing mice, crossed with strains bearing a loxP-flanked WSX-1 or 
IL-10R gene, would enable the relative importance of these cytokines to the progression 
of disease to be addressed. Further work will also be required to elucidate the signalling 
pathways responsible for this novel auto-regulatory network, in addition to confirming 
the existence of such a pathway during Leishmania donovani infection in man.   
 
In the absence of tools allowing the specific ablation or in vivo neutralisation of IL-27 
or the blockade of the IL-27 receptor, an alternative approach was necessary in order to 
address the function of IL-27 during disease progression. As several members of the 
IRF family are required for optimal IL-27 expression [497-501], it was hypothesised 
that mice deficient in IRF7 may have an impaired capacity for IL-27 production similar 
to other IRF-deficient strains, thus providing a useful way to address the role of IL-27 in 
chronic Leishmania donovani infection in vivo.  
 
A lack of IRF7 did not affect splenic pathology or parasite burden by day 28 of 
infection, in contrast to the higher parasite burden in the marginal zone of IRF7-
deficient mice during acute infection [502], and the impaired clearance of parasites from 
the liver of B6.Irf7-/- mice during chronic infection (Beattie et al, in press). No study has 
directly addressed any role for IRF7 in other related parasitic infections, however, mice 
lacking IRF1, IRF2 or IRF4 all show exacerbated lesion development and impaired 
parasite clearance after infection with Leishmania major [542-545]. Therefore it would 
seem that the protective role of IRF7 in the response to Leishmania donovani is organ 
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and disease stage-dependent, as it does not appear to contribute to the regulation of 
splenic pathology during chronic infection.  
 
Chronic infection led to enhanced expression of CD40 and more muted increases in 
CD86 expression by cDCs, consistent with that described in Chapter 3 and on splenic 
cDCs during acute infection of BALB/c mice [108]. A lack of IRF7 did not 
substantially alter this activation, with comparable responses occurring in the presence 
or absence of IRF7, similar to the comparable levels of CD86 expression by splenic 
cDCs from wildtype or IRF7-deficient mice infected with murine cytomegalovirus 
(MCMV) [546]. Splenic immune cell development was normal in B6.Irf7-/- mice (cf. 
Chapter 5), consistent with the normal splenic architecture and liver immune cell 
composition previously described ([502] and Beattie et al). IRF7-deficiency did not 
affect production of IL-27 during infection, with only a slight reduction in ex vivo IL-27 
production by cDCs from chronically infected B6.Irf7-/- mice compared to cDCs from 
wildtype animals. This provides the first evidence for intact production of IL-27 by 
splenic cDCs lacking IRF7 in response to an infection in vivo and extends recent 
observations that Irf7-/- BMDCs show normal IL-27 production in response to LPS in 
vitro [500]. Confirming the lack of a requirement for IRF7 in IL-27 production more 
generally, IL-27p28 was at similar highly elevated levels in sera from C57BL/6 and 
B6.Irf7-/- mice, revealing for the first time that systemic IL-27 is detectable during 
chronic L. donovani infection. In addition, IL-27 production by cDCs in response to 
LPS or IFNα in vitro was intact in IRF7-deficient cells, further suggesting that IRF7 is 
not required for IL-27 expression under a range of conditions. The slightly reduced 
levels of IL-27 protein in both cDC supernatants and serum from B6.Irf7-/- mice may be 
due to less efficient IL-27 induction, as IRF7 is critical for IFNα induction [547] and 
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IFNα potentiates IL-27 production by macrophages [497]. More work will be required 
to determine the signalling pathways leading to IL-27 production by cDCs during 
infection, but the data here would suggest that IRF7 is not necessarily required.  
 
Although again not directly addressing IRF7, several interactions between Leishmania 
spp and IRFs in APCs have been reported. IL-12p35 expression is induced directly by 
IRF1 and IRF8 activity after L. major infection of human DCs, a process that does not 
occur during infection with L. donovani and is suggested to contribute to the impaired 
IL-12 production by these cells in response to this parasite species [548]. Amastigotes 
of L. donovani [549] and L. amazonensis [400] are also capable of inhibiting IRF8 
and/or IRF1 expression, suggesting that IRFs are a target exploited by parasites in order 
to establish persistent infection. Indeed, severely impaired IL-12 production has been 
reported in L. major infected Irf1-/- [545] and Irf2-/- mice [544], underlying the key role 
for IRFs in effective anti-parasitic immunity. In this study IRF7 deficiency did not 
affect levels of serum IL-12p70 in chronically infected mice, in contrast to a model of 
acute MCMV infection where a lack of IRF7 leads to substantially increased serum IL-
12p40 and p70 protein levels, as well as increased mRNA encoding IL-12 subunits in 
splenic tissue [546]. This suggests that IRF7 plays a less important role in IL-12 
production during infection than other IRFs such as IRF1 and IRF2 (cf. Chapter 5), 
although further work will be required to address the exact role of IRF7 in IL-12 
production by cDCs as a result of in vivo infection; this study only assessed IL-12 in 
serum, rather than production by defined cell types. 
 
It was important to determine any impact of IRF7-deficiency on the splenic T cell 
response to L. donovani, as previous studies had suggested a role for IRF7 in the 
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optimal production of IFNγ by hepatic CD4+ T cells during chronic L. donovani 
infection (Beattie et al) and splenic CD8α+ T cells during viral infection [547]. In 
addition, several IRFs are required to generate effective CD4+ T cell responses to L. 
major [542-545, 550, 551], Toxoplasma gondii [552] and Listeria monocytogenes [553], 
with T cell IL-10 production also modulated by by IRF1 during P. berghei infection 
[554]. In contrast to viral infection, no defect was observed in the CD8α+ T cell IFNγ 
response, indicating that the generation of these effector cells during infection is not 
dependent on IRF7 itself, or IFNα induction. This is in contrast to mice lacking IRF4, 
which have CD8α+ T cells with severely impaired CTL function and are thus unable to 
control LCMV infection [555], in addition to IRF8-deficient mice which also show 
impaired CTL activity during viral infection [556]. Although cytotoxic mediators such 
as perforin or granzyme B  were not directly addressed in this study, the intact levels of 
IFNγ production detected from Irf7-/- CD8α+ T cells suggests that they would have 
normal functionality, at least in response to an intracellular pathogen.  
 
No significant deficit in IFNγ production by CD4+ T cells was observed at day 28 of 
infection in Irf7-/- mice, although the frequency of CD4+IFNγ+ T cells was slightly 
reduced in IRF7-deficient animals by this time point. This is in contrast to the impaired 
hepatic IFNγ response by this stage of infection, where CD4+ T cells capable of IFNγ 
production are significantly reduced in frequency (Beattie et al). Interestingly an 
enhanced capacity for IL-10 production by CD4+ T cells at day 28 of infection was 
evident in both the spleen and liver, and may therefore impact upon CD4+IFNγ+ T cell 
development. Whilst IRF4 is known to directly bind the Il10 promoter [557] and 
positively regulate IL-10 expression by CD4+ T cells [558], impaired IL-10 mRNA 
expression and protein production by splenocytes from Irf1-/- mice infected with T. 
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gondii has been reported [559], indicating that IRFs are capable of positive and negative 
regulation of IL-10 production by immune cells. Further work is required to determine 
the mechanistic basis behind the enhanced IL-10 production observed by CD4+ T cells 
lacking IRF7, but unlike the hepatic response (Beattie et al) the augmented CD4+ T cell-
derived IL-10 levels did not appear to significantly impact upon splenic parasite burden 
or pathology.  
 
As levels of cDC-derived and serum IL-27 were equivalent in chronically infected 
wildtype and IRF7-deficient mice, it was perhaps surprising that CD4+IL-10+ cells were 
slightly altered in frequency. However, the differentiation of CD4+ T cells co-producing 
IFNγ and IL-10 was not impaired by IRF7 deficiency, and it is cells of this phenotype 
that have been particularly associated with IL-27 for their differentiation [254, 262, 
486]. Taken together, it would appear that IRF7 is not required for IL-27 production by 
splenic cDCs in vitro or in vivo, has a limited role in effector T cell polarisation in the 
spleen during chronic parasitic infection and does not substantially impact upon splenic 
pathology during persistent disease. The reasons underlying the discrepancy between 
splenic and hepatic requirements for IRF7 will require further investigation. 
 
An integral element of this study was to address the impact of the profoundly altered 
cDC phenotype upon parameters of chronic disease in vivo. To do this a novel mouse 
system was deployed which enabled the continual ablation of CD11c-expressing cells 
during ongoing chronic infection with L. donovani. The CD11c-DTR strain originally 
developed by Jung et al could only be used for studies requiring transient DC depletion, 
as toxicity and death was observed 6-7 days after a single injection of DTx [560]. In this 
study no toxicity was observed in any naïve or infected CD11c.iDTR mice after 4 
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injections of DTx over a period of 7 days. Although this was an extended period of 
time, the period of CD11c depletion is not as sustained as the 11 [505, 506] or 14 
(Engwerda et al, unpublished) days of DTx administration without toxicity previously 
reported in CD11c-DOG mice, so it is not yet clear whether the CD11c.iDTR strain 
represents a suitable model for longer-term DC depletion studies.  
 
Levels of cDC depletion were consistently high, with ~90% of splenic CD11chiMHCIIhi 
cells depleted from naïve animals. However, other CD11c-expressing cells were also 
depleted, a caveat in the system rarely mentioned or addressed in previous studies. 
Strategies deployed to overcome this issue will be discussed later in this study. 
Importantly, the majority of the CD11chi splenic DC subsets were depleted after DTx 
administration to infected mice. Subset depletion has not been routinely addressed in 
previous DC ablation studies, although splenic CD11b+ and CD8α+ subsets are 
efficiently depleted in CD11c.DOG mice receiving DTx for 11 days [506]. Although 
the numbers were significantly reduced, DN cDCs were the only subset partially 
resistant to DTx administration, with approximately 25% of these cells remaining after 
DTx treatment. As there is some ambiguity as to the nature of this cDC subset and its 
relationship to other types of DC elicited during inflammation [47, 63, 64] (cf. Chapter 
1), it is possible that cells falling into this gate are replenishing more quickly from a 
monocyte precursor or express lower levels of CD11c than the other subsets and are 
thus less susceptible to DTx treatment. Further work will be required to address this, 
and to also further define any functional alterations in the DCs that remain after 
depletion.  
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Activity of the Itgax/CD11c promoter is not completely restricted to dendritic cells, 
with evidence of Itgax expression in lineages as distinct as CD8α+ T cells and plasma 
cells [561, 562]. As a result of this, administration of DTx to CD11c-DTR mice can 
lead to the depletion of a range of immune cells, including alveolar macrophages [563], 
CD169+ lymph node subcapsular sinus macrophages [564], splenic marginal zone and 
metallophillic macrophages [353, 509, 565], but not F4/80+ red pulp macrophages [353, 
506, 509, 565]. In light of this reported promoter promiscuity, it was crucial to 
determine any effects of DTx administration to CD11c.iDTR mice on cell types other 
than DCs.  
 
No significant alterations in the frequency or number of T cell subsets or B cells were 
apparent after ablation of CD11c+ cells. A small, but significant, decrease in 
NK1.1+CD11b+ cells was observed in spleens of naïve and infected CD11c.iDTR mice 
after DTx administration, however it is not clear whether this was due to toxin-mediated 
killing or simply a reflection of the lack of cDC-derived IL-15, previously shown to be 
essential for NK cell homeostasis and activation in the periphery [566]. There were no 
other substantial alterations in splenic immune cell compartments that may be 
attributable to DTx-mediated toxicity, although loss of CD169+ marginal zone 
macrophages was observed by immunohistochemistry; a similar effect to that observed 
in previous studies utilising different CD11c ablation systems [351, 565]. However, this 
technique also revealed the maintenance of F4/80+ red pulp macrophage populations 
after DTx ablation (not shown), indicating that macrophage populations in CD11c.iDTR 
mice respond in a similar fashion to other published CD11c-DTR strains.  
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Administration of DTx to CD11c.iDTR animals did however lead to substantial levels 
of splenic neutrophilia, particularly in naïve mice. This phenomena has not previously 
been reported in published studies involving DTx administration i.p., however 
neutrophilia is observed when CD11chi cDCs are ablated in a system based upon 
constitutive expression of the A subunit of DTx under control of the CD11c promoter 
[567], suggesting that this phenomenon may be due to the presence of the toxin itself. In 
addition, neutrophils readily phagocytose cells undergoing apoptosis [568] and so the 
observed influx of neutrophils in the spleen after DTx administration may also be due to 
DTx-induced death of CD11c-expressing cells. Despite some alterations in other 
immune cell frequencies, in general the main impacts of DTx administration to 
CD11c.iDTR mice were restricted to CD11c-expressing cell populations. However 
strategies to overcome the caveats introduced to the study by the alterations in NK and 
neutrophil frequency will be addressed later.  
 
Although less efficient than in naïve CD11c.iDTR mice, the strain enabled the effective 
depletion of CD11chiMHCIIhi cDCs from chronically infected mice with around 80% 
efficiency. This is similar to the 70-80% efficacy reported for depletion of splenic cDCs 
during infection with S. mansoni [506]. The impact of a relatively short period of 
CD11c ablation on disease progression was striking. Splenomegaly, a relatively crude 
indicator of splenic pathology, was dramatically reduced by depletion of CD11c-
expressing cells. The reduced level of splenic pathology was similar to that seen after 
inhibition of vascularisation by Sunitinib, a receptor tyrosine kinase inhibitor (RTKi) 
[569], as well as parasite killing after drug treatment.  
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Although not directly addressed in this study, DCs have been reported as potential 
mediators of angiogenic pathology via production of vascular endothelial growth factor 
(VEGF); a process induced by IL-10 and Prostoglandin E2 (PGE2) [570]. As IL-10 
production by cDCs is apparent from this study  and PGE2 is associated with L. 
donovani infection [571, 572],  it remains possible that ablation of CD11c+ cells reduces 
levels of IL-10 and PGE2-induced VEGF expression during infection and thus explains 
the dramatic changes in spleen size observed when these cells were depleted. 
Furthermore, a population of CD11b+ myeloid cells has been reported to control 
vascular changes at the site of L. major infection [573], suggesting the possibility that 
the other cell types depleted by DTx administration may also contribute to tissue 
remodelling. However, DCs are also known to produce anti-angiogenic factors such as 
soluble VEGF-receptor 1 (VEGFR1) after activation [574], so further work will be 
required to address the capacity for pro-angiogenic factor production by cDCs or 
CD11cint cell populations as a result of chronic Leishmania donovani infection. 
 
Although structural changes were not affected to the same degree as with Sunitinib 
treatment, there appeared to be some restoration / protection from destruction of splenic 
architecture; albeit far less striking than that previously reported [569]. Interestingly, 
Sunitinib is a RTKi with particular affinity for Flt3 and its administration is reported to 
prevent expansion of cDCs in vivo by inhibiting proliferative signals provided by Flt3L 
in the spleen microenvironment [49, 575]. Therefore it is possible that treatment with 
Sunitinib may prevent expansion of cDCs, leading to a similar reduction in frequency to 
that seen after DTx treatment. This could partially explain the similar effects on 
pathology due to the seemingly disparate interventions of RTKi treatment and CD11c 
depletion. Further work will be required in order to investigate the potential relationship 
between CD11c+ cells, Sunitinib and tissue remodelling during chronic infection.  
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As well as the dramatic impact on splenic pathology, ablation of CD11c-expressing 
cells during chronic infection significantly affected T cell cytokine production, levels of 
serum IL-10 and the initiation of Nitric Oxide (NO)-dependent parasite clearance. The 
majority of previous studies assessing the impact of in vivo dendritic cell depletion in 
infectious settings have been restricted to acute stages of infection and thus address the 
impact of DC ablation on T cell priming, such as the reduced effector responses to acute 
infection with L. donovani [353], Toxoplasma gondii [576], HSV-1 [577], Listeria 
monocytogenes and Plasmodium yoelii [578], Streptococcus pyogenes [579], murine-
tropic HTLV-1 [580] and M. tuberculosis [581]. As such, this study is one of the first to 
address the role of DCs in disease pathology by their ablation during ongoing chronic 
infection. 
 
In this study, depletion of CD11c+ cells after the establishment infection did not 
significantly affect IFNγ production by CD4+ T cells, with the frequency of these cells 
only slightly reduced after treatment; suggesting that DCs are not required to maintain 
the capacity for effector T cell responses after initial priming. This is similar to the 
effects of DC ablation on CD4+ T cell responses to M. tuberculosis where DC are 
critical for initial priming of CD4+ effector T cell responses, but dispensable for recall 
Th1 responses after vaccination [581]. However this is in contrast to CD11c-depletion 
during established infection with S. mansoni, where IFNγ+ production by CD4+ T cells 
is significantly reduced by ablation of CD11c-expressing cells [506]; suggesting that in 
some chronic infections CD11c+ cells are required for maintaining T cell IFNγ  
production. As this study and that of Phythian-Adams et al are the only to have assessed 
the impact of DC depletion during established chronic infection, further investigations 
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will be useful to clarify the role of DCs in a variety of chronic infectious disease 
settings. 
 
In contrast to the relatively intact effector T cell polarisation, the capacity for CD4+ T 
cell IL-10 production, either alone or alongside IFNγ, was reduced after ablation of 
CD11c+ cells, suggesting that T cells with this phenotype were dependent on cDCs for 
their expansion and/or maintenance, although the mechanisms behind this are not clear. 
The first possibility is that the cDC cytokine profile is key to their generation, and that 
the ablation of cells which express IL-10 and IL-27 during infection (cf. Chapter 3) 
prevents the development of CD4+IFNγ+IL-10+ T cells. Although IL-10 has been 
reported as a key factor for the differentiation of IL-10+ regulatory Tr1 cells [487, 582, 
583], it would appear that IFNγ+IL-10+ T cells can differentiate independently of IL-10 
[162, 528] and so the loss of IL-10+ cDCs after DTx administration is unlikely to impact 
upon their expansion.  
 
IL-27 has a well documented role in the generation of IL-10+ T cells [255, 259, 260, 
262, 486], and so the ablation of IL-27-producing cDCs could be expected to prevent 
the expansion of T cells with this phenotype. However, levels of serum IL-27p28 were 
unaffected by ablation of CD11c+ cells, suggesting that other cell types are also capable 
of IL-27 production during infection and that IL-27 would thus be available for the 
polarisation of T cells toward this phenotype in the absence of cDCs.  However the 
maintenance of systemic IL-27 levels does not rule out the lack of IL-27+ cDCs as a 
mechanism underlying the reduced expansion of CD4+IFNγ+IL-10+ T cells, as it is 
possible that local production of IL-27 was affected by CD11c ablation; further work 
will be required to address this.  
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The reduction in both serum IL-10 and cDCs expressing IL-10 may have also affected 
inflammatory cytokine production by other immune cell types, thus impacting on T cell 
polarisation. For example IL-6 from transferred BMDCs is known to inhibit the 
generation of CD4+IFNγ+IL-10+ T cells during therapeutic intervention of chronic L. 
donovani infection [391] and IL-6 production is directly inhibited by IL-10 [524, 584]. 
As such, the reduced IL-10 production after CD11c+ cell ablation during infection may 
have allowed greater expression of IL-6, thereby inhibiting CD4+IFNγ+IL-10+ T cell 
expansion. However, enhanced clearance of L. donovani has been reported in Il6-/- 
animals [585], suggesting that increased IL-6 levels may actually be detrimental to the 
host response.  
 
In addition to reduced IL-10 production by CD4+ T cells, ablation of CD11c-expressing 
cells also reduced serum levels of IL-10, indicating that both IL-10+ cDCs and CD4+ T 
cells, which are both significantly reduced in frequency after DTx administration, 
contribute to systemic IL-10 levels during infection. High levels of serum IL-10 during 
infection are well documented in clinical studies, with these levels decreasing 
significantly after successful drug treatment [586-590]. Serum from patients with active 
disease has also been shown to directly inhibit killing of L. donovani amastigotes by 
human macrophages in vitro- a mechanism strictly dependent upon IL-10 [390]. 
Furthermore, evidence for the direct suppression of NO production and parasite killing 
by IL-10 in vitro [591, 592] and in vivo [593] suggests a dominant role for IL-10 in 
suppressing NO-mediated parasite clearance during persistent infection. Supporting this 
evidence, the ablation of IL-10+ CD11c-expressing cells and the subsequent reduction in 
IL-10+ T cell expansion in this study led to a concomitant increase in splenic NO levels 
and reduced parasite burdens in this organ; despite the slight decrease in the frequency 
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of splenic CD4+IFNγ+ T cells. As such, it would appear that the outcome of chronic 
parasitisation in the spleen is determined by levels of IL-10, which when reduced, 
allows the remaining IFNγ to initiate NO-dependent parasite clearance. As discussed 
later in this study, multiple IL-10+ cell types appear to be capable of maintaining 
parasite persistence and pathology during infection; however further studies utilising 
strains of mice with cell-specific Cre-mediated ablation of the IL-10R will be required 
to determine whether a particular cell type requires sensitivity to IL-10 for disease 
establishment and/or progression. 
 
As neutrophils are capable of internalising and killing L. donovani [594] and contribute 
to early control of parasite number [595], can act as functional APCs via expression of 
MHCII [596, 597] and a B7-like molecule [598] and may modulate T cell cytokine 
[599] and chemokine [600] production during experimental leishmaniasis, it was 
important to address the potential issues introduced to the study by the influx of 
neutrophils observed after DTx administration. Neutrophil depletion was therefore 
carried out using 1A8, a Ly6G-specific antibody, which selectively depletes neutrophils 
and leaves other cell populations, such as inflammatory monocytes, intact [601].  
 
Ablation of neutrophils did not significantly alter the capacity for CD11c+ depletion to 
inhibit the expansion of IFNγ+IL-10+ T cells, nor did it impact upon T cell polarisation 
in CD11c-sufficient animals; despite the previously reported roles for neutrophils in 
modulating T cell cytokine production. Neutrophil influx as a result of DTx 
administration did not explain the reduced splenic pathology in CD11c-depleted 
animals, as 1A8 treatment did not prevent the reduced splenomegaly or enhanced NO 
production observed after CD11c depletion (not shown). Parasite burdens were higher 
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in 1A8 treated animals when CD11c+ cells were also depleted; however this is probably 
due to the dramatically enhanced parasite burdens seen after neutrophil depletion in 
chronically infected C57BL/6 mice (not shown and Yurkudal et al, in preparation). 
Therefore it is unlikely that the dramatic changes in pathology and CD4+IFNγ+IL-10+ T 
cell frequency observed after ablation of CD11c+ cells are caused by an influx of 
neutrophils as a result of DTx administration. 
 
A major observation during CD11c ablation experiments was the loss of CD11cint cells 
in addition to CD11chiMHCIIhi cDCs after administration of DTx. On careful 
examination of many of the published studies deploying similar CD11c depletion 
strategies, it is apparent that many DTR systems result in the loss of splenic CD11cint 
cell populations (for example see [506]). This fact has not been addressed previously, 
and so transfers of CD11chiMHCIIhi cDCs and CD11cint populations isolated from 
infected donors into infected, CD11c-depleted recipients were performed. Transfer of 
the CD11cint population was particularly important as CD45RB+ regulatory DCs and 
splenic NK cells are known to be significant sources of IL-10 during L. donovani 
infection [172, 392], express intermediate levels of CD11c and therefore comprise part 
of the CD11cint population depleted in this study.  
 
Whilst transfer of DCs back into CD11c-depleted animals has been reported previously, 
these studies used in vitro-derived BMDCs [602, 603] or minimally purified splenic 
DCs [576] as the transferred population, in most cases generated / isolated from naïve 
hosts. As such, this study is the first to attempt to reconstitute the CD11chiMHCIIhi 
compartment with splenic cDCs sorted to high purity from mice with ongoing infection 
and thus in an as physiologically relevant state as possible. However one potential 
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caveat is the number of cells available for transfer; transferred cells were ~10 fold fewer 
than the number of cells present in an unmanipulated, infected animal.  Despite this, 
significant effects on splenic pathology were observed after transfer, although no donor 
cells were detectable by flow cytometry 7 days later. This is perhaps unsurprising for 
the transferred splenic cDC population, which have a half-life considerably shorter than 
7 days [55, 56], but the CD11cint population will have contained cDC precursors [47], 
albeit at an extremely low frequency, and so may have been expected to differentiate 
into cDCs after transfer. Nevertheless the effects of cDC transfer on pathology were 
considerable, indicating the potency of these cells to manipulate immune responses. 
Highlighting this fact, transfer of only 30,000 CD11chi cDCs isolated from draining 
lymph nodes of mice responding to house dust mite antigen has been reported to 
modulate several parameters of systemic immune function [604].  
 
Of note, CD11chiMHCIIhi and CD11cint populations from infected mice were equally 
effective at reconstituting the pathological response in the spleen after transfer, although 
cDCs were the only population which facilitated the expansion of IFNγ+IL-10+ CD4+ T 
cells. As the CD11cint population will have contained NK cells, this is line with previous 
data showing that NK cells produce IL-10 during infection and when transferred from 
infected mice, exacerbate disease [392]. Furthermore, although it was not directly 
addressed in the previous study [172], the reconstitution of disease by CD11cint cells 
suggests that CD11cloCD45RB+ IL-10-producing DCs may also contribute directly to 
disease progression. However, the CD11cint population transferred here will have 
contained both NK cells and CD11clo DCs, so it is not possible to distinguish between 
the effects of each cell type.  
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The reconstitution of the progressive splenomegaly, parasite burden and serum IL-10 
levels by CD11cint cells occurred despite maintaining a reduced frequency of IL-10+ 
CD4+ T cells, suggesting that IL-10 from T cells does not greatly impact on parasite 
burden, splenic pathology or systemic levels of IL-10. This is consistent with previous 
work showing that dramatic improvements in parasite persistence and splenic pathology 
can be achieved by therapeutic infusion of LPS-activated BMDCs, irrespective of 
whether the splenic IL-10-producing CD4+ T cell frequency is reduced or maintained 
[391], in addition to the limited functional role of IL-10 production by IFNγ+ T cells in 
preventing Th1 responses after experimental vaccination against L. major [528]. Studies 
involving the adoptive transfer of IFNγ and IL-10 co-producing cells isolated from 
infected mice would be required to address the functional significance of T cells with 
this phenotype in relation to disease progression and pathology.  
 
The paradoxical finding that CD11c+ cells, including CD11chi cDCs, negatively regulate 
the host response to L. donovani is intriguing, given that these cells are critical for 
initiating effector immune responses and usually considered entirely beneficial during 
the host response to infection. However, a basis for DC dysfunction during chronic 
infection is well established, as the infusion of BMDCs leads to a dramatic reduction in 
parasite burden and splenic pathology (Moore et al, in preparation and [313, 391, 605, 
606]), suggesting that overwhelming the endogenous, functionally impaired DC 
populations with fully activated DCs is enough to ‘kick start’ the response to the 
parasite. The data presented here support this model, as an alternative approach leading 
to depletion of the impaired DC populations used in this study allows for a similar 
enhancement in the response to infection.  
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Taken together, this data reveals CD11chi cDCs as the critical cell population involved 
in the expansion of IFNγ+IL-10+ CD4+ T cells during chronic Leishmania donovani 
infection in vivo. Although cDCs in isolation are sufficient to maintain chronic 
infection, adoptive transfer of other CD11c-expressing cell populations affected by DTx 
administration suggests that other immune cell types such as NK cells, 
CD11cloCD45RB+ DCs or as yet unidentified CD11cint cell populations are also capable 
of mediating some elements of splenic pathology and disease progression.  
 
In conclusion, this chapter reveals that splenic cDC function during chronic infection is 
modulated by an auto-regulatory cytokine cascade, involving suppression of IL-12p70 
production by autocrine IL-10. This impaired IL-12 production is accompanied by 
production of IL-27, which inhibits IL-12-induced Th1 polarisation and presumably 
underlies the impaired capacity for these cells to generate Th1 responses in vitro. 
CD11c depletion and subsequent adoptive transfer approaches revealed a critical role 
for cDCs in the expansion of CD4+IFNγ+IL-10+ T cells and the capacity for cDCs to 
maintain splenic pathology and chronic infection. IRF7 appeared to be redundant in the 
regulation of chronic infection in the spleen, however in light of the critical role for 
IRF7 and the type 1 IFN pathway in regulating the development, cytokine profile and 
PRR signalling pathways of DCs, the next chapter focuses on the role for this 
transcription factor in the regulation of cDC development and activation in vitro and in 
vivo.  
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Figure 4.1 Autocrine IL-10 signalling inhibits IL-12p70 production by cDCs. CD11chi cDCs were 
sorted from pooled naïve or day 28 infected mice as previously described. cDCs were plated in triplicate 
at 1x106 cells/ml in complete RPMI. Where indicated, LPS (1µg/ml), goat IgG (10µg/ml), αIL-27p28 
(10µg/ml) and/or αIL-10R (1.3µg/ml) were added to to give the indicated final concentration. Cells were 
cultured for 24 hours and resulting supernatants assessed by ELISA for presence of IL-12p70 (A & C) 
and IL-10 (B & D). Data are from one experiment (naïve cDCs) or representative of two experiments 
(day 28 cDCs) and show the mean concentration of the indicated cytokine ±SEM from triplicate wells 
containing cDCs sorted from 3-4 pooled naïve or day 28 infected mice. *=p<0.05 **= p<0.01, 
***=p<0.001 for indicated treatment vs control conditions. 
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Figure 4.2 IL-27 inhibits IL-12 mediated Th1 induction in vitro by an IL-10-dependent mechanism. 
CD11chi cDCs were sorted to high purity from naïve C57BL/6 or naïve B6.Il10-/- mice. cDCs were 
cultured at a 1:5 ratio with sorted TCRβ+CD44loCD62Lhi OTII.RAG2-/- T cells in the presence of 5nM 
OVA(323-339). Where indicated IL-27 (20ng/ml) and/or IL-12 (3ng/ml) were added to media to give the 
indicated final concentration. Cells were cultured for 5 days, with fresh media, containing cytokines as 
appropriate, being added at day 3. After culture period, cells were restimulated with PMA and Ionomycin, 
in the presence of Brefeldin A, and assessed by intracellular cytokine staining for CD3ε+CD4+ T cell 
expression of IFNγ and IL-10. A shows representative flow plots of CD3ε+CD4+ gated cells from cultures 
containing cDCs from C57BL/6 mice. B and C show mean frequency ± SEM of IFNγ+ T cells in cultures 
containing cDCs from C57BL/6 or C57BL/6 vs B6.il10-/- mice, respectively. Data are from one 
experiment. *=p<0.05 **= p<0.01, ***=p<0.001 
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Figure 4.3 IRF7 is not required for IL-27 production in vitro or in vivo and splenic responses to 
chronic Leishmania donovani infection are unaffected in B6.Irf7-/- hosts. C57BL/6 and B6.Irf7-/- mice 
were infected with L. donovani and infection allowed to develop until day 28. A shows splenomegaly and 
B spleen parasite burden, determined as previously described. C and D show expression of CD40 and 
CD80 by cDC subsets from day 28 infected and naïve age-matched control animals, determined by flow 
cytometry. CD11chiMHCIIhi cDCs were sorted from pooled spleens of naïve and day 28 infected 
C57BL/6 and B6.Irf7-/- mice and cultured at 1x106 cells/ml for 24 hours. E shows levels of IL-27p28 
protein in culture supernatants, determined by ELISA. F and G show levels of of IL-27p28 and IL-12p70 
in sera from naïve and day 28 infected mice of both strains assessed by ELISA. cDCs were sorted from 
naïve C57BL/6 and B6.Irf7-/- mice and cultured for 24 hours in the presence of 1µg/ml LPS or 1000 U/ml 
IFNα. H shows culture supernatants assessed by ELISA for presence of IL-27p28. Data are pooled from 
two experiments (A & B), or representative of two experiments (C – H) and show mean ±SEM from n=3 
mice per group, per experiment. *=p<0.05 **= p<0.01, ***=p<0.001  
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Figure 4.4 Equivalent T cell responses in chronically infected mice deficient in IRF7. Splenocytes 
from naïve and day 28 infected C57BL/6 and B6.Irf7-/- mice were restimulated with PMA, Ionomycin and 
Brefeldin A as before. A shows viable CD3ε+ cells, divided into CD4+ and CD8α+ subpopulations for 
analysis. Intracellular cytokine staining allowed assessment of IFNγ and IL-10 production by CD8α+ (B 
& D) and CD4+ (C & E) T cells. A-C show representative flow plots, D and E show mean frequency 
±SEM of CD8α+ or CD4+ T cells with the indicated cytokine producing phenotype. Data are from n=3 
mice per group and representative of two separate experiments. *=p<0.05 
 
 
 
 
178 
 
 
 
 
 
 
Figure 4.5 Efficient conditional ablation of cDC subsets in CD11c.iDTR mice. CD11c.iDTR mice 
were generated as described (Chapter 2.1). In these mice, expression of Cre recombinase under the 
control of the CD11c-promoter (A i) allows cleavage of loxP flanking regions around a STOP sequence 
inserted into the ROSA26 locus (A ii), leading to Diptheria Toxin Receptor (DTR) expression only in 
those cells with CD11c promoter activity (A iii). B shows representative flow plots indicating ablation of 
CD11c-expressing cells in naïve mice after PBS or DTx injection, with numbers of cells in PBS treated 
(open bars) or DTx treated (closed bars) mice shown in C. D and E show effects of DTx treatment on the 
number of conventional CD4+, DN and CD8α+ DC subsets (open bars= PBS treated, closed =DTx 
treated). Dot plots are representative and data in C and E show mean numbers of indicated cells ±SEM 
from n=4-5 mice per group and are representative of three individual experiments. *=p<0.05, 
***=p<0.001 for DTx vs PBS treated mice 
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Figure 4.6 Effects of DTx administration on spleen cell composition in CD11c.iDTR mice. 
Alterations in the frequency and number of splenic T and B cells (A & B), CD4+ and CD8α+ T cells (C & 
D), NK cells (E & F) and neutrophils (G & H) were assessed by flow cytometry after administration of 
PBS (open bars) or DTx (closed bars) to naïve CD11c.iDTR mice at 48hr intervals over a 7 day period. 
Data are mean ± SEM from 4-5 mice per group and representative of two or three separate experiments. 
*=p<0.05 for DTx versus PBS treated mice. 
 
 
 
 
 
180 
 
 
 
 
 
 
Figure 4.7 Conditional ablation of CD11c+ cells during chronic infection reduces splenic pathology, 
enhances nitric oxide production and initiates parasite clearance. A. Naïve or infected CD11c.iDTR 
mice received PBS or DTx at 48hr intervals from day 21 until day 28 of infection. B&C. Alterations in 
the frequency and number of neutrophils in PBS treated (open bars) and DTx-treated mice. D. Depletion 
of CD11c-expressing cell populations was determined by flow cytometry. E and F show depletion levels 
expressed as a percentage loss of indicated CD11c+ cell populations or cDC subsets. G shows the effects 
of DTx administration on splenomegaly, determined as previously. H shows levels of nitric oxide in 
supernatant of adherent spleen cell cultures after 24 hours in complete RPMI, determined by Greiss assay. 
I shows spleen parasite burdens in PBS or DTx treated infected mice, determined as before. J shows 
levels of IL-27p28 in serum, determined by ELISA. Flow plots in D  are representative, data in B, C, E, 
F, H and I show mean ±SEM of indicated parameters from n=4 (naïve) or 5 (infected) mice per group 
and are representative of two experiments. G and J show mean values from pooled mice from two 
experiments, n=7/8 per group.  *=p<0.05 for DTx vs PBS treated mice. 
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Figure 4.8 Effects of DTx administration on splenic architecture in naïve and chronically infected 
CD11c.iDTR mice. A. Naïve and infected mice were treated with PBS or DTx according to the schedule 
previously described. Cryosections were taken from 5mm3 blocks of splenic tissue. Sections were 
assessed for expression of CD169, CD3ε and B220 by confocal microscopy. Representative tissue 
sections shown.  Scale bar = 100µm. 
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Figure 4.9 Ablation of CD11c+ cells during chronic infection impairs the generation of IL-10+ and 
IFNγ+IL-10+ antigen-specific T cells in vivo. Naïve or infected CD11c.iDTR mice received PBS or DTx 
at 48hr intervals from day 21 until day 28 of infection, as described previously. Splenocytes were isolated 
and restimulated with L. donovani antigen-pulsed BMDCs, in the presence of Brefeldin A. A shows 
cytokine production by CD3ε+CD4+ T cells assessed by flow cytometry after intracellular cytokine 
staining. The frequencies of antigen-specific IFNγ+ (B), IL-10+ (C) and IFNγ+IL-10+ (D), cells were 
quantified. Representative flow plots are shown in A , data in B, C and D show the mean frequency of T 
cells with indicated phenotype ±SEM in mice from two pooled experiments, n=7/8 per group.   
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Figure 4.10 Neutrophil influx due to DTx administration does not account for altered CD4+ T cell 
phenotype after ablation of CD11c+ cells during chronic infection. Infected C57BL/6 or CD11c.iDTR 
(undergoing CD11c-depletion to the schedule as previously described) mice were treated i.p at days 20, 
23 and 26 with 250µg Ly6G-specific 1A8 or isotype control 2A3 antibodies. A and B show representative 
flow plots depicting specific depletion of CD11b+Gr-1+ neutrophils (plots previously gated on CD11b+ 
cells). C and D show alterations in the frequency of CD11b+Gr-1+ and Ly6C+ cells after indicated 
treatment from CD11.iDTR and C57BL/6 mice, respectively. E and F show cytokine production by 
CD3ε+CD4+ T cells after restimulation with PMA and Ionomycin. G and H show quantified T cell 
cytokine responses after indicated treatments. Flow plots are representative, charts show mean ±SEM. 
Data are from one experiment with 4 or 5 mice per group.  
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Figure 4.11 Adoptive transfer of CD11c+ cells from chronically-infected mice confirms their key 
contribution to the maintenance of chronic disease. A shows experimental schedule involving 4ng/g 
DTx administration i.p. at the indicated time points, with adoptive transfer of sorted CD11c-expressing 
cell populations from congenic, day 21 infected donors at day 21. B shows sort gates and post sort purity 
of CD11chiMHCIIhi and CD11cint populations used for transfer. C shows remaining CD11c-expressing 
cells at day 28, stained for endogenous (CD45.2) and transferred (CD45.1) surface markers. D and E 
show splenomegaly and parasite burdens, determined as previously described. F shows IL-10 levels in 
sera from mice at day 28, determined by ELISA. Flow plots are representative, charts show mean ±SEM. 
Data are from of one experiment with 3-5 mice per group. *=p<0.05, **=p<0.01.  
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Figure 4.12 CD11chi cDCs are the major cell type facilitating expansion of splenic CD4+IFNγ+IL-10+ 
T cells during chronic infection in vivo. A shows representative flow plots indicating cytokine 
production by CD3ε+CD4+ T cells from mice as in 4.11 after restimulation with PMA and Ionomycin. B, 
C, and D show the mean percentages ±SEM of IFNγ+, IL-10+ and IFNγ+IL-10+ CD3ε+CD4+ T cells in the 
indicated groups. Data are from one experiment with 3-5 mice per group. *=p<0.05, **=p<0.01 
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Chapter 5:  IRF7 regulates the TLR2-induced activation of splenic 
cDCs in vivo. 
 
5.1 Introduction 
Interferon regulatory factor (IRF) 7, a member of the IRF family of transcription 
factors, is the ‘master regulator’ of type I interferon (IFN)-dependent immune responses 
and underpins their critical role in host defence [547]. However, IRFs are also essential 
for the full development of many components of the immune system [607], including 
dendritic cells. Splenic CD8α+ cDC development is exquisitely dependent on the 
expression of IRF8, with Irf8-/- mice entirely lacking this subset [608, 609]; a 
developmental deficiency that can be rescued by retroviral transduction of bone marrow 
precursors with IRF8 during DC development in vivo [610]. Differentiation of splenic 
CD4+ cDCs depends on IRF4 [611, 612], whereas DN cDCs express and at least 
partially rely on both IRF4 and IRF8 for their full development [611]. Non-lymphoid 
DCs such as Langerhans cells and dermal DCs also require IRF8 expression for normal 
development in vivo [613]. In addition, Irf2-/- mice selectively lack splenic CD4+ cDCs 
and epidermal DC subsets [614], whereas IRF1-deficient animals have a reduced 
number of splenic CD8α+ cDCs [615]. No study has yet established whether IRF7 is 
required for full splenic cDC development in vivo.  
 
In addition to playing a fundamental role in DC development, type I IFN and IRFs 
modulate several key elements of APC functionality. IRF2 is required for efficient IL-
12 production [616] and IRF1 and IRF8 directly enhance IL-12 production by 
interaction with promoters of the p40 [617, 618] and p35 [619] subunits, respectively. 
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Furthermore, IL-12p70 expression by human monocyte-derived DCs appears to be 
dependent on autocrine IFNα/β signalling, involving upregulation of IRF7 and IRF8 
[620], indicating that synergy between several IRF family members is required for full 
IL-12 production in both mouse and man. IRF1 appears to have additional roles in 
regulating DC cytokine production, with DCs generated from Irf1-/- mice showing 
impaired TNFα and IL-12 expression and instead producing high levels of IL-10 and 
TGFβ, with a corresponding loss of T cell polarising capacity in vitro [615].  
 
Type I IFN are known to augment costimulatory molecule expression by DCs and 
monocytes in mice and humans [621-624], but the specific IRFs involved are less 
clearly defined. PD-L1 and CD40 expression on endothelial cells is critically dependent 
on IRF1 [625, 626], with this transcription factor also required for in CD80 expression 
by monocytes in vitro - a situation where IRF7 appears to be redundant [627]. 
Nevertheless, there is some evidence for an interaction between IRF7 and costimulatory 
molecules, with an IRF7 binding site identified in the CD80 promoter that regulates 
expression in response to LPS stimulation of human monocytes [628]. Furthermore, 
large scale analysis of genes regulated by IRF7 in response to viral infection have 
identified CD80 as a potential target of this transcription factor in an in vitro system, 
suggesting a link between IRF7 and expression of certain costimulatory molecules 
[629]. However, the potential for IRF7 to regulate costimulatory molecule expression 
by splenic cDCs is currently unclear.  
 
Several IRFs have a significant impact on the regulation of signalling events after 
encounter with microbial stimuli and TLR ligation.  IRF5, capable of a direct interaction 
with the key TLR signalling adaptors MyD88 and TRAF6, is essential for cDC and 
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macrophage expression of pro-inflammatory cytokines after stimulation with a range of 
TLR ligands [630]. Also capable of interacting with MyD88, IRF4 competes with IRF5 
for binding to this adaptor and is thus capable of inhibiting IRF5 activation and 
preventing subsequent pro-inflammatory cytokine expression induced after TLR 
ligation [631]. In contrast, IRF8 positively regulates TNFα and IL-6 gene expression by 
cDCs in response to TLR stimulation, a process initiated by direct interaction with 
TRAF6 [632, 633]. IRF7 similarly interacts with MyD88 and TRAF6, with these 
interactions critical for its activation and the subsequent production of IFNα after TLR 
stimulation [634-636]. In addition, a direct dependence on IRF1 and IRF7 for IFNβ 
production as a result of TLR2 ligation has also been reported [637].  
 
In light of these previous observations, this chapter aims to investigate whether IRF7 is 
required for normal splenic cDC subset development in vivo, in addition to extending 
our knowledge of the complex interactions between IRFs and TLRs by characterising 
the role for IRF7 in the regulation of splenic cDC activation in response to microbial 
stimuli in vitro and in vivo.  
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5.2 Results 
5.2.1 IRF7 deficiency does not affect spleen cell composition  
Mice deficient in a range of IRFs have profound defects in the development of several 
immune cell compartments (reviewed in [607]). To determine any impact of IRF7 
deficiency on spleen cell development, cells from collagenase-digested splenic tissue of 
C57BL/6 and B6.Irf7-/- mice were assessed by flow cytometry for expression of a range 
of cell-specific surface markers. The frequency of CD3ε+ T cells was equivalent in 
wildtype and IRF7-deficient animals, at 11.26 ±0.47% and 10.15 ±0.14%, respectively 
(5.1A). A lack of IRF7 did not affect the composition of the CD3ε+ compartment, with 
CD3ε+CD4+ cells comprising 52.03 ±1.04% of T cells in C57BL/6 mice and 50.15 
±0.76% in IRF7-deficient animals (5.1B). CD8α+ T cells were similarly unaffected by 
the absence of IRF7, making up 34.79 ±0.76% and 35.09 ±0.72% of splenic CD3ε+ cells 
in wildtype and B6.Irf7-/- mice, respectively. The frequency of CD19+MHCII+ splenic B 
cells was unaffected by a lack of IRF7, with this population comprising 47.77 ±2.42% 
of C57BL/6 splenocytes and 52.12 ±3.40% in spleens of B6.Irf7-/- animals (5.1C). 
CD11b+Gr-1int monocytic cells were at an equivalent frequency in wildtype and IRF7-
deficient mice, at 1.79 ±0.17% and 2.02 ±0.07% of splenocytes, with CD11bhiGr-1hi 
neutrophils slightly increased in the absence of IRF7, at 1.02 ±0.21% and 1.54 ±0.37% 
in spleens of C57BL/6 and B6.Irf7-/- mice. Therefore, a lack of IRF7 does not 
substantially alter the composition of splenic immune cells in the steady state 
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5.2.2 Faithful splenic cDC development and equivalent steady-state TLR2 
expression in the absence of IRF7  
As several IRF family members are critical for full cDC subset development [608, 609, 
611-615], it was important to determine whether the splenic CD11chiMHCIIhi 
compartment was intact in steady-state IRF7-deficient mice. Flow cytometric analysis 
of collagenase-digested spleen tissue from C57BL/6 and B6.Irf7-/- mice revealed 
comparable populations of CD11chiMHCIIhi cells (5.2A). These cells comprised 1.15 
±0.06% of splenocytes in C57BL/6 mice and 0.96 ±0.08% in B6.Irf7-/- mice; equivalent 
to 1.05x106 ±1.72x104 and 8.96x105 ±1.02x105 cells, respectively (5.2B). Assessing the 
CD11chiMHCIIhi compartment for expression of CD4 and CD8α allowed the 
frequencies of cDC subsets to be determined in wildtype and IRF7-deficient animals 
(5.2C). CD4+ cDCs were the most abundant subset in both strains, at 42.32 ±1.01% and 
40.21 ±2.43% of CD11chiMHCIIhi cells in C57BL/6 and B6.Irf7-/- mice (5.2D). The DN 
subset made up 18.57 ±0.62% of wildtype cDCs, and 18.12 ±0.81% of these cells in 
B6.Irf7-/- mice, whereas the CD8α+ cDC subset comprised 17.20 ±0.38% and 16.49 
±0.79% of CD11chiMHCIIhi cells in steady-state wildtype and IRF7-deficient mice, 
respectively.  
 
To determine whether IRF7 deficiency altered the capacity for TLR expression by 
cDCs, CD11chiMHCIIhi cDCs from steady-state wildtype and B6.Irf7-/- mice were 
assessed for surface expression of TLR2 (5.2E). cDCs from both strains expressed 
equivalent amounts of TLR2, at 11.27 ±0.64 units on wildtype cDCs and 10.90 ±0.56 
on IRF7-deficient cells (5.2F). Taken together, this data indicates that IRF7 is not 
required for cDC subset development in vivo and that TLR2 expression by cDCs is not 
affected by its absence.  
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5.2.3 IRF7-deficient splenic cDCs are hyperactivated in response to a TLR2 
agonist in vitro 
To begin to assess the contribution of IRF7 to the regulation of TLR signalling in DCs 
as physiologically relevant as possible, CD11chi cDCs were sorted to high purity from 
spleens of C57BL/6 and B6.Irf7-/- mice (5.3A). Cells were cultured for a total of 24 
hours in vitro in the presence of the TLR2 agonist PAM3CSK4, and monitored at 
intervals by flow cytometry for levels of activation, as measured by changes in surface 
expression of MHCII, CD80 and CD86 (5.3B).  Stimulation of cDCs from both strains 
led to their activation, as indicated by progressively increasing expression of all three 
surface markers. However in all cases, cDCs which lacked expression of IRF7 were 
hyperactivated in response to TLR2 stimulation, with significantly greater fold increases 
in expression of CD80 (5.3C), CD86 (5.3D) and MHCII (5.3E) when compared with 
IRF7-sufficient cDCs stimulated in the same way.  
 
This was reflected by significantly greater fold increases in surface expression of CD80 
on B6.Irf7-/- cDCs at 2, 4, 8, 16 and 24 hours post-stimulation (p.s.) with PAM3CSK4, 
when compared to levels on unstimulated cDCs from the same strain. At 2hr p.s, 
wildtype cDCs had not upregulated expression of CD80, whereas IRF7-deficient cells 
had increased expression by 1.28 ±0.04 fold (p<0.01). By 4hr p.s, wildtype cDCs had 
1.08 ±0.02 fold higher expression of CD80, whereas IRF7-deficient cells had increased 
expression by 2.10 ±0.02 fold (p<0.001). Increased expression of CD80 reached 1.93 ± 
0.01 fold on B6.Irf7-/- cDCs by 8hrs, before stabilising at increases of 3.57 ±0.11 and 
3.79 ±0.12 fold at 16 and 24 hrs p.s; significantly lower than the progressive increases 
in CD80 expression observed on wildtype cDCs of 3.54 ±0.03 (p<0.001), 7.11 ±0.27 
(p<0.01) and 8.38 ±0.18 (p<0.01) fold at these time points.  
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Enhanced fold changes in surface CD86 expression in response to PAM3CSK4 
stimulation were also observed on IRF7-deficient cDCs, however these were only 
significant at 16 and 24 hours post-stimulation. This was reflected by a 21.39 ±0.85 fold 
increase in surface CD86 on wildtype cDCs at 16h p.s, compared with a 26.49 ±0.77 
fold increase (p<0.05) on cDCs lacking IRF7 at this time point. Enhanced CD86 
expression in the absence of IRF7 was also seen at 24hr p.s, with a 35.14 ±0.53 fold 
increase in surface CD86 on B6.Irf7-/- cDCs compared with a 22.39 ±0.87 (p<0.01) fold 
increase in expression on wildtype cDCs.  
 
MHCII upregulation in response to TLR2 stimulation occurred in a pattern similar to 
that seen with CD80, with IRF7 deficient cDCs being significantly more activated at all 
time points post-stimulation. Wildtype cDCs showed fairly modest fold increases in 
surface expression of 1.53 ±0.10, 1.73 ±0.04, 2.51 ±0.03, 2.52 ±0.08 and 2.32 ±0.01 at 
2, 4, 8, 16 and 24 hours post-stimulation. In contrast, B6.Irf7-/- cDCs showed 
significantly higher fold increases in MHCII expression of 2.42 ±0.05 (p<0.05), 3.11 
±0.05 (p<0.01), 4.35 ±0.01 (p<0.001), 5.59 ±0.23 (p<0.01) and 7.90 ±0.05 (p<0.001) at 
the same points post-stimulation. Therefore in the absence of IRF7, splenic cDCs 
become hyperactivated in response to TLR2 stimulation and show significantly 
exaggerated expression of the costimulatory molecules CD80 and CD86, as well as 
MHCII.  
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5.2.4 IRF7 deficiency has a limited impact on splenic cDC responses to TLR3, 
TLR4 and TLR9 signalling 
To determine whether a lack of IRF7 led to enhanced cDC activation in response to 
diverse TLR stimuli, an identical approach to that outlined previously was undertaken 
replacing PAM3CSK4 with ligands of TLR3 (Poly (I:C), TLR4 (LPS) and TLR9 
(ODN1668) and monitoring activation by changes in surface expression of CD80, 
CD86 and MHCII by flow cytometry at various intervals during in vitro culture (5.4). 
 
Unlike with TLR2 stimulation, a lack of IRF7 did not substantially alter the expression 
of costimulatory molecules in response to agonists of TLR3, TLR4 or TLR9. There 
were no significant differences in the fold increase in expression of CD80 (5.4A) or 
CD86 (5.4B) in response to Poly (I:C), with slightly higher fold increases in MHCII 
expression being observed, although only significant at 24hr p.s. This was represented 
by a 2.18 ±0.32 fold increase in surface MHCII on wildtype cDCs at 24hr p.s, compared 
with a 3.42 ±0.16 (p<0.05) fold change on B6.Irf7-/- cDCs (5.4C).  Similarly, a lack of 
IRF7 did not result in exaggerated costimulatory molecule expression in response to 
TLR4 stimulation, with, at several time points, slightly lower fold increases in 
expression of CD80 (5.4D) and CD86 (5.4E) on B6.Irf7-/- cDCs, compared to wildtype 
cells. However, none of these differences were significant. Fold increases in surface 
MHCII in response to LPS on wildtype and B6.Irf7-/- cDCs were equivalent at all time 
points post-stimulation (5.4F).  
 
In response to stimulation of TLR9 with ODN 1668, CD80 expression appeared to be 
affected by an absence of IRF7, with higher fold increases in CD80 expression on 
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B6.Irf7-/- cDCs at all time points post-stimulation, although only significantly so at 8hr 
and 16hr p.s. (5.4G). Wildtype cDCs showed 2.55 ±1.11 and 2.83 ±0.10 fold increases 
in surface CD80 at these time points, compared to 6.00 ±0.98 (p<0.05) and 8.39 ±1.04 
(p<0.01) fold increases on cDCs lacking IRF7. In contrast, there was no significant 
difference in levels of CD86 (5.4H) and MHCII (5.4I) expression as a result of IRF7-
deficiency at any time point after TLR9 stimulation of cDCs. In summary, the data 
obtained with agonists of TLR3, 4 and 9 showed only a variable and less pronounced 
capacity for increased activation of IRF7-deficient cDCs, suggesting that IRF7 may be 
playing a role in regulating specific signalling pathways downstream of TLR2.   
 
5.2.5 Exaggerated responses of Irf7-/- cDCs to TLR2 stimulation occur in the 
presence of wildtype cDCs and exogenous IFNα  
In order to further clarify the mechanism behind the exaggerated activation profile seen 
with B6.Irf7-/- cDCs after TLR2 stimulation, components of the response to TLR 
stimulation that may be absent when cells lack IRF7 were supplemented into cDC 
activation cultures. To determine whether factors produced by IRF7-sufficient cDCs 
after TLR2 stimulation may affect the activation of Irf7-/- cDCs, CD11chi cells were 
sorted to high purity from spleens of B6J.CD45.1 (wildtype,  IRF7-sufficient cells) and 
congenic (CD45.2) B6.Irf7-/- animals (5.5A). Sorted cDCs were then cultured at an 
approximately 50:50 ratio (5.5B) and stimulated with PAM3CSK4, as before. Gating on 
CD45.1 or CD45.2 during flow cytometric analysis allowed an assessment of activation, 
measured as the fold increase in CD86 expression over unstimulated cells, on wildtype 
and IRF7-deficient cDCs cultured in the same microenvironment. The presence of 
wildtype cDCs did not prevent the exaggerated expression of CD86 on cDCs after 
activation previously observed on IRF7-deficient cells (5.5C). Activation levels were 
195 
 
higher on cDCs lacking IRF7 at all time points post-stimulation, with significantly 
enhanced fold increases in CD86 expression of 20.38 ±0.01 on wildtype cDCs 
compared to 24.97 ±0.35 fold (p<0.01) on B6.Irf7-/- cells at 16hr p.s, in addition to 
increases of 31.76 ±0.79 fold compared to 38.02 ±0.02 (p<0.01) fold on wildtype and 
IRF7-deficient cDCs, respectively, at 24 hours post-stimulation. 
IFNα is a major immune mediator which critically depends on IRF7 for its expression. 
As such, exogenous IFNα was added to cultures containing wildtype or IRF7-deficient 
cDCs to determine whether a lack of IFNα production in response to TLR2 stimulation 
was behind the exaggerated activation profile of B6.Irf7-/- cDCs.   
 
Addition of exogenous IFNα did not prevent greater expression of CD80 on B6.Irf7-/- 
cDCs, with significantly enhanced fold increases in surface expression on these cells at 
all time points post-stimulation (5.5D). Wildtype cDCs showed modest fold increases in 
CD80 expression of 0.79 ±0.06, 1.09 ± 0.01, 2.04 ±0.06, 3.56 ±0.01 and 3.89 ±0.05 at 2, 
4 8, 16 and 24 hours post-stimulation. This was in contrast to the more exaggerated 
expression of CD80 seen on B6.Irf7-/- cDCs, with increases of 1.38 ±0.01, 2.08 ±0.09, 
3.64 ±0.01 and 6.84 ±0.27 fold (all p<0.01 compared to wildtype cDCs) at 2, 4, 8 and 
16hr p.s, in addition to 8.46 ±0.05 fold (p<0.001) at 24hr post stimulation.  
 
Exaggerated CD86 expression on cDCs lacking IRF7 was similarly unaffected by the 
presence of exogenous IFNα, with higher fold increases in CD80 expression on these 
cells at all time points, although only significantly so at 4, 16 and 24hr post-stimulation 
(5.5E). Unlike CD80 expression, the fold increases in CD86 upregulation on cDCs from 
both strains were higher in the presence of IFNα, at approximately twice that in its 
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absence. At 4hr post-stimulation, wildtype cDCs showed a 10.23 ±0.11 fold increase in 
CD86, compared to a 12.86 ±0.11 (p<0.01) fold increase on IRF7-deficient cells. CD86 
expression was increased 38.61 ±2.19 and 45.77 ±4.79 fold at 16 and 24hr post-
stimulation, compared with 52.13 ±1.88  and 68.44 ±3.87 (both p<0.05) fold  increases 
on B6.Irf7-/- cDCs at these time points.  
 
Similarly, the exaggerated expression of MHCII previously observed after stimulation 
of IRF7-deficient cDCs with PAM3CSK4 was not prevented by exogenous IFNα (5.5F). 
B6.Irf7-/- cDCs in the presence of IFNα showed significantly enhanced upregulation of 
surface MHCII compared to wildtype cDCs at all time points post-stimulation. 
Wildtype cDCs showed 1.44 ±0.02, 1.63 ±0.01, 2.48 ±0.05, 2.39 ±0.02 and 2.06 ±0.08 
fold increases in expression of surface MHCII at 2, 4, 8, 16 and 24 hours post-
stimulation. cDCs isolated from IRF7-deficient mice showed significantly higher fold 
increases in surface MHCII expression, at 2.26 ±0.06 (p<0.01), 2.78 ±0.01 (p<0.001), 
4.20 ±0.01 (p<0.01), 4.95 ±0.02(p<0.001) and 4.89 ±0.01 (p<0.001) fold at the 
respective time points post-stimulation.  
 
Therefore, addition of either wildtype cDCs or exogenous IFNα was unable to prevent 
the exaggerated activation profile of B6.Irf7-/- cDCs in response to TLR2 stimulation, 
suggesting that IRF7 may be a component of the regulatory network activated after TLR 
stimulation in splenic cDCs.  
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5.2.6 Cytokine production by IRF7-deficient cDCs in vitro 
CD11chiMHCIIhi splenic cDCs were sorted from naïve C57BL/6 and B6.Irf7-/- mice and 
cultured for 24 hours in the presence of LPS or PAM3CSK4 with or without exogenous 
IFNα. Levels of IL-12p70 (5.6A&C) and IL-10 (5.6B&D) were determined in culture 
supernatant by ELISA. IL-12p70 production by cDCs in the absence of exogenous 
stimulation was impaired when cDCs lacked IRF7, represented by IL-12p70 levels of 
13.7 ±1.21pg/ml in culture supernatant of wildtype cDCs and 4.94 ±0.80pg/ml (p<0.01) 
of cDCs isolated from B6.Irf7-/- mice. In response to stimulation with LPS, IRF7-
deficiency severely impaired IL-12p70 production by cDCs, with wildtype cells 
producing 127.06 ±19.08 pg/ml after 24 hours and Irf7-/- cDCs producing 16.51 
±5.85pg/ml (p<0.01) after culture. The addition of exogenous IFNα did not alter this 
defective response, with wildtype cDCs producing 104.18 ±3.54 pg/ml of IL-12p70, 
compared to only 19.52 ±1.78 pg/ml (p<0.001) from IRF7-deficient cells after culture 
with both LPS + IFNα. Similarly impaired IL-12p70 production was observed in IRF7-
deficient cells cultured with PAM3CSK4, with IL-12p70 at 83.72 ±11.60pg/ml in culture 
supernatant from wildtype cells and 19.84 ±7.51pg/ml (p<0.01) from cDCs lacking 
IRF7. Again, exogenous IFNα did not affect this deficiency, with wildtype cDCs 
producing 107.51 ±9.84pg/ml of IL-12p70 in the presence of both PAM3CSK4 and 
IFNα, and culture supernatants of cDCs isolated from B6.Irf7-/- mice only containing 
21.33 ±3.31pg/ml (p<0.01).  
 
In contrast to the defective IL-12p70 production by IRF7-deficient cDCs, IL-10 levels 
in culture supernatants of cDCs isolated from B6.Irf7-/- mice contained significantly 
higher levels of IL-10 when stimulated with either LPS or PAM3CSK4 (5.6B&D). This 
was represented by an increase in IL-10 production from 233.26 ±9.80pg/ml by 
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wildtype cDCs to 355.85 ±17.52pg/ml (p<0.01) by Irf7-/- cDCs after culture with LPS 
and from 534.56 ±10.97pg/ml to 871.53 ±8.67pg/ml (p<0.01) after culture with 
PAM3CSK4. Exogenous IFNα did not affect this altered cytokine production, with 
wildtype cDCs producing significantly less IL-10 in response to culture with both LPS 
and IFNα, at 211.94 ±22.13pg/ml from wildtype cDCs and 379.76 ±15.89pg/ml 
(p<0.001) from cDCs deficient in IRF7. Similarly, culture in the presence of both 
PAM3CSK4 and IFNα did not affect the differential production of IL-10, with wildtype 
cDCs producing 508.47 ±20.09pg/ml and IRF7-deficient cells producing 846.42 
±28.53pg/ml (p<0.001). Therefore, a lack of IRF7 in splenic cDCs leads to impaired IL-
12p70 and enhanced IL-10 production in response to TLR2 and TLR4 ligands in vitro.  
 
5.2.7 Acute infection with Leishmania donovani in IRF7-deficient mice 
To address the potential relevance of the in vitro observations, a model of acute 
infection was employed in order to assess the impact of IRF7-deficiency on CD11chi 
dendritic cell activation in response to in vivo pathogen encounter. As such, C57BL/6 
and B6.Irf7-/- mice were infected i.v. with a high dose of L. donovani amastigotes and 
infection allowed to establish for 24 hours. Mice were killed at this time point and 
spleens isolated. Spleen mass of both strains was increased as a result of infection, from 
0.10 ±0.01mg in naïve C57BL/6 mice to 0.14 ±0.01 at 24hr post-infection (5.7A). 
Spleens of B6.Irf7-/- animals also increased in mass, from 0.11 ±0.01mg in naïve 
animals to 0.18 ±0.02 (p<0.05) by 24 hours of infection. Although slightly larger in 
infected B6.Irf7-/- animals, spleens were not significantly increased in size compared to 
infected wildtype mice. Splenic parasite burdens at 24 hours post-infection were 
determined by flow cytometry, and were not significantly altered as a result of IRF7-
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deficiency (5.7B). Spleens of C57BL/6 mice contained 2.29x106 ±3.37x105 parasites, 
whereas IRF7-deficient animals contained 2.39x106 ±9.57x105 amastigotes.  
 
In agreement with previous observations, splenic CD11chiMHCIIhi cells were at an 
equivalent frequency of 1.06 ±0.08% and 1.06 ±0.07% in naïve wildtype and B6.Irf7-/- 
mice, respectively (5.7C). Upon infection, the proportion of these cells amongst total 
splenocytes significantly decreased, to 0.48 ±0.07% and 0.40 ±0.03% (both p<0.01) by 
24 hours post-infection.  
 
cDC activation as a result of acute infection with L. donovani was assessed by flow 
cytometry on CD11chiMHCIIhi cells from C57BL/6 and B6.Irf7-/- mice, with activation 
levels expressed as the fold increase in surface costimulatory molecule expression on 
splenic cDCs from 24-hour infected mice, compared to the same cells from uninfected 
mice of the respective strain (5.7D). Acute infection with L. donovani led to modest 
increases in costimulatory molecule expression on cDCs from both strains of mice. 
Although not significantly so, CD40 upregulation on cDCs was impaired in infected 
IRF7-deficient mice, with CD40 expression increased 1.92 ±0.32 fold on wildtype 
cDCs, compared to 1.35 ±0.17 fold on IRF7 deficient cells. CD80 expression was 
barely enhanced as a result of infection in both strains, with C57BL/6 cDCs 
upregulating surface CD80 by 1.09 ±0.41 fold and B6.Irf7-/- cells showing a slight 
decrease in expression of 0.78 ±0.14 fold, relative to naïve cDCs of this genotype.  
Changes in surface CD86 expression were broadly equivalent in both strains, at 1.46 
±0.53 fold on wildtype cells and 1.57 ±0.22 fold on IRF7-deficient cDCs. Therefore, in 
vivo activation of cDCs as a result of acute L. donovani infection was broadly 
equivalent in the presence or absence of IRF7. 
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5.2.8 Global IRF7 deficiency limits cDC activation in response to TLR stimulation 
in vivo 
To directly assess the contribution of IRF7 to the regulation of cDC activation in 
response to defined TLR ligands in vivo, C57BL/6 and B6.Irf7-/- mice were injected 
intravenously with TLR agonists and splenic cDC activation determined 24 hours later 
by flow cytometry (5.8). Splenic CD11chiMHCIIhi cDCs (5.8A) from both strains of 
mice were assessed for expression of CD80 and CD86 after intravenous injection of 
PBS or LPS (5.8B). Activation levels of cDCs from both strains were expressed as the 
fold increase in levels of surface CD80 or CD86 on cDCs from spleens of LPS-injected 
mice, compared to spleens of mice receiving PBS i.v. (5.8C). cDCs from wildtype mice 
showed a 2.34 ±0.31 fold increase in surface CD80, alongside a 4.88 ±0.76 fold 
increase in surface CD86 after LPS injection, whereas cDCs from B6.Irf7-/- mice 
receiving LPS i.v. showed smaller increases in CD80 and CD86 expression of 1.86 
±0.06 fold and 2.91 ±0.42 fold, respectively, 24 hours post-injection. However, these 
differences in activation were not significant.  
 
As TLR2 signalling appeared to be affected most profoundly by a lack of IRF7 in vitro, 
PBS or PAM3CSK4 were administered to C57BL/6 and B6.Irf7-/- mice and cDC 
activation assessed by flow cytometry as before.  Similar to that observed after injection 
of LPS, as well as in vitro, expression of CD86 occurred with a biphasic pattern, 
whereby a proportion of cDCs expressed high levels of costimulatory molecules when 
compared to cDCs from PBS-injected animals (5.8D). There was no significant 
difference in the fold increase in surface expression of CD80 on cDCs after PAM3CSK4 
administration, at 2.36 ±0.08 fold and 2.35 ±0.13 fold on cDCs from wildtype or 
B6.Irf7-/- mice, respectively (5.8E). In contrast, upregulation of CD86 expression was 
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significantly impaired in B6.Irf7-/- mice, with wildtype cDCs showing a 6.04 ±0.18 fold 
increase in surface CD86 after PAM3CSK4 injection, compared with 4.37 ±0.28 fold 
(p<0.01) on cDCs from IRF7-deficient animals. In summary, in vivo administration of 
TLR agonists suggested that, in contrast to in vitro data, IRF7 may be required for 
optimum expression of this costimulatory molecule in vivo.  
 
5.2.9 In vivo administration of PAM3CSK4 to microchimeric mice reveals enhanced 
CD86 expression on IRF7-deficient cDCs  
Although useful in determining the systemic function of particular genes, mice with a 
global deficiency in immune-related genes may not provide a full complement of 
signals required for effective immune cell activation. Therefore microchimeric mice, in 
which a minority of hematopoietic cells of the desired genotype develop within an 
wildtype host, were used for in vivo inflammation studies to address the role of IRF7 in 
cDC activation in response to TLR2 signalling (5.9). B6J.CD45.1 mice were used as 
recipient animals and injected i.p. with Busulfan, before resting overnight and receiving 
bone marrow cells intravenously from congenic donor mice of the desired genotype; 
either C57BL/6 (wildtype) or B6.Irf7-/- (5.9A). After leaving to engraft for a period of 7-
14 days, microchimeric mice were injected with PBS or PAM3CSK4 i.v., and dendritic 
cells assessed for expression of CD80 and CD86 by flow cytometry.  
 
Spleens of microchimeric mice contained CD11chiMHCIIhi cDCs derived from both 
host (CD45.1) and donor (CD45.2) genotypes (5.9B). There was no difference in the 
ability of C57BL/6 or B6.Irf7-/- bone marrow to engraft, with equivalent frequencies of 
endogenous vs chimeric cDCs regardless of which strain of donor mice was used. By 
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comparing surface expression of CD80 and CD86 on endogenous and chimeric cDCs 
after either PBS or PAM3CSK4 injection, levels of activation could be determined by 
expressing the fold change of CD80 (5.9C) or CD86 (5.9D) expression on chimeric 
cDCs as a result of TLR2 stimulation in vivo. There was no significant difference in 
fold upregulation of CD80 by endogenous cDCs compared to wildtype chimeric cDCs, 
at 2.33 ±0.10 fold and 2.45 ±0.32 fold, respectively. Comparable upregulation of CD80 
was also seen when endogenous cDCs were compared to IRF7-deficient chimeric cDCs, 
with 2.61 ±0.11 and 2.54 ±0.10 fold increases in CD80 expression on the respective 
cDC populations from spleens of mice 24 hours after PAM3CSK4 injection.  
 
CD86 upregulation after PAM3CSK4 administration was also comparable on 
endogenous cDCs when compared to C57BL/6 chimeric cDCs, at 3.54 ±0.47 and 3.51 
±0.70 fold, respectively, when compared with cDCs of either population in spleens of 
PBS-treated mice. In contrast, a lack of IRF7 in chimeric cDCs led to significantly 
exaggerated expression of CD86 after TLR2 stimulation, with these cells increasing 
surface CD86 expression 5.47 ±0.18 fold by 24 hours, compared with 4.08 ±0.11 fold 
(p<0.01) on endogenous cDCs in these microchimeric mice.  
 
In summary, a lack of IRF7 expression by cDCs stimulated within an IRF7-sufficient 
environment led to exaggerated expression of CD86 and so suggests that, in the 
presence of an intact immune environment, cDCs lacking IRF7 are not capable of 
effectively regulating CD86 expression in response to TLR2 stimulation in vivo. 
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5.3 Discussion 
This study reveals a novel role for IRF7 in regulating TLR2-induced costimulatory 
molecule expression by splenic cDCs in vitro and in vivo.  Unlike many other members 
of this transcription factor family, IRF7 is redundant with respect to the in vivo 
development of cDC subsets. However, a lack of IRF7 expression by cDCs results in 
exaggerated costimulatory molecule expression and altered cytokine producing potential 
in vitro. Although TLR ligand administration to mice with global IRF7-deficiency fails 
to recapitulate the in vitro data, administration of PAM3CSK4 to microchimeric mice 
indicates a key role for IRF7 in the regulation of CD86 expression by splenic cDCs in 
vivo.  
 
IRF7 appears to play a limited role in the development of cDC subsets and other splenic 
immune cell types, supporting previous data showing normal cell distribution in the 
spleens of B6.Irf7-/- mice by immunohistochemistry [502] and in the livers of IRF7-
deficient mice by flow cytometry (Beattie et al, in press). However this is in stark 
contrast to mice lacking expression of other IRF family members, with normal cDC (cf. 
above), CD8α+ T cell [638, 639] and NK cell [640-642] development relying on the 
expression of several IRFs, suggesting either that compensatory mechanisms for 
immune cell development exist in the absence of IRF7, or that the functions of this 
transcription factor are more restricted than other members of the same family. 
 
As IRF7 is critical for the optimal induction of type I IFN expression, it was surprising 
that a deficiency in this transcription factor led to alterations in the response of cDCs to 
ligation of TLR2; signalling through which was, until recently, not thought to lead to 
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type I IFN expression [643]. However it is now becoming clear that TLR2 signalling 
can lead to type I IFN production under some conditions. This was first observed during 
the response of mice to vaccinia virus, where a subset of Ly6Chi inflammatory 
monocytes produced type I IFN in an IRF3 and IRF7-dependent manner after TLR2-
mediated recognition of viral ligands [644]. This was proposed to be restricted to both 
inflammatory monocytes and virus-derived stimuli. However, more recent studies have 
revealed a capacity for type I IFN production in other cell types and in response to 
diverse TLR2 ligands, including PAM3CSK4 [637, 645]. This is thought to be dependent 
upon the localisation of TLR2 to endolysosomal membranes, with subsequent signalling 
from this compartment leading to IFNα/β production- more akin to the mechanisms 
employed by TLR3, TLR7 and TLR9 [646, 647]. The location of TLR2 to endosomal 
compartments and subsequent IFNα/β production may, as with TLR4, be dependent 
upon TRAF3, as forced localisation of TRAF3 to the plasma membrane enables IFNβ 
production after PAM3CSK4 stimulation, rather than the classical plasma membrane-
restricted signalling that initiates pro-inflammatory cytokine production in response to 
TLR2 [648]. However it is still unclear as to the precise molecular mechanisms leading 
to TLR2-induced IFNα/β production.  
   
Although IFNα production is critically dependent upon IRF7, IFNβ production in 
response to LPS stimulation occurs at normal levels in IRF7-deficient cells [547]. 
However, the recent studies showing type I IFN production in response to endosomal 
TLR2 signalling all revealed a key requirement for IRF7 in the induction of IFNβ [637, 
645, 649]. Therefore, in addition to a lack of IFNα, cDCs stimulated with TLR2 ligands 
would also presumably lack IFNβ production. Although IFNβ has been shown to be 
required for maximal costimulatory molecule expression on peritoneal macrophages in 
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response to LPS stimulation [622], splenic cDCs which are deficient in the IFNαβ 
receptor (IFNαβR) and thus cannot respond to either type I IFN, show greatly enhanced 
expression of CD80 and CD86 in response to infection with Listeria monocytogenes in 
vivo [650]. As the data presented here show that IRF7 deficiency led to exaggerated co-
stimulatory molecule expression on cDCs after TLR2 but not TLR4 signalling and 
exogenous IFNα could not prevent this occurring, this allows for a hypothetical model 
to be generated by which the TLR-mediated induction of IFNβ can, at least in splenic 
cDCs, also contribute to the regulation of co-stimulatory molecule expression under 
certain conditions (5.10). The effects of exogenous IFNβ on the activation of Irf7-/- 
cDCs stimulated with TLR2 ligands in vitro would allow this to be tested, as would the 
stimulation of cDCs lacking the IFNβ receptor in vitro or in vivo.  
 
Although IFNβ may provide some explanation as to the impaired regulation of 
costimulatory molecule expression, as PAM3CSK4-stimulated IRF7-deficient cDCs 
from cultures containing a 50:50 mix of wildtype cDCs also showed exaggerated CD86 
expression, it is possible that a type I IFN independent mechanism may also contribute 
to these observations. Tripartite motif-containing (TRIM) proteins comprise a family of 
type I IFN-inducible factors with diverse roles in the immune system [651]. Of 
particular relevance is TRIM30α, recently found to contain a putative IRF7 binding 
sequence in its promoter region (Phillips, unpublished). This protein acts to restrict NF-
κB –mediated signalling downstream of TLR ligation by interacting with TAK1 and 
degrading TAB2 and TAB3 [195]. Interestingly TAB2 itself also contains a putative 
IRF7-binding element (Phillips, unpublished), suggesting that IRF7 may be capable of 
regulating the activation of NF-κB directly and through the actions of TRIM30α. As 
enhanced costimulatory molecule expression is dependent on NF-κB [652, 653], it is 
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possible that when this pathway is not correctly regulated, as may be the case in IRF7-
deficient cDCs, that this results in a failure to regulate CD86 expression and thus leads 
to enhanced accumulation of this costimulatory molecule on cDCs. Further work will be 
required to confirm whether IRF7 does directly interact with TRIM30α, perhaps by 
chromatin immunoprecipitation assays, and to provide molecular evidence for the 
hypothetical mechanism described. 
 
The altered cytokine profile of cDCs lacking IRF7 and stimulated in vitro was 
interesting, as it appeared to show uncoupling of costimulatory molecule expression and 
cytokine production in response to TLR stimulation. In particular, the greatly reduced 
production of IL-12p70 by IRF7-deficient cDCs in response to TLR2 signalling was 
surprising, given the exaggerated expression of costimulatory molecules occurring 
simultaneously on these cells. This was unexpected, as previous reports have described 
exaggerated inflammatory cytokine production in the absence of IRF7, with MCMV 
infected B6.Irf7-/- mice having significantly elevated levels of serum IL-12p70 
compared to wildtype animals, associated with enhanced IFNγ production but only 
moderate changes in host pathology [546]. Exacerbated pro-inflammatory cytokine 
production has also been reported in IRF7-deficient mice in a model of liver pathology; 
although this appears to be due to a failure in the IFNα-mediated induction of soluble 
IL-1Rα rather than any direct regulation of cytokine gene expression by IRF7 [649]. 
However, these studies did not address cytokine production from defined cell 
populations, and so the enhanced levels of systemic cytokines could be due to 
differential responses of distinct immune cell populations when deficient in IRF7.  
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In light of the reduced IL-12p70 production by IRF7-deficient cDCs in response to both 
TLR2 and TLR4 signalling, a potential mechanism for this observed defect is suggested 
by the reported requirement for cooperation between IRF1 and IRF8 in order to 
generate maximal IL-12 production by APCs [550, 552, 616-619, 654]. As IRF7 has 
been shown to interact with IRF8 [655] and is predicted to bind both IRF1 and IRF8 
[629, 656], it is possible that in the absence of IRF7, full induction of IRF1 and IRF8 
expression does not occur and thus IL-12 production is impaired. This is also supported 
by data showing that TRIM21, a putative target of IRF7 (Phillips, unpublished), is 
required for the ubiquitination of IRF8 and maximal IL-12 gene expression [657]. As 
such, it is feasible that IRF7 is required for full IL-12 production via the direct and 
indirect activation of other IRFs.  
 
Alongside their defective production of IL-12p70, cDCs deficient in IRF7 produced 
elevated levels of IL-10 in response to TLR ligation. This is similar to IRF1-deficient 
splenic DCs, which show impaired IL-12 and enhanced IL-10 production in vitro [615]. 
However, splenic DCs from Irf1-/- mice have limited upregulation of costimulatory 
molecule expression in response to TLR ligation: a phenotype distinct from 
PAM3CSK4-stimulated splenic cDCs lacking IRF7 and indicating that differential 
mechanisms underlie these broadly similar observations. It is possible that the enhanced 
IL-10 production by both IRF1 and IRF7-deficient cDCs underlies the impaired 
capacity for IL-12p70 production- similar to the autocrine regulation of IL-12 
production by IL-10 discussed earlier in this study (cf. Chapter 3). Alternatively, as IL-
10 suppresses costimulatory molecule expression by APCs [658-660], it is possible that 
the enhanced IL-10 expression by IRF7-deficient cDCs is part of a negative feedback 
mechanism aimed at limiting the exaggerated costimulatory molecule expression that 
occurs on these cells. However, as Irf7-/- cDCs stimulated with both LPS and 
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PAM3CSK4 showed enhanced IL-10 production, yet only those stimulated through 
TLR2 showed exaggerated costimulatory molecule expression, this potential 
mechanism is unlikely to be the sole reason for the enhanced IL-10 production by IRF7-
deficient cDCs. Although no direct links between IRF7 and IL-10 production are 
known, IRF4 can directly modulate IL-10 gene expression (cf. Chapter 4 and [557, 
558]) and so the direct regulation of IL-10 production is a possibility. As enhanced IL-
10 production is also observed in IRF7-deficient hepatic (Beattie et al) and splenic 
(Chapter 4) CD4+ T cells during inflammation in vivo, it is possible that IRF7 is playing 
a role in regulating the expression of this cytokine in a range of cell types.  
 
Despite some ambiguity as to the receptor-ligand interactions involved, there is 
evidence that conserved elements of Leishmania donovani are recognised by TLR2 (cf. 
Chapter 3) and so infection with this pathogen was suitable to assess the impact of IRF7 
deficiency on in vivo cDC activation in response to TLR2 signalling. However, in 
contrast to the in vitro data, splenic cDCs from mice with a global deficiciency in IRF7 
did not display exaggerated expression of co-stimulatory molecule expression after 
infection in vivo. This is likely due to the requirement for type I IFN production for 
optimal co-stimulatory molecule expression, as detailed above. However in light of the 
complexities surrounding the recognition of L. donovani by PRRs, it was also possible 
that this model of inflammation was not eliciting a strong enough response, or did not 
provide enough available TLR ligands for optimal cDC activation. Therefore the 
injection of defined TLR ligands i.v. was carried out in order to attempt to deliver TLR 
ligands to splenic cDCs as efficiently as possible.  
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Systemic administration of TLR ligands led to similar observations as those seen after 
infection with L. donovani, with cDCs from C57BL/6 and B6.Irf7-/- mice having 
equivalent costimulatory molecule expression 24hrs after LPS injection in vivo. cDCs 
from both strains had equivalent expression of CD80  in response to PAM3CSK4 
injection, although significantly reduced expression of CD86 when isolated from 
B6.Irf7-/- animals. This strongly suggested that in mice with a global IRF7 deficiency, 
optimal expression of CD86 did not occur due to a lack of IRF7-dependent immune 
mediators in these animals.  
 
Although this could have been addressed by the injection of recombinant IFNα and/or 
IFNβ, other factors downstream of IRF7 signalling may have also been involved, such 
as IL-6 [629], so a different approach was taken. This took advantage of the capacity for 
Busulfan, an alkylating agent, to partially ablate the stem cell compartment in mice and 
allow for the generation of microchimeric animals bearing populations of donor-derived 
hematopoietic cells from congenic wildtype or IRF7-deficient backgrounds, which will 
develop in an intact, IRF7-sufficient microenvironment (Moore et al and [661, 662]). 
Injecting these mice with a TLR2 ligand revealed that CD86, but not CD80, expression 
was upregulated to a greater extent on IRF7-deficient cDCs in vivo; strongly implicating 
a role for IRF7-dependent factors in both the initial expression and subsequent 
regulation of costimulatory molecule expression. As CD86 is a key co-stimulatory 
molecule implicated in the generation of bystander activated T cells, such as occurs 
during infection with L. donovani [405], work is currently ongoing to determine 
whether a lack of IRF7 enhances the capacity for bystander activation of CD8α+ T cells 
in vitro.  
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In summary, this data reveals a novel role for IRF7 in the regulation of TLR2-induced 
costimulatory molecule expression by splenic cDCs in vitro and in vivo. This appears to 
be distinct from the regulation of pro-inflammatory cytokine production, as cDCs 
displaying exaggerated costimulatory molecule expression in vitro had a significantly 
impaired capacity for IL-12p70 production. In contrast, IL-10 production was enhanced, 
suggesting the potential for an autocrine negative feedback loop functioning to restrict 
this hyperactivation. Although the molecular mechanisms remain to be experimentally 
determined, preliminary data suggesting interactions between IRF7 and regulators of 
TLR-induced NF-κB expression provide a potential explanation as to the dysregulated 
costimulatory molecule expression observed. As regulating the expression of 
costimulatory molecules by cDCs is critical to the effective control of immune 
responses, further elucidating the pathways required for the efficient regulation of DC 
function will allow a greater understanding of DC biology, as well as revealing potential 
novel therapeutic targets for future development.  
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Figure 5.1 IRF7 deficiency does not affect spleen cell composition. The frequency of A, splenic CD3ε+ 
T cells, B, CD4+ and CD8α+ T cells, C, CD19+MHCII+ B cells and D, CD11b+ monocytes and 
CD11b+Gr-1+ neutrophils were assessed by flow cytometry in steady state C57BL/6 (open bars) and 
B6.Irf7-/- (closed bars) mice.  Data show representative flow plots and where quantified show the mean 
frequency ±SEM of indicated cell type in spleens of 4-5 mice per group. Representative of three separate 
experiments.   
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Figure 5.2 Splenic cDC subset development and TLR2 expression is independent of IRF7. The 
presence of splenic CD11chiMHCIIhi cDCs in C57BL/6 and B6.Irf7-/- mice was determined by flow 
cytometry (A&B). CD4+, DN and CD8α+ cDC subset frequency was determined in the CD11chiMHCIIhi 
compartment of wildtype and IRF7-deficinet animals (C&D). Expression of TLR2 on CD11chiMHCIIhi 
cells from C57BL/6 and B6.Irf7-/- mice was determined by flow cytometry (E&F). Flow plots and 
histograms in A, C and E are representative, data in B, D and F show mean frequency ±SEM of indicated 
cell population in C57BL/6 (open bars) and B6.Irf7-/- (closed bars) mice. Histograms in E are gated on 
CD11chiMHCIIhi cells gated as in A and show specific TLR2 staining (open line) compared to isotype 
control antibody (filled histogram). Data are from n=4-5 mice per group and representative of three 
separate experiments.  
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Figure 5.3 IRF7-deficient splenic cDCs are hyperresponsive to a TLR2 agonist in vitro.  A. CD11chi 
cDCs were sorted to ~99% purity from the spleens of C57BL/6 and B6.Irf7-/- mice. Cells were cultured in 
triplicate at 1x106 cells/ml in the presence of 10µg/ml PAM3CSK4. At the indicated times post-
stimulation, cells were removed and assessed by flow cytometry for expression of CD80, CD86 and 
MHCII. Flow plots showing progressive cDC activation in terms of CD86 and MHCII expression are 
shown in B, the fold increase in surface expression of CD80, CD86 and MHCII on cDCs at the indicated 
time point over unstimulated cDCs are shown in C, D and E, respectively. A and B show representative 
flow plots, C-E show mean fold increase ±SEM in surface expression of indicated proteins on cDCs from 
C57BL/6 (open bars) or B6.Irf7-/- (closed bars) mice, compared to unstimulated cDCs from the same 
strain. Data are pooled from three individual experiments. *=p<0.05 **= p<0.01, ***=p<0.001.  
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Figure 5.4 IRF7 deficiency has a limited impact on splenic cDC responses to TLR3, TLR4 and 
TLR9 signalling. Splenic CD11chi cDCs were sorted from C57BL/6 and B6.Irf7-/- mice as before. Cells 
were plated, in triplicate, and stimulated with 100µg/ml Poly (I:C), 1µg/ml LPS or 10µg/ml ODN:1668. 
At the indicated times post-stimulation, cells were removed and assessed by flow cytometry for their fold 
increase in expression of CD80 (A, D&G), CD86 (B, E&H) and MHCII (C, F and I) over unstimulated 
cDCs. Data show mean fold increase ±SEM in surface expression of indicated proteins on triplicate wells 
containing cDCs from C57BL/6 (open bars) or B6.Irf7-/- (closed bars) mice, compared to unstimulated 
cDCs from the same strain. Data are pooled from two individual experiments. *=p<0.05 **= p<0.01,  
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Figure 5.5 Exaggerated CD86 expression after TLR2 stimulation occurs in the presence of IRF7-
sufficient cDCs and exogenous IFNα . A. Splenic CD11chi cDCs were sorted from C57BL/6, B6.Irf7-/- 
and congenic B6J.CD45.1 mice. B. cDCs from B6.Irf7-/- and B6J.CD45.1 mice were cultured at ~50:50 
ratio to a final concentration of 1x106 cells/ml, in the presence of 10µg/ml PAM3CSK4. C. The fold 
increase in expression of CD86 on cDCs from either strain, in the same well, was determined by flow 
cytometry at the indicated times post-stimulation. D-F, C57BL/6 and Irf7-/- cDCs were cultured, in 
triplicate, in the presence of 10µg/ml PAM3CSK4 and 1000 U/ml IFNα. At the indicated times post-
stimulation, cells were removed and assessed by flow cytometry for their fold increase in expression of 
CD80 (D), CD86 (E) and MHCII (F) over unstimulated cDCs. A and B show representative flow plots, 
C-F show mean fold increase ±SEM in surface expression of indicated proteins on cDCs from 
B6J.CD45.1 (open bars in C), C57BL/6 (open bars in D-F) or B6.Irf7-/- (closed bars) mice, compared to 
unstimulated cDCs from the same strain. Data are from one (B-C) or two (D-F) experiments. *=p<0.05 
**= p<0.01, ***=p<0.001  
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Figure 5.6 Cytokine production by IRF7-deficient cDCs in vitro. CD11chi cDCs were sorted from 
spleens of C57BL/6 and B6.Irf7-/- mice and cultured in triplicate for 24 hours in the presence of 10µg/ml 
PAM3CSK4, 1µg/ml LPS and 1000U/ml IFNα, or combinations thereof. After culture, supernatants were 
assessed by ELISA for presence of IL-12p70 (A&C) or IL-10 (B&D). Data show mean concentration of 
cytokine from triplicate wells ±SEM and are representative of two experiments.  **= p<0.01 *=p<0.001 
 
 
 
 
 
217 
 
 
 
 
 
 
 
 
Figure 5.7 Acute infection with Leishmania donovani in IRF7-deficient mice. C57BL/6 and B6.Irf7-/- 
mice were infected via the lateral tail vein with a high dose (4.5x107) of L. donovani. A. At 24hr post 
infection, spleen mass in infected and naïve control animals was determined. B. Parasite burden in 
spleens of infected mice were determined by flow cytometry. C. The frequency of splenic 
CD11chiMHCIIhi cDCs in naïve and infected mice was assessed by flow cytometry. D. Activation levels 
of cDCs as a result of acute infection were determined by quantifying the fold change in MFI of surface 
CD40, CD80 and CD86 on cDCs from infected mice compared with those from naïve animals. Data are 
mean ±SEM (B-D) and from one experiment with three mice per group. *=p<0.05 **= p<0.01 
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Figure 5.8 Global IRF7 deficiency limits cDC activation in response to TLR stimulation in vivo. A-
C. C57BL/6 and B6.Irf7-/- mice received intravenous injections of 5µg/mouse LPS or D&E, 5µg/mouse 
PAM3CSK4 in 200µl PBS, or 200µl PBS alone. After 24 hours, activation of splenic CD11chiMHCIIhi 
cDCs (shown in A) after LPS (B&C) or PAM3CSK4 (D&E) administration in vivo was assessed by 
quantifying changes in surface expression of CD80 and CD86 by flow cytometry. Flow plots and 
histograms in A, B and D are representative, data in C and E show the mean fold change in indicated 
surface protein ±SEM on cDCs from C57BL/6 (open bars) and B6.Irf7-/- (closed bars) mice after TLR 
agonist injection compared to cDCs from mice receiving PBS only. Data are from one (A-C) or 
representative of two (D&E) experiments with 3 or 4 mice per group. **= p<0.01 
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Figure 5.9 In vivo administration of PAM3CSK4 to microchimeric mice reveals enhanced CD86 
expression on IRF7-deficient cDCs. B6.Irf7-/- or C57BL/6 microchimeric mice were generated by bone 
marrow transfer into Busulfan-treated congenic B6J.CD45.1 hosts (cf. Chapter 2). A. 7 to 14 days post-
engraftment, microchimeric mice bearing Irf7-/- or C57BL/6 chimeric cell populations received 
5µg/mouse PAM3CSK4 intravenously (A). Splenic CD11chiMHCIIhi cDC compartments in microchimeric 
animals were comprised of endogenous (CD45.1+) and chimeric (CD45.1-) cell populations (B). After 24 
hours, activation of splenic cDCs after PAM3CSK4 administration in vivo was assessed by quantifying 
changes in surface expression of CD80 (C) and CD86 (D) by flow cytometry. Flow plots in B are 
representative, data in C and D show the mean fold change in indicated surface protein ±SEM on cDCs 
from the indicated endogenous or chimeric cell compartments in microchimeric mice after PAM3CSK4 
injection (closed bars) compared to cDCs from mice receiving PBS only (open bars). **= p<0.01 
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Figure 5.10 Hypothetical model for the differential impact of IRF7-deficiency on TLR2 and TLR4-
mediated activation of cDCs. In wildtype cDCs, ligation of TLR2 and TLR4 leads to efficient induction 
of IFNα and IFNβ and allows for the regulated expression of costimulatory molecules. When cDCs 
deficient in IRF7 are stimulated with a TLR4 ligand, IFNα induction is abolished, but IFNβ expression is 
intact. This allows for the regulated expression of costimulatory molecules on cDCs. When IRF7-
deficient cDCs are stimulated with a TLR2 ligand, production of both IFNα and IFNβ is abolished and 
this leads to the dysregulated expression of costimulatory molecules.  
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Chapter 6: Concluding discussion 
Although DCs have a fundamental role in the generation of effective antigen-specific 
immune responses [9], it is now clear that they also significantly contribute to the 
regulation of immunity [124]. However, the majority of previous studies have focussed 
on maintaining tolerance to tissue associated antigen or examined the regulatory role of 
immature, in vitro derived or non-conventional DC populations during infection. This 
study demonstrates for the first time that CD11chi cDCs are major negative regulators of 
immune responses to pathogens in vivo, highlighting their functional plasticity and 
revealing a novel, paradoxical capacity for these potent APCs to inhibit effective 
immunity to the protozoan parasite, Leishmania donovani.  
 
The identification of a regulatory cytokine network operating at the level of the cDC 
extends our knowledge of the profound alterations in APC function during chronic 
infection. Impaired production of IL-12 by cDC subsets ex vivo was in accordance with 
previous work [108], with the data here supplementing these observations by describing 
the inhibition of IL-12p70 production as a result of autocrine IL-10 signalling in cDCs 
during infection. In addition, infection led to substantial production of IL-27 by cDC 
subsets, providing the first evidence that experimental infection with L. donovani results 
in expression of this pleiotropic effector/regulatory cytokine at the protein level. The 
combination of enhanced IL-10 and IL-27 production, alongside suppressed IL-12 
expression, inhibited the capacity for cDCs to drive Th1 polarisation in vitro, with 
further work suggesting an added function for IL-27 in directly limiting effector T cell 
polarisation (6.1).  
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It is still unclear as to how IL-27 can have such divergent effects on immune function, 
but with recent studies reporting that IL-27 can directly antagonise cytokine signalling 
[663] and that optimal IL-10 production by macrophages requires IL-27 expression 
[664], it is evident that this cytokine plays a central role in multiple immunoregulatory 
pathways. As the mechanisms underlying the inhibitory role of cDC-derived IL-10 and 
IL-27 during infection are still unclear, further studies are needed to determine whether 
cDCs, T cells or both require IL-10 and/or IL-27 receptor expression in order to 
establish the regulatory cytokine network proposed. Conditional ablation of these 
receptors on specific cell types would enable this to be addressed 
 
The dramatic improvement in splenic pathology and disease progression after the 
ablation of CD11c-expressing cells in vivo strongly implicated DCs as contributors to 
the establishment of chronic infection. However, this experimental approach resulted in 
the depletion of many other CD11c-expressing cell populations – a caveat not addressed 
by previous in vivo ablation studies. As such, a major role for cDCs in disease 
progression was confirmed by the isolation of CD11chiMHCIIhi cells from infected mice 
and their subsequent adoptive transfer to infected animals depleted of endogenous DC 
populations. Interestingly, transfer of CD11cint cells also led to a significant restoration 
of many elements of pathology, suggesting that cells within this heterogeneous 
population contribute to chronic infection with L. donovani. However, cDCs had a 
unique capacity to drive the differentiation of IFNγ and IL-10 dual producing CD4+ T 
cells in vivo. Therefore, these combined depletion and complementation approaches 
indicate for the first time that CD11chi cDCs can be detrimental to host protection 
during chronic infection and provide the first evidence that IL-10 and IL-27 producing 
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APCs critically contribute to the generation of IL-10 and IFNγ co-producing T cells in 
vivo (6.2).   
 
An outstanding question of relevance to this study is whether individual cDC subsets 
make distinct contributions to pathology and disease progression during infection with 
L. donovani. It is not currently possible to perform the conditional ablation of individual 
cDC subsets in vivo; with the exception of partially depleting CD8α+ cDCs by 
cytochrome C injection [111]. However, mice constitutively lacking this subset are 
available [106] and a novel strain based on a similar inducible DTR system to that used 
here should allow for the conditional ablation of a range of CD11c+ DC populations in 
the near future [665]. Until then it is difficult to speculate as to whether an individual 
subset may play a more significant role during infection. However, the relatively subtle 
phenotypic differences between the subsets ex vivo identified in this study suggest that 
some functional redundancy may exist.  
 
Solid data regarding the question of why and how splenic cDC function is so 
profoundly altered during infection remain elusive. As cDCs themselves are rarely 
infected, the stromal compartment is likely to play a major role; highlighted by the 
impact of infection on splenic stroma and the subsequent expansion of regulatory DCs 
[172]. Bone marrow stromal cells are also heavily parasitised, hinting at the potential 
for alterations in cDC developmental microenvironments to impact upon their 
functionality after differentiation. However this is all speculative at this stage.   
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Complementing the data discussed above, this study identified a novel function for 
IRF7 in regulating the response of splenic cDCs to activation with TLR2 agonists in 
vivo. Although seemingly disconnected at first glance, a more complete understanding 
of the regulation of splenic cDC function is important in the context of chronic parasitic 
infection, as well as a multitude of other cases. Although the molecular mechanisms 
remain to be determined, the data presented here strongly indicate that IRF7 regulates 
costimulatory molecule expression by cDCs. Taken alongside bioinformatic data 
indicating that the promoters of various negative regulators of TLR signalling contain 
putative IRF7 binding sites (Phillips et al, unpublished), it is conceivable that this 
function may be due to the direct interaction of IRF7 and components of signalling 
pathways downstream of TLRs. A more complete characterisation of the targets of IRF7 
and molecular mechanisms involved will be required to confirm this.  
 
Any research focussing on a neglected tropical disease has an ultimate aim to generate a 
greater understanding of the pathological mechanisms involved and thus contribute to 
the development of potential novel therapeutic interventions. Although not focussed on 
directly applied topics such as vaccine development or drug discovery, this study made 
several novel observations regarding chronic Leishmania donovani infection that may 
impact upon therapeutic development in the future.  
 
The paradoxical capacity for splenic cDCs to inhibit effective immune responses to L. 
donovani suggests that strategies aimed at harnessing the usually powerful stimulatory 
capacity of these cells would be ineffective if deployed against infection with this 
parasite. For example, delivery of antigen specifically to cDC subsets is currently in 
preclinical development for prophylactic vaccines against HIV, Malaria and pneumonic 
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plague [146, 666, 667]. Although these are not therapeutic vaccines, similar approaches 
administered during ongoing infection with L. donovani would be likely to fail as a 
result of the impaired cDC function identified in this study. Indeed, the rational design 
of therapeutic vaccine candidates that were specifically targeted to APCs other than 
DCs would appear to be the most sensible option, if pursued at all. 
 
In light of the dramatic improvements in pathology and disease progression after 
ablation of cDCs during infection, a seemingly logical progression would be to consider 
the specific ablation of these cells during infection in humans. However, with no direct 
evidence of similarly impaired splenic DC function in patients as yet and the multitude 
of  potential issues surrounding the depletion of crucial immune cell populations such  
as DCs, this is unlikely to be pursued. Nevertheless, the specific targeting of cDCs with 
pharmacological compounds, such as ERK inhibitors, is theoretically feasible: 
potentially allowing for the negative functions of these cells to be reversed.  However in 
reality any strategies associated with the modulation of DC function are unlikely to be 
developed solely for diseases such as visceral leishmaniasis - a novel therapeutic would 
be required to have a primary indication for conditions associated with wealth, not 
poverty.  
 
The evidence of a profound suppressive role for IL-10 at the level of the APC during L. 
donovani infection adds to the growing body of evidence supporting an assessment of 
biological anti-IL-10 therapy as an adjunct to chemotherapy in humans. Although this 
concept is strongly backed up by data from preclinical studies [321], any biological 
therapy is likely to have a limited impact on the burden of disease in endemic areas, 
again due to the extreme cost associated developing these products. However, 
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investigating DC function in groups of patients before and after anti-IL-10 therapy 
could address whether similar IL-10-mediated modulation of DC cytokine production is 
also a feature of human disease.   
 
In summary, the data presented here reveal new insight into the immunopathological 
mechanisms underlying chronic infection with Leishmania donovani. The detrimental 
impact of cDCs on protective immunity suggests a previously unknown capacity for 
CD11chi lymphoid resident DCs to regulate immune responses, indicating the 
considerable functional plasticity of these cells during infection. Although many 
outstanding questions remain, this study serves to highlight the diverse function of these 
fascinating cells across a spectrum of immune mediated disease and furthers our 
understanding of the immunoregulatory networks fundamental to our survival.  
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Figure 6.1 An autoregulatory cytokine cascade at the level of the cDC impairs 
efficient Th1 polarisation. Production of IL-10 by cDCs during chronic infection 
contributes to the inhibition of effector T cell polarisation by impairing IL-12 
expression as a result of autocrine uptake by cDCs. It is feasible that cDC-derived IL-10 
may additionally act directly on the T cell. IL-27 is also produced by cDCs as a result of 
infection, which contributes to the impaired Th1 polarisation by limiting IL-12 induced 
IFNγ production in vitro through an unknown mechanism, at least partially dependent 
upon cDC-derived IL-10.  
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A                                                     B 
 
 
Figure 6.2 Model of splenic cDC function during chronic infection. A. cDC subsets 
produce IL-10 and IL-27 as a result of chronic infection, favouring the generation, 
maintenance and/or expansion of CD4+ T cells capable of co-producing IFNγ and IL-10. 
Production of IL-10 by cDCs and CD4+ T cells (also from other sources not depicted) 
impairs IFNγ-mediated parasite killing by macrophages, allowing for persistent disease. 
B. Conditional ablation of cDCs during infection removes a source of IL-10 and IL-27, 
limiting the numbers of IL-10+ Th1 cells and reducing the overall abundance of IL-10. 
Alongside dramatic improvements in splenic pathology, residual levels of IFNγ allow 
for increased NO production by macrophages, parasite killing and enhanced host 
resistance.  
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Abbreviations 
  APC Antigen presenting cell 
APC  Allophycocyanin (fluorochrome) 
B7-H1 see PD-L1 
BM Bone marrow  
BMDC Bone marrow derived dendritic cell 
BrdU 5-bromo 2-deoxyuridine 
BSA Bovine serum albumin 
CCR Chemokine receptor 
CD Cluster of differentiation 
cDC  Conventional CD11chiMHCIIhi dendritic cell  
CDP Common dendritic cell progenitor 
CFSE Carboxyfluorescein succinimidyl ester 
CLP Common lymphoid progenitor 
CMP Common myeloid progenitor 
CTL Cytotoxic T lymphocyte 
DC Dendritic cell 
DC-SIGN Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin 
DMEM Dulbecco’s modified eagle’s medium 
DN Double negative 
DNA Deoxyribonucleic acid 
DTR Diphtheria toxin receptor 
DTx Diphtheria toxin  
EAE Experimental autoimmune encephalomyelitis 
EBI3 Epstein-Barr virus-induced gene 3 
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ELISA Enzyme-linked immunosorbant assay 
ERK Extracellular signal-related kinase 
FACS Fluorescence-activated cell sorting 
FCS Foetal calf serum 
FITC Fluorescein isothiocyanate 
Flt3 Fms-like tyrosine kinase receptor-3 
Flt3L Fms-like tyrosine kinase receptor-3 ligand 
GM-CSF Granulocyte macrophage colony-stimulating factor 
GSK3 Glycogen synthase kinase-3 
GVHD Graft-versus host disease 
HPRT Hypoxanthine-guanine phosphoribosyltransferase 
HTLV-1 Human T-lymphotropic virus 
i.p  Intraperitoneal 
i.v Intravenous 
ICOS Inducible co-stimulatory molecule 
iDC Inflammatory monocyte-derived dendritic cell 
IDO Indoleamine 2,3-dioxygenase 
IFN Interferon 
IgG Immunoglobulin 
IL  Interleukin 
iNOS Inducible nitric oxide synthase 
IRAK Interleukin-1 receptor-associated kinase 
IRF  Interferon regulatory factor 
ISRE Interferon stimulated response element 
iTr35 Induced IL-35+ regulatory T cell 
LC Langerhans cell 
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LC Langerhans cell 
LCMV Lymphocytic choriomeningitis virus 
LDU Leishman-Donovan Unit 
LPG Lipophosphoglycan 
LPS Lipopolysaccharide 
LTα  Lymphotoxin- α 
MCMV Murine cytomegalovirus 
mDC Myeloid dendritic cell 
MDP Macrophage-dendritic cell progenitor 
MHC Major Histocompatibility complex 
MLR Mixed leukocyte reaction 
MMM  Marginal metallophillic macrophage 
MMR Macrophage mannose receptor 
MONO Monocyte 
mRNA Messenger ribonucleic acid 
mTOR Mammalian target of rapamycin 
MyD88 Myeloid differentiation primary response gene 88 
MZM Marginal zone macrophage 
NF-κB Nuclear factor κB 
NK Natural killer 
NO Nitric oxide 
OVA Ovalbumin 
p.s. Post-stimulation  
PAMP Pathogen-associate molecular pattern 
PBS Phosphate-buffered saline 
pDC Plasmacytoid dendritic cell 
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PD-L1 Programmed death ligand 1 
PE Phycoerythrin 
Pre-cDC Conventional dendritic cell precursor 
Pre-DC Dendritic cell precursor 
Pro-DC Common dendritic cell progenitor (alternative nomenclature) 
PRR Pattern recognition receptor 
qRT-PCR Quantitative real-time reverse transcription polymerase chain reaction 
RALDH Retinaldehyde dehydrogenase 
RORγt Retinoic acid-related orphan receptor-γt 
Sbv Sodium stibogluconate 
SOCS Suppressor of cytokine signalling 
STAT Signal transducer and activator of transcription 
Syk Spleen tyrosine kinase 
TCR T cell receptor 
TGF Transforming growth factor 
Th1 T helper 1 
Th17 T helper 17 
Th2 T helper 2 
Tip-DC TNFα and iNOS-expressing inflammatory dendritic cell 
TIRAP Toll-interleukin 1 receptor domain containing adaptor protein 
TLR Toll-like receptor 
TNF Tumour necrosis factor 
Tr1 Regulatory T cell type 1 
TRAF6 Tumour necrosis factor receptor-associated factor-6 
Treg Regulatory T cell 
TRIM  Tripartite motif-containing protein 
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VEGF Vascular endothelial growth factor 
VL Visceral leishmaniasis 
WSX-1 IL-27 receptor α chain 
WT Wildtype 
αIL-10R anti-IL-10 receptor 
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